Education. Evidence. Regrowth.
Prioritize knowledge. Make better choices.
Sort good studies from the bad.
Get bigger hair gains.
PhD's, resarchers, & consumer advocates.
Founder, researcher, & consumer advocate
Our team of PhD’s, researchers, & more
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
I have attached my before and afters of my progress since joining this group...
I’m convinced I’ve recovered to probably the hairline I had 3 years ago. Super stoked…
My friends actually told me, “Your hairline improved. Your hair looks thicker...
I also feel my hair has a different texture to it now…
Firstly thank you for your work in this field. I am immensely grateful that...
I just wanted to thank you for all your research, for introducing me to this method...
To be honest I am having fun with all this and I still don’t know how much...
I see a massive amount of regrowth that is all less than about 8 cm long...
150+ member experiences.
Scroll DownPopular treatments. But do they work?
Top-selling ingredients, quantified.
The truth about hair loss "best sellers".
Xyon Health
Strut Health
Happy Head
DS Laboratories
Advanced Trichology
Fully Vital
Xyon Health
DrFormulas
Revivogen MD
Standardized rubrics to evaluate all treatments.
Is this treatment well studied?
How much regrowth can you expect?
Is this treatment safe & sustainable?
Apps, tools, guides, freebies, & more.
100+ free articles.
Our team’s peer-reviewed studies.
Education. Evidence. Regrowth.
PhD's, resarchers, & consumer advocates.
Discover how we conduct our research.
Have questions? Contact us.
Our library of before-after photos.
Read the experiences of members
Oral minoxidil has become one of the most popular treatments for pattern hair loss, and for good reason. In clinical trials, it works just as well or even outperforms 5% topical minoxidil, with investigator assessments rating oral minoxidil as performing better than topical minoxidil. [1]Penha, M.A., Miot, H.A., Kasprzak, M., Müller Ramos, P. (2024). Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatology. 160(6). 600-605. … Continue reading[2]Ramos, P.M., Sinclair, R.D., Kasprzak, M., Miot, H.A. (2020). Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. … Continue reading
Oral minoxidil is also affordable, convenient, and, with the increasing popularity of telemedicine, as accessible as ever.
But there’s a trade-off.
Oral and topical minoxidil work the same way. Minoxidil is enzymatically activated, converted into minoxidil sulfate (the active form of the drug), interacts with the cells in the hair follicle, and, in turn, enhances hair growth.
With the use of topical minoxidil, this activation process happens in the hair follicle itself. With oral minoxidil, some of this happens in the liver, in a metabolic process called first-pass metabolism.
The minoxidil and active minoxidil sulfate then travel through the blood to the scalp and into the hair follicles themselves, where they support hair growth. But because the blood delivers minoxidil sulfate throughout the whole body, it also results in significant exposure to different parts of the body, like the cardiovascular system.
As a result, oral minoxidil has an increased risk of cardiovascular side effects that we don’t typically see with topical minoxidil. These may include:
However, these side effects typically only occur once the active minoxidil sulfate reaches cardiovascular tissue via the bloodstream. If we can reduce the blood levels of active minoxidil sulfate, we can, in theory, reduce the risk of side effects with oral minoxidil while (hopefully) still maintaining the directionally better results.
This is the premise of sublingual minoxidil, a form of oral minoxidil that dissolves under the tongue.
This article explains the science behind sublingual minoxidil, why it works, and why, in all likelihood, it could be a better form of minoxidil.
A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Topical minoxidil is one of two FDA-approved treatments for androgenic alopecia (AGA). It’s been studied since the 1980s. Regrowth tends to peak between months four and eight of treatment, and in people who keep using it, the gains hold through at least year five.
The catch is that it only works for about 40 to 60% of people who try it. Surveys of people who quit topical minoxidil find that most of them stopped because they didn’t see results.
The reason for this is twofold:
Oral minoxidil, on the other hand, is metabolized differently. Instead, part of the oral minoxidil taken orally is activated by sulfotransferase in the liver. It then travels from the bloodstream to the scalp, where it delivers active minoxidil sulfate to hair follicles and supports growth. It also delivers inactive minoxidil, which is then activated by sulfotransferase enzymes in the scalp.
In other words, oral minoxidil overcomes both critical barriers to efficacy with topical minoxidil. It delivers more inactive minoxidil and supplies minoxidil sulfate to the follicle without having to rely on sulfotransferase enzymes in the scalp alone.
But the bloodstream doesn’t just deliver active minoxidil sulfate to the scalp, it also delivers it systemically, including to sensitive tissues like the cardiovascular system. Because minoxidil sulfate is a potent vasodilator (i.e., it relaxes the smooth muscle in blood vessel walls), it can have a significant effect on the cardiovascular system.
As a result, oral minoxidil carries a risk of cardiovascular side effects that we don’t typically see with topical minoxidil, where only around 1.4% of the applied dose reaches the bloodstream. These side effects are typically very rare, but can include:[5]Jimenez-Cauhe, J., Lo Sicco, K.I., Shapiro, J., Hermosa-Gelbard, A., Burgos-Blasco, P., Melian-Olivera, A., Ortega-Quijano, D., Pindado-Ortega, C., Buendia-Castaño, D., Asz-Sigall, D., Vaño-Galvan, … Continue reading
But what if there was a way to deliver active minoxidil to the follicles without exposing the rest of the body to minoxidil sulfate? Could there be an opportunity for us to harness the benefits of oral minoxidil while minimizing the side effects?
Sublingual minoxidil might be the answer. Let’s unpack the research.
When taken sublingually, oral minoxidil bypasses first-pass hepatic metabolism. In other words, it skips metabolic processing in the liver, including by the sulfotransferase enzyme. So instead of minoxidil sulfate being delivered to follicles alongside the inactive minoxidil, sublingual minoxidil means only the inactive minoxidil is transported via the bloodstream to the scalp, not minoxidil sulfate.
With less active minoxidil sulfate in the bloodstream to interact with tissues other than the scalp, you would expect to see a lower rate of side effects.
And that’s exactly what researchers found.
In a randomized, double-blind, placebo-controlled phase I trial, published in 2021, researchers tested the effects of three doses of sublingual minoxidil, 0.45 mg, 1.35 mg, and 4.05 mg, in 40 men and women with AGA. [6]Bokhari, L., Jones, L.A., Sinclair, R.D. (2022). Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial. … Continue reading
The sublingual minoxidil was considered effective. At 24 weeks, hair density improved in a dose-dependent way: roughly 45% of patients on 0.45 mg showed improvement in frontal density and 55% at the vertex, rising to nearly 67% in both areas with a 4.05 mg dose.
However, because there was no oral minoxidil group in this study, we don’t know how it compares to oral minoxidil for efficacy or side effects.
In a hallmark study, researchers directly compared the efficacy and safety of oral minoxidil with sublingual minoxidil. [7]Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C., Müller Ramos, P. (2025). Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized clinical … Continue reading
110 men with AGA (Norwood-Hamilton 3V, 4V, and 5V) were enrolled. One group took 5 mg of sublingual minoxidil daily plus an oral placebo. The other took 5 mg of oral minoxidil daily plus a sublingual placebo. Total and non-vellus hair density were measured in the vertex by trichoscopy with hair-to-hair matching, and three dermatologists blind to treatment scored global photographs.
After 24 weeks:
While sublingual numbers were directionally a little higher, both sublingual and oral minoxidil were measured as having about the same impact on hair growth.
However, side effects are where the groups separated:
At the end of the study, the authors concluded that sublingual minoxidil and oral minoxidil were about on par in terms of efficacy. Both were well tolerated, with less frequent palpitations in the sublingual group. The authors attribute the absence of palpitations to minoxidil escaping hepatic metabolism.
A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
The original publishers of the 2021 study revisited their original data, using hair-to-hair matching software to track the diameter of individual hairs from baseline to week 24.[8]Sinclair, R., Sicinska, J., Bokhari, L., Kasprzak, M. (2025). Sublingual minoxidil increases fibre diameter in male androgenetic alopecia: a proxy for reversal of hair follicle miniaturization. … Continue reading
There were considerable differences across doses and placebo:
Because hair follicle miniaturization and the resultant shrinking of hair diameter are significant drivers of pattern hair loss, thickening of hair diameter suggests sublingual minoxidil may address a significant underlying factor in hair loss.
Notably, this is the first human evidence that a minoxidil treatment thickens existing hairs, consistent with the vellus-to-terminal reconversion seen in a humanized mouse model.[9]Gilhar, A., Keren, A., Paus, R. (2023). Vellus-to-terminal hair follicle reconversion occurs in male pattern balding and is promoted by minoxidil and platelet-rich plasma: in vivo evidence from a new … Continue reading
However, like the original study, we are limited in our ability to compare this directly to oral minoxidil.
In a 2026 randomized, double-blind, placebo-controlled trial, researchers assessed the effect of sublingual minoxidil in transgender people recorded female at birth and taking full-dose testosterone.[10]Tang, G.T., Leemaqz, S., Bhoyrul, B., Eisman, S., Kasprzak, M., Sicinska, J., Sinclair, R., Cheung, A.S. (2026). Treatment of androgenetic alopecia in transgender people receiving testosterone … Continue reading This group develops AGA at about 2.5 times the rate of cisgender women, and finasteride is generally a poor fit because it can interfere with masculinization.
Participants were randomized to sublingual minoxidil (titrated to 1.35 mg twice daily) or placebo for 24 weeks, then moved to 2.5 mg twice daily in an open-label extension through week 48. Blood pressure, heart rate, and testosterone were measured at every visit.
At 24 weeks, midfrontal total hair count rose by 15.7 hairs/cm² more on minoxidil than on placebo (p=0.03), and non-vellus hair count by 12.7 hairs/cm² more (p=0.04). At 24 weeks, sublingual minoxidil didn’t beat placebo for vertex hair growth but eventually outpaced placebo by week 48. Self-rated vertex improvement was 57% on minoxidil versus 30% on placebo. There was no difference between groups in postural hypotension, hypertrichosis, or any other side effect, and sublingual minoxidil didn’t impact blood pressure, heart rate, or testosterone levels.
Andrés-Lencina and colleagues reviewed 87 patients (73 women, 14 men) treated with a compounded sublingual minoxidil spray at their clinic.[11]Andrés-Lencina, J.J., Brisco, F., Ricart, J.M., Gómez-Zubiaur, A. (2025). Tolerance and Safety Profile of Sublingual Minoxidil in the Treatment of Androgenic Alopecia. Actas Dermo-Sifiliográficas. … Continue reading Median doses were 0.5 mg per day for women and 1 mg per day for men. Three months in, patients were surveyed by phone about side effects.
The authors compared their results against two large oral minoxidil series. Side effects were less frequent with sublingual minoxidil than in a 435-patient oral minoxidil study that used the same phone survey, and about as frequent as in a 1,404-patient oral minoxidil study that relied on medical records rather than patient surveys.[12]Sanabria, B., de Nardo, V.T., Miot, H.A., Ramos, P.M. (2021). Adverse effects of low-dose Oral Minoxidil for androgenetic alopecia in 435 patients. Journal of the American Academy of Dermatology. … Continue reading[13]Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., et al. (2021). Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of … Continue reading
All in, while more research is needed, the existing research suggests sublingual minoxidil seems to perform on par with or directionally better than oral minoxidil. Even better, it seems to do so with a much lower risk of some side effects.
According to these studies, it seems the cardiovascular impact of minoxidil may be, in part, related to the spike of the active drug in the blood. If we can prevent a spike of active minoxidil sulfate in the blood, we can, in theory, reduce the risk of side effects with oral minoxidil while (hopefully) keeping the directionally better regrowth.
However, sublingual delivery doesn’t seem to reduce the risk of other side effects like hypertrichosis, insomnia, headache, dizziness, and fluid retention. However, all but hypertrichosis remained rare.
If you have lower sulfotransferase levels in your scalp, you might be worried that sublingual minoxidil might not be as effective as oral minoxidil. After all, if the advantage of oral minoxidil is that it bypasses the need for minoxidil activation in the scalp, then we would expect that bypassing activation in the liver with sublingual minoxidil could theoretically lead to subpar results (compared to regular oral minoxidil).
Except this doesn’t seem to be true. In research comparing oral and sublingual minoxidil, they generally perform about the same despite the fact that sublingual minoxidil bypasses this essential step.
Why might this be the case? There are two reasons:
As a result, it doesn’t seem that there is a disadvantage to using sublingual minoxidil when it comes to expected growth potential.
Sublingual minoxidil has been tested at various doses in the research, as low as 0.45 mg and as high as 5 mg. While doses of 0.45 mg, 1.35 mg, 2.5 mg, 4.05 mg, and 5 mg have all shown favorable results, only 5 mg has data to support its non-inferiority to standard oral minoxidil. 1.35 mg and 2.5 mg were rated as more effective than placebo, but weren’t validated against standard oral minoxidil.
This doesn’t mean doses lower than 5 mg won’t be effective, but it is the most evidence-backed dose when it comes to sublingual minoxidil.
Ulo just released their Sublingual Minoxidil Rx. It’s an orange-flavored, rapidly dissolving tablet that easily dissolves under the tongue. It’s a convenient, easy way to take oral minoxidil while harnessing the potential of sublingual delivery.
A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Sublingual minoxidil made its way into research on the premise that its delivery route might have less of an impact on the cardiovascular system. And in a landmark head-to-head trial, researchers found exactly that. Heart palpitations occurred in 0% of men taking 5 mg of sublingual minoxidil, compared with 9% of men taking 5 mg of standard oral minoxidil. And importantly, it was just as effective: both groups grew the same amount of hair over six months.
Oral minoxidil’s cardiovascular effects are driven by a spike in the active form of minoxidil, minoxidil sulfate, in the blood. That surge in active minoxidil dips blood pressure and contributes to related side effects.
Sublingual minoxidil minimizes the spike in the active form of minoxidil by bypassing the first-pass metabolism responsible for its activation. Instead, minoxidil gets supplied directly to the scalp tissue, and at higher amounts than topical minoxidil.
This is also why sublingual minoxidil performs on par with oral minoxidil: by delivering higher amounts to the hair follicle, more minoxidil can be converted to the active form in the follicles. By providing a higher dose of minoxidil to follicles, both oral and sublingual minoxidil outperform topical minoxidil.
In general, research around sublingual minoxidil is still in its infancy. However, the early clinical data make it a reasonable option for anyone looking to explore other forms of minoxidil that are best suited to their needs and preferences when approaching hair loss.
References[+]
| ↑1 | Penha, M.A., Miot, H.A., Kasprzak, M., Müller Ramos, P. (2024). Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatology. 160(6). 600-605. Available at: https://doi.org/10.1001/jamadermatol.2024.0284 |
|---|---|
| ↑2 | Ramos, P.M., Sinclair, R.D., Kasprzak, M., Miot, H.A. (2020). Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. Journal of the American Academy of Dermatology. 82(1). 252-253. Available at: https://doi.org/10.1016/j.jaad.2019.08.060 |
| ↑3 | Chitalia, J., Dhurat, R., Goren, A., McCoy, J., Kovacevic, M., Situm, M., Naccarato, T., Lotti, T. (2018). Characterization of follicular minoxidil sulfotransferase activity in a cohort of pattern hair loss patients from the Indian subcontinent. Dermatologic Therapy. 31(6). e12688. |
| ↑4 | Goren, A., Shapiro, J., Roberts, J., Desai, N., Zarrab, Z., Pietrzak, A., Lotti, T. (2015). Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatologic Therapy. 28(1). 13-16. Available at: https://doi.org/10.1111/dth.12164 |
| ↑5 | Jimenez-Cauhe, J., Lo Sicco, K.I., Shapiro, J., Hermosa-Gelbard, A., Burgos-Blasco, P., Melian-Olivera, A., Ortega-Quijano, D., Pindado-Ortega, C., Buendia-Castaño, D., Asz-Sigall, D., Vaño-Galvan, S. (2025). Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review. Journal of Clinical Medicine. 14(6). 1805. Available at: https://doi.org/10.3390/jcm14061805 |
| ↑6 | Bokhari, L., Jones, L.A., Sinclair, R.D. (2022). Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(1). e62-e66. Available at: https://doi.org/10.1111/jdv.17623 |
| ↑7 | Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C., Müller Ramos, P. (2025). Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized clinical trial. Journal of the European Academy of Dermatology and Venereology. 39(8). e700-e702. Available at: https://doi.org/10.1111/jdv.20508 |
| ↑8 | Sinclair, R., Sicinska, J., Bokhari, L., Kasprzak, M. (2025). Sublingual minoxidil increases fibre diameter in male androgenetic alopecia: a proxy for reversal of hair follicle miniaturization. Clinical and Experimental Dermatology. 50(7). 1362-1365. Available at: https://doi.org/10.1093/ced/llaf012 |
| ↑9 | Gilhar, A., Keren, A., Paus, R. (2023). Vellus-to-terminal hair follicle reconversion occurs in male pattern balding and is promoted by minoxidil and platelet-rich plasma: in vivo evidence from a new humanized mouse model of androgenetic alopecia. Acta Dermato-Venereologica. 103. 12320. |
| ↑10 | Tang, G.T., Leemaqz, S., Bhoyrul, B., Eisman, S., Kasprzak, M., Sicinska, J., Sinclair, R., Cheung, A.S. (2026). Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial. Journal of the American Academy of Dermatology. 95. 724-733. Available at: https://doi.org/10.1016/j.jaad.2026.05.020 |
| ↑11 | Andrés-Lencina, J.J., Brisco, F., Ricart, J.M., Gómez-Zubiaur, A. (2025). Tolerance and Safety Profile of Sublingual Minoxidil in the Treatment of Androgenic Alopecia. Actas Dermo-Sifiliográficas. 116(2). 122-123. Available at: https://doi.org/10.1016/j.ad.2023.09.031 |
| ↑12 | Sanabria, B., de Nardo, V.T., Miot, H.A., Ramos, P.M. (2021). Adverse effects of low-dose Oral Minoxidil for androgenetic alopecia in 435 patients. Journal of the American Academy of Dermatology. 84(4). 1175-1178. |
| ↑13 | Vañó-Galván, S., Pirmez, R., Hermosa-Gelbard, A., et al. (2021). Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology. 84(6). 1644-1651. Available at: https://doi.org/10.1016/j.jaad.2021.02.054 |
| ↑14 | Ramos, P.M., Goren, A., Sinclair, R., Miot, H.A. (2020). Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. Journal of the European Academy of Dermatology and Venereology. 34(1). e40-e41. |
The hair loss industry is rife with quick-fix solutions, fleeting fads, and ineffective natural supplements. There are, however, tried-and-tested prescription medications that can reliably combat hair loss and promote regrowth. Does this mean we can rely on Rx vendors to always provide safe, dependable, and evidence-based treatments? Unfortunately, the world of prescription hair loss medication can be prone to the same issues that plague over-the-counter solutions. What’s worse, Rx drugs pose a real danger of severe side effects.
Happy Head is a telehealth company specializing in hair-loss medications. For many years, we happily recommended their products: they provided proven treatments and were one of the only places to find effective options like topical dutasteride. Unfortunately, issues have become apparent that are typical of wider problems with the hair loss industry.
If you’ve been using Happy Head and are pleased with the results, there should be nothing to worry about. Their offerings of minoxidil, finasteride, and dutasteride, among others, are powerful tools against hair loss and can drive real, meaningful improvements.
However, their model has critical oversights, some involving consumer safety, and after years of voicing our concerns with no changes, we were inspired to launch Ulo to fix these exact problems. This article will detail the six major reasons why we lost faith in recommending them to our readers.
Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed* Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you. *Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.Interested in Topical Dutasteride?
In an industry with a limited number of established pharmaceutical options, it can be hard to stand out. Happy Head’s unique selling point is its DNA Kit and Customized Hair Growth Treatment, which, they claim, reveals which treatments will work for your unique DNA.
The pitch is this: there are certain gene variants that underlie how hair loss develops, and others that can predict how well hair loss drugs will work. For $298, Happy Head provides a home DNA test; you take a swab and send it back for analysis. This enables them to generate reports on your personal genetic makeup and recommend treatments accordingly.
They provide two reports:
It sounds impressively technical, but what is the science behind this “breakthrough innovation”?
It’s important to note that genetic factors are heavily involved in our predisposition to hair loss. Androgenic alopecia (AGA) is highly heritable, with family studies suggesting genetics account for around 80% of predisposition in men. It is, however, a polygenic trait, meaning that many genes each contribute small effects rather than a single “baldness gene.”[1]Heath, A. C., Nyholt, D. R., Gillespie, N. A., & Martin, N. G. (2003). Genetic basis of male pattern baldness. *Journal of Investigative Dermatology.* 121(6). 1561–1564. Available at: … Continue reading
AGA is driven by hormonal activity: as levels of an androgen called dihydrotestosterone (DHT) rise, it can cause miniaturization of hair follicles that progressively shortens the hair growth phase, leading to hairs that are thin, short, and sparse.[2]Trüeb, R. M. (2002). Molecular mechanisms of androgenetic alopecia. *Experimental Gerontology.* 37(8–9). 981–990. Available at: https://doi.org/10.1016/S0531-5565(02)00093-1 Because of this association with androgen activity, the androgen receptor locus (region of DNA) is most heavily associated with hair loss.[3]Sadasivam, I. P., Sambandam, R., Kaliyaperumal, D., & Dileep, J. E. (2024). Androgenetic alopecia in men: An update on genetics. *Indian Journal of Dermatology.* 69(3). 282. Available at: … Continue reading
Other genes involved in androgen activity, such as SRD5A2, which plays a role in androgen metabolism, are also associated with susceptibility to hair loss. Genes involved in other pathways important to hair follicle development, such as the WNT pathway, may also play a role.[4]Gupta, A. K., Dennis, D. J., Economopoulos, V., & Piguet, V. (2026). The genetic landscape of androgenetic alopecia: Current knowledge and future perspectives. *Biology.* 15(2). 192. Available … Continue reading
This research may tell us how likely someone is to develop AGA as they grow older. Of course, for most people already seeking treatment for AGA, this information isn’t particularly useful. Clinical diagnosis is typically based on the appearance of the hair, scalp examination, and family history, rather than on genetic tests. However, there are some cases where genetic insights might be useful.
Treatments that target hormonal aspects of AGA, like finasteride and dutasteride, won’t work for other causes of hair loss. Some hair loss is the result of nutrient deficiencies, many of which are caused by genetic variation. For example, biotin deficiency can lead to alopecia because biotin is essential for keratin production, a key component of hair. Mutations in the BTD gene, encoding an enzyme called biotinidase, which is essential for the body to use biotin, can therefore cause hair loss. However, most biotin deficiencies are diagnosed in children, and hair loss is apparent from a young age.[5]Yang, Y., Yang, J. Y., & Chen, X. J. (2020). Biotinidase deficiency characterized by skin and hair findings. *Clinics in Dermatology.* 38(4). 477–483. Available at: … Continue reading
The autoimmune condition alopecia areata may also have a genetic basis, and predispositions have been identified in genes involved in the immune system.[6]Biran, R., Zlotogorski, A., & Ramot, Y. (2015). The genetics of alopecia areata: new approaches, new findings, new treatments. *Journal of Dermatological Science.* 78(1). 11–20. Available at: … Continue reading
The Hair and Scalp Report provided by Happy Head after DNA testing lists genetic predispositions for 33 traits, ranging from autoimmune hair loss (e.g., alopecia areata) to scalp hydration and vitamin deficiencies. If you thought you had AGA, but instead had a different cause of hair loss, some insight into the underlying genetics could prove useful in rare cases.
However, clinicians typically distinguish among different forms of alopecia by physical examination and, in rare cases, by blood tests. If you want to understand your hair loss, visiting a physician is a far more reliable route. What’s more, the Rx products that Happy Head offers require a diagnosis prior to being prescribed, so you will have to see a healthcare practitioner regardless of your underlying genetics.
The main promise of Happy Head’s genetic testing is that it can identify “which treatments will work for your unique DNA”. Given the range of options available to people suffering from hair loss and the sometimes unpredictable nature of treatment responses, it’s an enticing prospect. But does the science back up Happy Head’s bold claims?
We’ve investigated the potential of genetic testing for personalized hair loss treatment before, and you can read our in-depth report here.
Happy Head provides a Treatment Insight Report, which highlights “14-16 genetic traits for medication sensitivity and baldness patterns”. Helpfully, the company has detailed these genetic traits, the associated genes, and the studies supporting their use, so we can assess how powerful their predictions might be. You can find the full list here.
The test assesses the presence of a kind of genetic variation called single-nucleotide polymorphisms (SNPs, normally pronounced “snips”). DNA is made up of genes, which in turn are comprised of individual units called nucleotides. When a gene is “read”, the sequence of nucleotides will determine what protein is made, and therefore what effect the gene will have. SNPs are variations in these nucleotides; change the nucleotide, and you might change the impact of the gene.[7]Nelson, M. R., Marnellos, G., Kammerer, S., Hoyal, C. R., Shi, M. M., Cantor, C. R., & Braun, A. (2004). Large-scale validation of single nucleotide polymorphisms in gene regions. *Genome … Continue reading,[8]National Human Genome Research Institute. (n.d.). Single nucleotide polymorphisms (SNPs). *Genome.gov.* Available at: https://www.genome.gov/genetics-glossary/Single-Nucleotide-Polymorphisms-SNPs
For example, if we know that a SNP changes the activity of a gene involved in drug metabolism, we might be able to predict how well certain drugs are going to work.

Figure 2. Single Nucleotide Polymorphisms (SNPs). When a SNP occurs, one nucleotide (the component of genes and the letters in the DNA code) is substituted for another. This can change the effect of the gene. Image from the NHS National Genetics and Genomics Education Centre[9]Wikimedia Commons. (n.d.). Single nucleotide polymorphism substitution mutation diagram – cytosine to thymine. *Wikimedia Commons.* Available at: … Continue reading. Used under Creative Commons license.
We’ll take a look at the “genetic traits” identified in the Happy Head test and see if SNPs in the genes they assess might have predictive power. Most of these traits are related to drug efficacy: “Minoxidil Effectiveness”, “ Dutasteride Metabolism”, etc.
First, we’ll take a look at the limited cases where SNPs might actually provide some insight.
Minoxidil is FDA-approved for androgenic alopecia and is a reliable treatment with many years of clinical evidence. However, the efficacy of minoxidil can be unpredictable, and one source of the variation in response has been identified: an enzyme called SULT1A1. For minoxidil to work, it needs to first be converted into minoxidil sulfate in the body. This conversion is performed by sulfotransferases, most notably SULT1A1.
Consequently, the amount of SULT1A1 in the scalp may predict the amount of active minoxidil.[10]Pietrauszka, K., & Bergler-Czop, B. (2022). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: … Continue reading Therefore, the gene that produces SULT1A1, also called SULT1A1 (gene names get italicised), could impact minoxidil efficacy.
One study found that a SNP in the SULT1A1 gene can alter the activity of the enzyme.[11]Yu, X., Dhakal, I. B., Beggs, M., Edavana, V. K., Williams, S., Zhang, X., Mercer, K., et al. (2010). Functional genetic variants in the 3′-untranslated region of sulfotransferase isoform 1A1 … Continue reading However, they also concluded that this genetic variation can’t account for the differences in SULT1A1 activity observed in the total population.
The key factor in the efficacy of minoxidil is the activity of SULT1A1 in the scalp. Having the gene that makes a certain enzyme doesn’t mean that it’s expressed (turned on) in all the cells and tissues in the body. As such, there are likely to be multiple underlying mechanisms for differences in SULT1A1 activity in the scalp. Still, the evidence suggests that variations in the SULT1A1 gene could predict minoxidil activity.
There is also limited evidence that certain genes may be linked to responsiveness to dutasteride. A 2019 study looked at SNPs across the whole genomes of men who had taken dutasteride and assessed if specific genes correlated with response.[12]Rhie, A., Son, H.-Y., Kwak, S. J., Lee, S., Kim, D. Y., Lew, B.-L., Sim, W.-Y., et al. (2019). Genetic variations associated with response to dutasteride in the treatment of male subjects with … Continue reading
From a sample of 42 men, the researchers looked for genes in which SNPs most commonly occurred among the best and worst responders. They identified a handful of genes that may be associated with response to dutasteride.

Figure 3. Cumulative effect of SNPs on response to dutasteride. There is a correlation between SNPs in 6 genes and response to dutasteride. Adapted from Figure 1.[13]Rhie, A., Son, H.-Y., Kwak, S. J., Lee, S., Kim, D. Y., Lew, B.-L., Sim, W.-Y., et al. (2019). Genetic variations associated with response to dutasteride in the treatment of male subjects with … Continue reading Image used under Creative Commons license.
The sample size is quite small, and the correlation between the presence of SNPs and response to dutasteride isn’t that strong. Importantly, the predictive power of the identified genes is cumulative: the model the researchers used considers multiple genes simultaneously, rather than the predictive power of SNPs in individual genes.
The Happy Head Treatment Insights include four of the six genes most associated with dutasteride effectiveness in the study. However, these are spread over three different “traits”. The predictive power of their model is therefore likely to be weak. However, the evidence does provide some scientific basis for the insights from the genetic test.
We’ve looked at two examples where elements of Happy Head’s “genetic traits” might have some predictive power. SULT1A1 expression is likely associated with minoxidil efficacy, whereas genetic determinants of dutasteride efficacy would require stronger, more robust models that incorporate multiple genes to have any predictive value.
So what about the evidence supporting the other traits? Unfortunately, the DNA testing approach for personalized hair loss plans is largely based on over-extrapolation from data with little or no link to hair loss.
For example, Trait #5, Finasteride Effectiveness, lists SRD5A1 and SRD5A2 as genes related to this trait. The literature cited includes research that shows these genes are associated with prostate cancer and benign prostate hyperplasia, and one study that suggests variations in SRD5A2 can be associated with decreased risk of hair loss.[14]Hayes, V. M., Severi, G., Padilla, E. J. D., Morris, H. A., Tilley, W. D., Southey, M. C., English, D. R., et al. (2007). 5α‐reductase type 2 gene variant associations with prostate cancer risk, … Continue reading,[15]Li, X., Huang, Y., Fu, X., Chen, C., Zhang, D., Yan, L., Xie, Y., Mao, Y., & Li, Y. (2010). Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene … Continue reading
The implication is that, because SRD5A2 is associated with higher DHT levels, this would increase finasteride efficacy, as finasteride inhibits DHT. However, there is no clinical evidence at all to suggest this is the case.
Happy Head also cites a review paper that outlines some ways genetic markers could provide personalized AGA medicine. Interestingly, the authors of the paper work for a company called Fagron Genomics, which manufactures genetic tests for personalized AGA medicine.[16]Vila-Vecilla, L., Russo, V., & Torres de Souza, G. (2024). Genomic markers and personalized medicine in androgenetic alopecia: a comprehensive review. *Cosmetics.* 11(5). 148. Available at: … Continue reading
Trait #9 is Topical Retinoic Acid Effectiveness, which lists associated genes as CRABP2, CYP26B1, and RXRG. Retinoic acid is a common additive in hair loss, especially in the form of tretinoin. However, the research cited by Happy Head to support the use of these genes for prediction has no relation to hair loss or AGA. One paper discusses CRABP2 in skin aging, while another highlights the role of CYP26 in cancer.[17]Bielli, A., Scioli, M. G., D’Amico, F., Tarquini, C., Agostinelli, S., Costanza, G., Doldo, E., et al. (2019). Cellular retinoic acid binding protein-II expression and its potential role in skin … Continue reading,[18]Stevison, F., Jing, J., Tripathy, S., & Isoherranen, N. (2015). Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer. *Advances in Pharmacology.* 74. 373–412. … Continue reading
One study shows that changes in CRABP2 expression can increase serum retinoic acid levels in the umbilical cord of newborns. The relevance of the finding to hair loss is unclear.[19]Manolescu, D. C., El-Kares, R., Lakhal-Chaieb, L., Montpetit, A., Bhat, P. V., & Goodyer, P. (2010). Newborn serum retinoic acid level is associated with variants of genes in the retinol … Continue reading
The story is similar for the rest of the genetic traits: over-extrapolation of limited data from tangentially related studies. While genetic variation may be able to provide meaningful insights into hair loss drug efficacy in the future, there is currently insufficient data to back up Happy Head’s bold claims.
Latanoprost has become a popular component of topical hair loss treatments since a 2011 study suggested that it could increase hair density in men with AGA.[20]Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by … Continue reading However, serious concerns have been raised about the drug’s long-term safety and efficacy.
Originally developed as a medication for glaucoma, latanoprost was tested as a treatment for AGA when users of the drug noted increased hair growth in their eyelashes. The 2011 study demonstrated significant increases in hair counts and hair density for 0.1% topical latanoprost compared to placebo. However, 50% of men in the study didn’t show any improvement at all, or got worse.
Given these results from a small study (16 participants in total), a 2018 follow-up study compared latanoprost with minoxidil and explored combination therapies. Unfortunately, the study design was flawed, with high participant dropout rates and poorly defined study groups and procedures.[21]Bloch, L. D., Escudeiro, C. C., Sarruf, F. D., & Sakai Valente, N. Y. (2018). Latanoprost and minoxidil: comparative double-blind, placebo-controlled study for the treatment of hair loss. … Continue reading
Other studies investigating latanoprost for alopecia areata have proven inconclusive, with low response rates.[22]Mehta, J. S., Raman, J., Gupta, N., & Thoung, D. (2003). Cutaneous latanoprost in the treatment of alopecia areata. *Eye.* 17(3). 444–446. Available at: https://doi.org/10.1038/sj.eye.6700354,[23]Faghihi, G., Andalib, F., & Asilian, A. (2009). The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. *European Journal of Dermatology.* 19(6). 586–587. … Continue reading
As such, the verdict is still out on how effective latanoprost is at treating AGA and other hair loss conditions, with much more research required. Importantly, however, there are significant safety concerns associated with the drug.
Long-term use of latanoprost in patients with glaucoma can cause changes in iris color. Clinical data suggest this affects around 10% of people after a year of use, though some studies indicate the incidence could be as high as 70%.[24]Teus, M. A., Arranz-Marquez, E., & Lucea-Suescun, P. (2002). Incidence of iris colour change in latanoprost treated eyes. *British Journal of Ophthalmology.* 86(10). 1085–1088. Available at: … Continue reading Given the potential for systemic absorption of the drug when applied topically, or for the drug to enter the eyes when applied to the head, this could pose a risk for those using it as a hair loss cure. What’s more, hair loss treatments are typically taken consistently for many years, increasing lifetime exposure.
For glaucoma patients, the potential for changes in iris pigmentation is likely weighed against the benefits of a proven treatment for a debilitating condition. For those looking to treat hair loss, this risk is associated with a drug that is, so far, clinically unproven. In this context, the inclusion of latanoprost in hair-loss medications could be seen as irresponsible.
You can read our in-depth article about latanoprost here.
The use of propylene glycol is a widespread problem in the hair growth industry. It’s used as an excipient, meaning it serves as an “inactive” ingredient that helps to stabilize the active drugs or increase their availability. For drugs like minoxidil, which is poorly water-soluble, propylene glycol helps keep the solution uniform and consistent. It can also enhance the penetration of drugs by affecting the barrier of the stratum corneum, the outermost layer of the skin.[25]Carrer, V., Alonso, C., Pont, M., Zanuy, M., Córdoba, M., Espinosa, S., Barba, C., Oliver, M. A., Martí, M., & Coderch, L. (2020). Effect of propylene glycol on the skin penetration of drugs. … Continue reading,[26]Lessmann, H., Schnuch, A., Geier, J., Uter, W. (2005). Skin-sensitizing and irritant properties of propylene glycol. Contact Dermatitis. 53(5). 247-259. Available at: … Continue reading
Unfortunately, propylene glycol is also widely recognized as an irritant and a cause of contact dermatitis. This effect will only be compounded by once or twice daily application in topical formulations. One retrospective study found that 6.4% of minoxidil users experience some skin irritation, and many of these reactions will be the result of propylene glycol.[27]Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatology and Therapy (Heidelb). 13(5). 1157-1169. Available at: … Continue reading.
Skin irritation is a common reason for people to discontinue treatment with topical hair loss products. More careful formulation could lead to better adherence and, ultimately, better results.
The use of irritants like propylene glycol leads us to our fourth concern: the use of corticosteroids. Daily application of irritants to the scalp can lead to significant inflammation, which is actively detrimental to hair growth. To combat this, telehealth companies have turned to corticosteroids like hydrocortisone and fluocinolone. These steroids mimic the activity of cortisol to suppress inflammation and local immune response.[28]Stacey, S. K., & McEleney, M. (2021). Topical corticosteroids: choice and application. *American Family Physician.* 103(6). 337–343. Available at: https://pubmed.ncbi.nlm.nih.gov/33719380/
However, corticosteroids are designed for intermittent use when treating acute inflammation. They are not designed for twice-daily application over the course of many years. The steroids wear down the stratum corneum and epidermis, and can lead to long-term side effects like spider veins.[29]Torok, H. M., Jones, T., Rich, P., Smith, S., & Tschen, E. (2005). Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. *Cutis.* … Continue reading

Figure 4. Telangiectasias or Spider Veins. Long-term use of corticosteroids can wear down the skin, leading to long-term damage like spider veins.[30]Wikimedia Commons. (n.d.). Telangiectasias. *Wikimedia Commons.* Available at: https://commons.wikimedia.org/wiki/File:Telangiectasias.jpg Image used under Creative Commons License.
The corticosteroids used in hair growth products are typically low-potency, meaning they can be used for longer periods of time than high- or medium-potency products. Happy Head, for example, uses 1% hydrocortisone in its TopicalRx Finasteride & Minoxidil formulation. However, one study showed that after only 2 weeks, 1% hydrocortisone can lead to a significant reduction in epidermal thickness. Although the skin recovered after multiple weeks of use, , this was only after treatment was ended.[31]Aschoff, R., Schmitt, J., Knuschke, P., Koch, E., Bräutigam, M., & Meurer, M. (2011). Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved … Continue reading
In clinical trials, 1% hydrocortisone can lead to skin atrophy (thinning) after 6 to 12 months in a small percentage of patients.[32]Guin, J. D. (1981). Complications of topical hydrocortisone. *Journal of the American Academy of Dermatology.* 4(4). 417–422. Available at: https://doi.org/10.1016/S0190-9622(81)70040-9,[33]Lenane, P., Macarthur, C., Parkin, P. C., Krafchik, B., DeGroot, J., Khambalia, A., & Pope, E. (2014). Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a … Continue reading However, as we’ve already noted, hair loss products should be designed for daily application for many years. The unnecessary inclusion of potentially harmful ingredients, with no clear benefit, is a major concern.
One of the most important factors for drug producers and telehealth companies to consider when formulating their products is bioavailability: the extent to which the active ingredient is absorbed and used in the body. For common drugs like minoxidil and finasteride, this is fairly straightforward, as they are bioavailable on their own without much chemical modification.
Dutasteride, on the other hand, is poorly soluble in water and needs to be formulated with lipids. This is why it’s typically sold as a soft-gel capsule rather than a pill.
There are emerging concerns that some telehealth companies may be dispensing oral dutasteride in compounded capsule formulations that differ from the soft-gel, lipid-based versions used in clinical trials. When dutasteride is compounded as a powder and combined with other ingredients (such as oral minoxidil, vitamins, or biotin) into a single capsule, its absorption may be reduced.
To see if compounded dutasteride pills had reduced efficacy, we ran a small test. One participant took 3 pills of 0.5 mg powdered dutasteride (i.e., 1.5 mg total) and then checked changes in their blood DHT levels 12 hours later. Like finasteride, dutasteride works by reducing levels of DHT, and we’d normally expect to see around 80-90% reduction in serum DHT with only 1 mg of dutasteride, based on pharmacology data.[34]Gisleskog, P. O., Hermann, D., Hammarlund‐Udenaes, M., & Karlsson, M. O. (1998). A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors … Continue reading
However, we saw a reduction of only 13.6%. It is safe to assume that this level of DHT reduction will lead to substantially lower effectiveness for the drug. While rigorous, peer-reviewed research is needed to confirm the extent of these differences, the findings are enough to raise serious concerns.
Happy Head compounds its dutasteride with minoxidil and vitamin D3 in a “SuperCapsuleTM”. While these compounded pills are designed to make taking them daily easier, they may be blocking their hair growth capabilities. The lack of evidence for the efficacy of dutasteride when it’s compounded in this way makes it difficult to understand the benefits of combining the drugs rather than providing the tried-and-tested gel-form capsule.
Oral Dutasteride Hair gains bigger than finasteride? Dutasteride makes this possible, if prescribed* Take the next step in your hair regrowth journey. Get started today with a provider who can prescribe a topical solution tailored for you. *Only available in the U.S. Prescriptions not guaranteed. Restrictions apply. Off-label products are not endorsed by the FDA.Interested in Oral Dutasteride?
It is possible to provide personalized hair loss treatment. Rather than using marketing buzzwords and expensive, unproven DNA testing, vendors and telehealth companies can focus on the type and extent of hair loss, the tolerability of side effects, and ongoing management.
After years of advocating for better standards across the industry and pushing for improved formulations, we saw many telehealth brands move in the opposite direction. That experience ultimately led us to cofound Ulo, a telehealth company dedicated exclusively to hair growth, with the goal of fixing the problems we repeatedly observed and offering consumers treatment plans that are genuinely personalized and grounded in clinical evidence.
Ulo is built around three core principles: evidence, personalization, and consumer safety. Unlike some brands that rely heavily on unproven testing or trend-driven ingredients, Ulo states that it builds treatment plans around established therapies, physician oversight, and independently vetted formulations.
Ulo is committed to addressing several common industry practices highlighted in this article:
This model underscores what telehealth hair-loss providers could do differently: prioritize proven drug-delivery systems, avoid unnecessary or potentially harmful additives, provide genuine physician-led personalization, and set realistic expectations for outcomes.
The rise of telehealth hair-loss companies has made prescription treatments more accessible than ever, but accessibility does not always guarantee quality. While the concerns with Happy Head we’ve listed here raise serious questions about the brand and its products, they are not isolated to one company. Unfortunately, overstated claims, untested formulations, and unnecessary inclusion of risky components are common.
As this review highlights, differences in formulation, ingredient selection, and evidence standards can impact both safety and results. The takeaway is simple: effective hair-loss treatment is rarely about novelty or trendy new ingredients. Instead, prioritize providers that emphasize proven formulations, transparent evidence, and ongoing medical oversight.
References[+]
| ↑1 | Heath, A. C., Nyholt, D. R., Gillespie, N. A., & Martin, N. G. (2003). Genetic basis of male pattern baldness. *Journal of Investigative Dermatology.* 121(6). 1561–1564. Available at: https://doi.org/10.1111/j.1523-1747.2003.12615.x |
|---|---|
| ↑2 | Trüeb, R. M. (2002). Molecular mechanisms of androgenetic alopecia. *Experimental Gerontology.* 37(8–9). 981–990. Available at: https://doi.org/10.1016/S0531-5565(02)00093-1 |
| ↑3 | Sadasivam, I. P., Sambandam, R., Kaliyaperumal, D., & Dileep, J. E. (2024). Androgenetic alopecia in men: An update on genetics. *Indian Journal of Dermatology.* 69(3). 282. Available at: https://doi.org/10.4103/ijd.ijd_729_23 |
| ↑4 | Gupta, A. K., Dennis, D. J., Economopoulos, V., & Piguet, V. (2026). The genetic landscape of androgenetic alopecia: Current knowledge and future perspectives. *Biology.* 15(2). 192. Available at: https://doi.org/10.3390/biology15020192 |
| ↑5 | Yang, Y., Yang, J. Y., & Chen, X. J. (2020). Biotinidase deficiency characterized by skin and hair findings. *Clinics in Dermatology.* 38(4). 477–483. Available at: https://doi.org/10.1016/j.clindermatol.2020.03.004 |
| ↑6 | Biran, R., Zlotogorski, A., & Ramot, Y. (2015). The genetics of alopecia areata: new approaches, new findings, new treatments. *Journal of Dermatological Science.* 78(1). 11–20. Available at: https://doi.org/10.1016/j.jdermsci.2015.01.004 |
| ↑7 | Nelson, M. R., Marnellos, G., Kammerer, S., Hoyal, C. R., Shi, M. M., Cantor, C. R., & Braun, A. (2004). Large-scale validation of single nucleotide polymorphisms in gene regions. *Genome Research.* 14(8). 1664–1668. Available at: https://doi.org/10.1101/gr.2421604 |
| ↑8 | National Human Genome Research Institute. (n.d.). Single nucleotide polymorphisms (SNPs). *Genome.gov.* Available at: https://www.genome.gov/genetics-glossary/Single-Nucleotide-Polymorphisms-SNPs |
| ↑9 | Wikimedia Commons. (n.d.). Single nucleotide polymorphism substitution mutation diagram – cytosine to thymine. *Wikimedia Commons.* Available at: https://commons.wikimedia.org/wiki/File:Single_nucleotide_polymorphism_substitution_mutation_diagram_-_cytosine_to_thymine.png |
| ↑10 | Pietrauszka, K., & Bergler-Czop, B. (2022). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology / Postępy Dermatologii i Alergologii. 39(3). 472–478. Available at: https://doi.org/10.5114/ada.2020.99947 |
| ↑11 | Yu, X., Dhakal, I. B., Beggs, M., Edavana, V. K., Williams, S., Zhang, X., Mercer, K., et al. (2010). Functional genetic variants in the 3′-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. *Toxicological Sciences.* 118(2). 391–403. Available at: https://doi.org/10.1093/toxsci/kfq296 |
| ↑12 | Rhie, A., Son, H.-Y., Kwak, S. J., Lee, S., Kim, D. Y., Lew, B.-L., Sim, W.-Y., et al. (2019). Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. *PLoS One.* 14(9). e0222533. Available at: https://doi.org/10.1371/journal.pone.0222533 |
| ↑13 | Rhie, A., Son, H.-Y., Kwak, S. J., Lee, S., Kim, D. Y., Lew, B.-L., Sim, W.-Y., et al. (2019). Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. *PLoS One.* 14(9). e0222533. Available at: https://doi.org/10.1371/journal.pone.0222533 |
| ↑14 | Hayes, V. M., Severi, G., Padilla, E. J. D., Morris, H. A., Tilley, W. D., Southey, M. C., English, D. R., et al. (2007). 5α‐reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. *International Journal of Cancer.* 120(4). 776–780. Available at: https://doi.org/10.1002/ijc.22408 |
| ↑15 | Li, X., Huang, Y., Fu, X., Chen, C., Zhang, D., Yan, L., Xie, Y., Mao, Y., & Li, Y. (2010). Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer. *Mutagenesis.* 26(3). 371–383. Available at: https://doi.org/10.1093/mutage/geq103 |
| ↑16 | Vila-Vecilla, L., Russo, V., & Torres de Souza, G. (2024). Genomic markers and personalized medicine in androgenetic alopecia: a comprehensive review. *Cosmetics.* 11(5). 148. Available at: https://doi.org/10.3390/cosmetics11050148 |
| ↑17 | Bielli, A., Scioli, M. G., D’Amico, F., Tarquini, C., Agostinelli, S., Costanza, G., Doldo, E., et al. (2019). Cellular retinoic acid binding protein-II expression and its potential role in skin aging. *Aging (Albany NY).* 11(6). 1619. Available at: https://doi.org/10.18632/aging.101813 |
| ↑18 | Stevison, F., Jing, J., Tripathy, S., & Isoherranen, N. (2015). Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer. *Advances in Pharmacology.* 74. 373–412. Available at: https://doi.org/10.1016/bs.apha.2015.04.006 |
| ↑19 | Manolescu, D. C., El-Kares, R., Lakhal-Chaieb, L., Montpetit, A., Bhat, P. V., & Goodyer, P. (2010). Newborn serum retinoic acid level is associated with variants of genes in the retinol metabolism pathway. *Pediatric Research.* 67(6). 598–602. Available at: https://doi.org/10.1203/PDR.0b013e3181dcf18a |
| ↑20 | Blume-Peytavi, U., Lönnfors, S., Hillmann, K., & Garcia Bartels, N. (2012). A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. *Journal of the American Academy of Dermatology.* 66(5). 794–800. Available at: https://doi.org/10.1016/j.jaad.2011.05.026 |
| ↑21 | Bloch, L. D., Escudeiro, C. C., Sarruf, F. D., & Sakai Valente, N. Y. (2018). Latanoprost and minoxidil: comparative double-blind, placebo-controlled study for the treatment of hair loss. *Surgical & Cosmetic Dermatology.* 10(1). 39–43. Available at: https://doi.org/10.5935/scd1984-8773.20181011015 |
| ↑22 | Mehta, J. S., Raman, J., Gupta, N., & Thoung, D. (2003). Cutaneous latanoprost in the treatment of alopecia areata. *Eye.* 17(3). 444–446. Available at: https://doi.org/10.1038/sj.eye.6700354 |
| ↑23 | Faghihi, G., Andalib, F., & Asilian, A. (2009). The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows. *European Journal of Dermatology.* 19(6). 586–587. Available at: https://doi.org/10.1684/ejd.2009.0766 |
| ↑24 | Teus, M. A., Arranz-Marquez, E., & Lucea-Suescun, P. (2002). Incidence of iris colour change in latanoprost treated eyes. *British Journal of Ophthalmology.* 86(10). 1085–1088. Available at: https://doi.org/10.1136/bjo.86.10.1085 |
| ↑25 | Carrer, V., Alonso, C., Pont, M., Zanuy, M., Córdoba, M., Espinosa, S., Barba, C., Oliver, M. A., Martí, M., & Coderch, L. (2020). Effect of propylene glycol on the skin penetration of drugs. *Archives of Dermatological Research.* 312(5). 337–352. Available at: https://doi.org/10.1007/s00403-019-02017-5 |
| ↑26 | Lessmann, H., Schnuch, A., Geier, J., Uter, W. (2005). Skin-sensitizing and irritant properties of propylene glycol. Contact Dermatitis. 53(5). 247-259. Available at: https://doi.org/10.1111/j.0105-1873.2005.00693.x. |
| ↑27 | Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatology and Therapy (Heidelb). 13(5). 1157-1169. Available at: https://doi.org/10.1007/s13555-023-00919-x |
| ↑28 | Stacey, S. K., & McEleney, M. (2021). Topical corticosteroids: choice and application. *American Family Physician.* 103(6). 337–343. Available at: https://pubmed.ncbi.nlm.nih.gov/33719380/ |
| ↑29 | Torok, H. M., Jones, T., Rich, P., Smith, S., & Tschen, E. (2005). Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. *Cutis.* 75(1). 57–62. Available at: https://pubmed.ncbi.nlm.nih.gov/15732437/ |
| ↑30 | Wikimedia Commons. (n.d.). Telangiectasias. *Wikimedia Commons.* Available at: https://commons.wikimedia.org/wiki/File:Telangiectasias.jpg |
| ↑31 | Aschoff, R., Schmitt, J., Knuschke, P., Koch, E., Bräutigam, M., & Meurer, M. (2011). Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. *Experimental Dermatology.* 20(10). 832–836. Available at: https://doi.org/10.1111/j.1600-0625.2011.01335.x |
| ↑32 | Guin, J. D. (1981). Complications of topical hydrocortisone. *Journal of the American Academy of Dermatology.* 4(4). 417–422. Available at: https://doi.org/10.1016/S0190-9622(81)70040-9 |
| ↑33 | Lenane, P., Macarthur, C., Parkin, P. C., Krafchik, B., DeGroot, J., Khambalia, A., & Pope, E. (2014). Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial. *JAMA Dermatology.* 150(1). 47–50. Available at: doi:10.1001/jamadermatol.2013.5764 |
| ↑34 | Gisleskog, P. O., Hermann, D., Hammarlund‐Udenaes, M., & Karlsson, M. O. (1998). A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride. *Clinical Pharmacology & Therapeutics.* 64(6). 636–647. Available at: https://doi.org/10.1016/S0009-9236(98)90054-6 |
If you are noticing a receding hairline, widening part, reduced density, or progressively finer hairs, a blood DHT test can sound like a logical next step.
Dihydrotestosterone (DHT) is often described as the hormone responsible for androgenic alopecia (AGA). That framing can make the question seem straightforward. If DHT contributes to follicular miniaturization, wouldn’t a high DHT result show whether DHT is causing your hair loss?
There are other understandable reasons to want the test, too. You may be trying to distinguish AGA from stress-related shedding or a nutritional problem. You may want an objective explanation for a visible change in your hair. Or if you are considering a treatment such as finasteride, you may wonder whether your baseline DHT level could predict whether the medication will work for you.
A blood test can feel more definitive than looking at the scalp. It provides a number, a laboratory reference range, and apparently clear categories such as “normal” or “high.” But hair follicles do not respond only to the amount of DHT circulating in the bloodstream. They respond to a combination of local DHT production, androgen-receptor signaling, genetic susceptibility, and site-specific biology within the scalp.
That does not make serum DHT meaningless. It is a real hormonal measurement, and hormone testing can be appropriate when someone has signs of androgen excess or another possible endocrine disorder. However, interpreting a DHT result as a direct test for AGA can be misleading.
To understand why, it helps to separate two related but different questions:
Dihydrotestosterone, or DHT, is an androgen hormone created from the conversion of testosterone by 5-alpha-reductase.[1]Kinter KJ, Amraei R, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: … Continue reading

Dihydrotestosterone.[2]Wikimedia Commons. (no date). Dihydrotestosterone. Available at: https://commons.wikimedia.org/wiki/File:Androstanolone.svg (Accessed: September 2026)
DHT binds to the androgen receptor, a protein inside certain cells that acts as a molecular receiver for androgen signals. Once DHT binds, the androgen receptor can influence the expression of genes involved in tissue growth, development, and function.
There are several forms of 5-alpha-reductase. In hair biology, the two most often discussed are:
Both enzymes can contribute to the local conversion of testosterone into DHT, but their distribution and relative importance vary by tissue, sex, and scalp location.
DHT is not inherently “bad”. It has important physiological roles, particularly in male sexual development and in androgen-dependent tissues. The apparent contradiction is that DHT can stimulate terminal hair growth in some areas, such as the beard, chest, and other body sites, while contributing to progressive miniaturization of susceptible scalp follicles.
This is not because beard and scalp follicles receive different blood DHT concentrations, but because follicles in different areas of the body interpret androgen signals differently. Their local enzyme activity, androgen-receptor expression, surrounding signaling environment, and genetic programming all differ.[3]Itami, S., Sonoda, T., Kurata, S., Takayasu, S. (1994). Mechanism of action of androgen in hair follicles. Journal of Dermatological Sciences. S98-103. Available at: … Continue reading,[4]Rutberg, S.E., Kolpack, M.L., Gourley, J.A., Tan, G., Henry, J.P., Shander, D. (2006). Differences in expression of specific biomarkers distinguish human beard from scalp dermal papilla cells. … Continue reading
AGA is best understood as an interaction among several factors:
In other words, AGA is not simply “high DHT”. It is a condition in which particular scalp follicles are susceptible to androgen-mediated change.
Human hair follicle research illustrates this point. In a study of frontal and occipital scalp follicles from men and women with AGA, Sawaya and Price found site- and sex-specific differences in levels of androgen receptors, type I and type II 5-alpha-reductase, and aromatase.[5]Sawaya, M.E., Price, V.H. (1997). Different levels of 5-alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Journal of … Continue reading Frontal follicles had higher androgen-receptor and 5-alpha-reductase levels, while occipital follicles had higher aromatase levels. The differences were also quantitatively distinct between women and men.
This helps explain why hair loss often follows a pattern. In many men, the frontal scalp, temples, and vertex are more vulnerable than the occipital scalp. In many women, thinning is more apparent over the central scalp or widening part line, while the frontal hairline may be relatively preserved.
It also explains why balding and non-balding follicles can behave differently within the same person. Two follicles may be exposed to the same circulating DHT concentration, yet one remains stable while the other progressively miniaturizes.
Consider two people with the same serum DHT results:
The blood test may look similar. The clinical hair outcome may be completely different.
That is why a serum result cannot substitute for assessment of the scalp itself.
A blood DHT test measures the concentration of DHT in serum at one particular point in time. It does not directly measure what is occurring inside your scalp follicles.
A reported result can also be influenced by several factors:
DHT measurement can be technically challenging, especially at the relatively low concentrations often found in women. Where hormone testing is clinically necessary, assay quality matters. For example, endocrine guidance commonly emphasizes high-quality testosterone measurement and assessment of related markers such as sex hormone-binding globulin (SHBG), rather than treating DHT as a standalone diagnostic marker.[6]Elhassan, Y.S., Hawley, J.M., Cussen, L., Abbara, A., Clarke, S.A., Kempegowda, P., Dhillon-Smith, R.K., Thadani, P., Busby, M., Owusu-Darkwah, L., Marrington, R., Duncan, C.W., Semple, R.K., … Continue reading
A blood DHT result does not tell you:
Serum and scalp DHT are related pharmacodynamic measures: medications that reduce DHT systemically can also reduce it in the scalp. But they are not interchangeable measures. A serum concentration is not a direct readout of follicular androgen signaling or a diagnostic marker of scalp miniaturization.
The evidence is mixed. Some studies report group-level differences in circulating androgen markers between people with AGA and control participants. However, group differences do not automatically create a useful diagnostic test for an individual patient.
| Research finding | What it means clinically |
| A group with AGA has a higher average DHT value than a control group | DHT may be associated with AGA biology in that study population |
| Individual values overlap substantially between groups | A single DHT result cannot reliably distinguish who does and does not have AGA |
| DHT is not associated with hair-loss severity | A higher result does not necessarily mean more severe miniaturization |
| No validated diagnostic cutoff exists | A clinician cannot diagnose AGA solely from a serum DHT number |
For example, Urysiak-Czubatka and colleagues found elevated serum DHT levels in some participants with AGA and in controls. Mean differences were not significant across alopecia types and controls, and DHT elevation was not correlated with the degrees of hair loss progression.[7]Urysiak-Czubatka, I., Kmiec, M, L., Broniarczyk-Dyla, G. (2014). Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Advances in Dermatology … Continue reading The authors concluded that the diagnostic usefulness of serum DHT was questionable, particularly for women.
Similarly, a retrospective study in men reported higher average serum DHT and free testosterone in AGA cases than in controls, but found no significant differences in DHT or free testosterone across different clinical severity grades of AGA.[8]Zhang, Y., Xu, J., Jing, J., Wu, X., Lv, Z. (2018). Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men. Medical Science Monitor. 24. … Continue reading
These findings can coexist. DHT may be biologically relevant to AGA, yet remain a poor standalone diagnostic test. It stands to reason, therefore, that there is currently no validated serum DHT cutoff for diagnosing AGA.
No. A normal blood DHT level does not rule out AGA. A person can have normal circulating testosterone and DHT concentrations while genetically susceptible scalp follicles still respond to local androgen signaling with progressive miniaturization. The relevant issue is not only how much androgen is present in the blood, but how a particular follicle processes and responds to that androgen exposure.
This is particularly relevant to female pattern hair loss. Many women with a typical frontal-central or diffuse pattern of thinning have normal circulating androgen concentrations and no other obvious signs of androgen excess.
That does not mean androgens are irrelevant. It actually means that normal systemic hormone values do not rule out local androgen-mediated effects in susceptible follicles.
Hormone results should therefore be interpreted in context:
Not reliably.
Finasteride can substantially reduce DHT in both the blood and scalp at relatively low doses.[9]Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W.P., Cotterill, P.C., Thiboutot, D.M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S.J., Griffin, E.I., Weiss, D., … Continue reading But the relationship between DHT suppression and visible hair improvement is not linear: in clinical dose-ranging studies, 1 mg and 5 mg daily delivered similar hair-growth benefits.[10]Roberts, J.L., Fiedler, V., Imperato-McGinley, J., Whiting, D., Olsen, E., Shupack, J., Stough, D., DeVillez, R., Rietschel, R., Savin, R., Bergfeld, W., Swinehart, J., Funicella, T., Hordinsky, M., … Continue reading
These findings support the pharmacology of finasteride. It reduces DHT systemically and within the scalp. But they do not establish that a baseline serum DHT test predicts an individual’s clinical response.
The chain from medication to visible hair outcome includes several steps:
A post-treatment DHT result can show that the drug is exerting an expected hormonal effect, but it cannot tell you with certainty whether hair density, hair caliber, shedding, or progression will improve.
Baseline serum DHT has not been validated as a “finasteride responder test.” Nor does greater serum DHT suppression automatically mean proportionally greater regrowth.
Treatment response is better assessed through standardized clinical measures, such as:
For many people, stabilization rather than dramatic regrowth is still a meaningful treatment outcome.
Hormone testing can be appropriate when hair loss occurs alongside signs suggesting androgen excess or a broader endocrine condition. In that setting, testing should be used to investigate the clinical picture rather than as an AGA home-screening panel.
In women, clinicians might consider endocrine evaluation when there is:
Depending on the history and examination, a clinician may order tests such as total testosterone, a calculated or high-quality free-testosterone measurement, SHBG, DHEAS, 17-hydroxyprogesterone, prolactin, thyroid testing, or other targeted investigations.[11]Elhassan, Y.S., Hawley, J.M., Cussen, L., Abbara, A., Clarke, S.A., Kempegowda, P., Dhillon-Smith, R.K., Thadani, P., Busby, M., Owusu-Darkwah, L., Marrington, R., Duncan, W.C., Semple, R.K., … Continue reading,[12]Vujovic, A., Del Marmol, V. (2014). The Female Pattern Hair Loss: Review of Etiopathogenesis and Diagnosis. Biomed Research International. 767628. Available at: https://doi.org/10.1155/2014/767628 DHT is not generally recommended as the central test in a biochemical work-up for androgen excess.
The practical question is usually not “Is my DHT high enough to cause AGA?” It is, “Do my symptoms and examination suggest an endocrine disorder that needs investigation alongside my hair loss?”
AGA is primarily a clinical diagnosis. A dermatologist or hair-loss clinician evaluates the pattern of hair loss and looks for evidence of follicular miniaturization.
Assessment typically involves:[13]Kuczara, A., Waskiel-Burnat, A., Rakowska, A., Olsewska, M., Rudnicka, L. (2024). Trichoscopy of Androgenetic Alopecia: A Systematic Review. Journal of Clinical Medicine. 13(7). 1962. Available at: … Continue reading
Hair shaft diameter variability is one of the most useful trichoscopic features of AGA. Reviews identify hair-diameter diversity, vellus hairs, and the peripilar sign among valuable diagnostic indicators. A diagnostic guideline also recommends comparing density and hair caliber across scalp areas and notes that biopsy is generally reserved for cases of uncertainty or when alternative diagnoses, such as scarring alopecia or diffuse alopecia areata, must be considered.
The key diagnostic evidence is therefore found in the scalp, rather than in a single DHT concentration.
A serum DHT test is a biological measurement that can be relevant in certain endocrine contexts, and can also reflect the systemic hormonal effects of drugs like finasteride. But it does not measure follicular DHT exposure, androgen receptor sensitivity, local enzyme activity, genetic susceptibility, or the degree of scalp hair miniaturization.
Normal DHT cannot rule out AGA. High DHT cannot establish that AGA is the cause of hair loss. The most useful diagnostic question is “what is happening to the follicles on my scalp?” For suspected AGA, diagnosis and treatment monitoring should prioritize clinical pattern, standardized photographs, hair-caliber changes, trichoscopy where available, exclusion of competing diagnoses, and medication safety.
References[+]
| ↑1 | Kinter KJ, Amraei R, Anekar AA. Biochemistry, Dihydrotestosterone. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557634/ |
|---|---|
| ↑2 | Wikimedia Commons. (no date). Dihydrotestosterone. Available at: https://commons.wikimedia.org/wiki/File:Androstanolone.svg (Accessed: September 2026) |
| ↑3 | Itami, S., Sonoda, T., Kurata, S., Takayasu, S. (1994). Mechanism of action of androgen in hair follicles. Journal of Dermatological Sciences. S98-103. Available at: https://doi.org/10.1016/0923-1811(94)90040-x |
| ↑4 | Rutberg, S.E., Kolpack, M.L., Gourley, J.A., Tan, G., Henry, J.P., Shander, D. (2006). Differences in expression of specific biomarkers distinguish human beard from scalp dermal papilla cells. Journal of Investigative Dermatology. 126(12). 2583-2595. Available at: https://doi.org/10.1038/sj.jid.5700454 |
| ↑5 | Sawaya, M.E., Price, V.H. (1997). Different levels of 5-alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. Journal of Investigative Dermatology. 109(3). 296-300. Available at: https://doi.org/10.1111/1523-1747.ep12335779 |
| ↑6 | Elhassan, Y.S., Hawley, J.M., Cussen, L., Abbara, A., Clarke, S.A., Kempegowda, P., Dhillon-Smith, R.K., Thadani, P., Busby, M., Owusu-Darkwah, L., Marrington, R., Duncan, C.W., Semple, R.K., Quinton, R., O’Reilly, M.W. (2025). Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women. Clinical Endocrinology. 103(4). 540-566. Available at: https://doi.org/10.1111/cen.15265 |
| ↑7 | Urysiak-Czubatka, I., Kmiec, M, L., Broniarczyk-Dyla, G. (2014). Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. Advances in Dermatology and Allergology. 31(4). 207-215. Available at: https://doi.org/10.5114/pdia.2014.40925 |
| ↑8 | Zhang, Y., Xu, J., Jing, J., Wu, X., Lv, Z. (2018). Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men. Medical Science Monitor. 24. 7770-7777. Available at: https://doi.org/10.12659/MSM.913116 |
| ↑9 | Drake, L., Hordinsky, M., Fiedler, V., Swinehart, J., Unger, W.P., Cotterill, P.C., Thiboutot, D.M., Lowe, N., Jacobson, C., Whiting, D., Stieglitz, S., Kraus, S.J., Griffin, E.I., Weiss, D., Carrington, P., Gencheff, C., Cole, G.W., Pariser, D.M., Epstein, E.S., Tanaka, W., Dallob, A., Vandormael, K., Geissler, L., Waldstreicher, J. (1999). The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology. 41(4). 550-554. PMID: 10495374. Available at: https://pubmed.ncbi.nlm.nih.gov/10495374/ |
| ↑10 | Roberts, J.L., Fiedler, V., Imperato-McGinley, J., Whiting, D., Olsen, E., Shupack, J., Stough, D., DeVillez, R., Rietschel, R., Savin, R., Bergfeld, W., Swinehart, J., Funicella, T., Hordinsky, M., Lowe, N., Katz, I., Lucky, A., Drake, L., Price, V.H., Weiss, D., Whitmore, E., Millikan, L., Muller, S., Gencheff, C. (1999). Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology. 41(4). 555-563. PMID: 10495375. Available at: https://pubmed.ncbi.nlm.nih.gov/10495375/ |
| ↑11 | Elhassan, Y.S., Hawley, J.M., Cussen, L., Abbara, A., Clarke, S.A., Kempegowda, P., Dhillon-Smith, R.K., Thadani, P., Busby, M., Owusu-Darkwah, L., Marrington, R., Duncan, W.C., Semple, R.K., Quinton, R., O’Reilly, M.W. (2025). Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women. Clinical Endocrinology. 103(4). 540-566. Available at https://doi.org/10.1111/cen.15265 |
| ↑12 | Vujovic, A., Del Marmol, V. (2014). The Female Pattern Hair Loss: Review of Etiopathogenesis and Diagnosis. Biomed Research International. 767628. Available at: https://doi.org/10.1155/2014/767628 |
| ↑13 | Kuczara, A., Waskiel-Burnat, A., Rakowska, A., Olsewska, M., Rudnicka, L. (2024). Trichoscopy of Androgenetic Alopecia: A Systematic Review. Journal of Clinical Medicine. 13(7). 1962. Available at: https://doi.org/10.3390/jcm13071962 |
For decades, the medical treatment of androgenic alopecia (AGA), or male and female pattern hair loss, has largely centered on two strategies:
Those approaches can help many people, but neither works for everyone. It’s also clear that some miniaturized follicles stop producing cosmetically meaningful hairs, even when androgen signaling is reduced. This has created demand for treatments that target other aspects of the hair-loss process: inflammation, fibrosis, growth-factor signaling, stem-cell activity, and hair-cycle regulation.
ABS-201 represents one of the more unusual attempts. Rather than targeting DHT, 5-alpha-reductase, or the androgen receptor directly, ABS-201 is designed to block the prolactin receptor (PRLR). ABS-201 is a monoclonal antibody. It is a laboratory-made protein designed to bind to a specific target (in this case, the prolactin receptor). By binding to that receptor, ABS-201 aims to prevent prolactin from activating it.
That target may initially sound surprising. Prolactin is best known for its role in lactation, but it is also active in the skin and hair follicles. Laboratory research suggests that prolactin signaling can promote the transition of follicles into catagen, the regressive phase of the hair cycle, and can inhibit hair shaft growth under experimental conditions.[1]Jin, S-E., Kim, J., Sung, J-H. (2024). Recent approaches of antibody therapeutics in androgenetic alopecia. Frontiers in Pharmacology. 15(1434961). Available at: … Continue reading
The question is whether blocking this pathway can meaningfully reverse hair follicle miniaturization in humans with AGA. At present, the answer is not known. ABS-201 is in an early Phase 1/2a trial, and the publicly available human data so far are primarily preliminary safety and pharmacokinetic data rather than proof of hair regrowth.[2]absci. (no date). Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR). Absci. Available at: … Continue reading
To understand the rationale and its limitations, we interviewed Absci’s founder (we made a video you can watch here). He shared the company’s interpretation of earlier anti-PRLR research, preliminary experiments using human scalp tissue, and its expectations for the ongoing ABS-201 trial. In this article, we examine those claims alongside the published evidence and the questions that remain unanswered.
Hormones and signaling proteins influence cells by binding to receptors, molecular “docking stations”, on or within cells. When prolactin binds the prolactin receptor, it activates downstream signaling pathways that can alter cell behavior.
ABS-201 is a monoclonal antibody designed to bind the prolactin receptor (PRLR). In principle, an antibody that occupies the receptor and prevents productive prolactin signaling could dampen prolactin-related activity in tissues that express PRLR, including the hair follicle. Human scalp follicles have been shown to express both prolactin and PRLR, supporting the idea that local prolactin signaling may influence follicle biology.[3]Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, which Serves as an Autocrine and/or Paracrine … Continue reading
ABS-201 is not designed to lower circulating prolactin concentrations in the way dopamine agonists can be used to treat certain forms of hyperprolactinemia. Instead, it is intended to interfere with signaling at the prolactin receptor itself.
That makes the proposed hair-loss mechanism distinct from that of finasteride or dutasteride. Those drugs reduce conversion of testosterone to DHT, thereby addressing an established driver of follicular miniaturization in genetically susceptible scalp regions. ABS-201 instead aims to alter a separate signaling pathway that may affect hair-cycle regulation. In cultured human scalp follicles, prolactin exposure has been associated with reduced hair shaft elongation, reduced keratinocyte proliferation, increased apoptosis, and earlier entry into catagen, the regressive phase of the hair cycle.[4]Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, which Serves as an Autocrine and/or Paracrine … Continue reading,[5]Grymowicz, M., Rudnicka, E., Podfigurna, A., Napierala, P., Smolarczyk, R., Smolarczyk, K., Meczekalski, B. (2020). Hormonal Effects on Hair Follicles. International Journal of Molecular Sciences. … Continue reading
It is important not to overstate this distinction. AGA remains, by definition and by extensive evidence, an androgen-responsive condition. A prolactin-receptor antibody should not yet be framed as proving that prolactin is “upstream of DHT”, or as replacing the central role of androgen signaling in pattern hair loss. That proposed hierarchy remains a hypothesis, not a settled conclusion.
Absci’s founder did not reject the role of androgens when we spoke. Instead, he proposed that prolactin might interact with androgen signaling in the hair follicle.
“Androgens are a part of it, but from what we’re seeing, prolactin actually sits potentially upstream of the androgen receptor.”
In other words, Absci thinks prolactin may influence how hair follicles respond to androgens. The company says its laboratory findings support that possibility, but it has not been shown that prolactin drives androgen signaling in people with AGA, or that blocking prolactin could replace the need to target DHT.
The case for studying PRLR in hair loss did not begin with ABS-201. Human scalp follicles can both express prolactin and respond to it, meaning that the follicle may be both a source and a target of local prolactin signaling. In organ-culture experiments, prolactin and its receptor were more strongly expressed during catagen, the phase in which a follicle regresses after active growth.[6]Jin, S-E., Kim, J., Sung, J-H. (2024). Recent approaches of antibody therapeutics in androgenetic alopecia. Frontiers in Pharmacology. 15(1434961). Available at: … Continue reading
In the same line of research, exposure of isolated human scalp follicles to relatively high concentrations of prolactin reduced hair-shaft elongation, reduced proliferation of hair-matrix keratinocytes, increased markers of apoptosis (programmed cell death), and promoted premature entry into catagen.[7]Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine … Continue reading
That does not mean that every person with AGA has elevated serum prolactin, nor does it establish that prolactin is the dominant cause of pattern hair loss. In fact, clinical literature on hyperprolactinemia and diffuse hair loss is mixed; moderately elevated circulating prolactin does not appear to be a universal explanation for hair shedding.[8]Lutz, G. (2012). Hair loss and hyperprolactinemia in women. Dermato Endocrinology. 4(1). 65-71. Available at: https://doi.org/10.4161/derm.19472
One argument for investigating PRLR in AGA concerns local rather than systemic signaling. A person may not need dramatically abnormal blood prolactin for local PRLR signaling to influence hair follicle biology.
In our interview, Absci’s founder emphasized the distinction between prolactin circulating in the blood and prolactin produced locally in tissues. As he put it:
“You could have normal systemic levels of prolactin that come from the pituitary, but an increased level of prolactin within the scalp”
This could help explain why a normal blood test would not necessarily rule out local PRLR signaling. It does not, however, demonstrate that excess local prolactin causes AGA or identify which patients might benefit from blocking its receptor.
In a small ex vivo study using scalp tissue from two healthy women, estrogen increased prolactin and prolactin receptor expression in selected regions of the skin and hair follicles. The researchers also found increased expression of both genes in cultured outer root sheath cells. But the study did not test whether these changes affected hair growth or whether blocking PRLR would alter estrogen’s effects. It therefore complicates a simple “more PRLR means more hair loss” explanation without telling us whether a PRLR-blocking antibody would help or harm people with AGA.[9]Langan, E.A., Ramot, Y., Hanning, A., et al. (2010). Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair … Continue reading
Much of the excitement around prolactin-receptor blockade in hair loss stems from preclinical work on a related anti-PRLR antibody, originally developed within Bayer’s research program and subsequently licensed for development as HMI-115. The treatment has been reported to produce unusually striking regrowth in stump-tailed macaques, a primate species often used in AGA research because some animals develop patterned scalp hair loss that resembles aspects of human male- and female-pattern hair loss.[10]Ekkehard, M., Joachim, S., Jorn, K., Christiane, O. (2017). Prolactin receptor antibody for male and female pattern hair loss. World Intellectual Property Organization. Available at: … Continue reading Reports describe an increase in terminal hair growth and persistent changes after treatment withdrawal.
The macaque findings are genuinely intriguing for two reasons. First, primate data are more relevant to human hair biology than standard mouse studies. Mouse hair follicles cycle in synchronized waves across large areas of skin; human scalp follicles cycle asynchronously. A drug that generates a dramatic result in mice can therefore fail to translate to human pattern hair loss.
Second, the reported durability of the macaque response, if confirmed in fully published data, would be particularly notable. AGA is chronic and progressive, and most established treatments require continued use to preserve their benefits. A therapy that triggered durable restoration of follicular growth capacity after dosing stopped would challenge the usual treatment model.
However, animal findings, no matter how dramatic, are not clinical proof. Differences in species, dosing, disease biology, hair-cycle timing, study design, and measurement methods can all affect translation. Until robust human trial data are available, the primate studies should be treated as a reason for cautious interest, not a prediction of equivalent results in people.
HMI-115 is another anti-PRLR monoclonal antibody currently being developed by Hope Medicine. In a small open-label Phase 1b study, the company reported that 12 male participants experienced a mean increase of 14 non-vellus hairs per cm2 after 24 weeks of treatment.[11]Hope Medicine. (2024). Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia. Hope Medicine. Available at: https://www.hopemedinc.com/company-release-37 … Continue reading
The result was encouraging enough to justify further research, but it cannot establish efficacy on its own. The study was small, open-label, and lacked a placebo control. Hair counts can be affected by photography, hair-clipping technique, image analysis, the definition of “non-vellus” hair, natural cycling variation, and regression toward the mean. Without randomization and a placebo comparison, it is impossible to know how much of the observed change was due to the drug.
HMI-115 nonetheless helped validate PRLR as a clinically testable hair-loss target and advanced to a larger randomized Phase 2 evaluation.
ABS-201 targets the same receptor, but is a different antibody developed by Absci, not a new name for HMI-115. The company says it used generative AI and experimental validation to engineer ABS-201 with properties intended to support infrequent dosing. In its interim Phase 1 update, Absci estimated a half-life of at least 65 days following a single intravenous dose, suggesting the possibility of two or three injections over six months if future studies confirm the pharmacology and clinical benefit.[12]Absci. (2026). Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR). Absci. Available at: … Continue reading
That is a potentially attractive practical profile. Pattern hair loss treatments often struggle with adherence: topical therapies can be burdensome, and daily tablets may be unacceptable to some patients. An intermittently administered antibody could be convenient, but convenience only matters if the therapy ultimately proves safe, effective, and appropriately priced.
Absci’s central argument is pharmacological rather than simply practical. Its founder told us the company modeled receptor occupancy (the proportion of prolactin receptors bound by the drug at a given dose and time point) using publicly disclosed pharmacokinetic data for HMI-115 and estimated that occupancy in the earlier human study rose to roughly 70-73% before fluctuating.
Absci contrasts this with its prediction that ABS-201 can maintain PRLR occupancy above 90% for approximately six months. It proposes that insufficiently sustained blockage could help explain why HMI-115’s early human hair-count findings were more modest than the macaque results. These are company-generated estimates and an explanation to be tested, not proof that HMI-115 participants were underdosed.
A central part of Absci’s rationale for ABS-201 is receptor occupancy.
In our interview, Absci described a hypothesis that anti-PRLR treatment may need to maintain very high receptor occupancy, reportedly above 90%, to reduce prolactin signaling sufficiently to produce meaningful hair-growth effects. The company has publicly described its ABS-201 dose selection as targeting predicted PRLR occupancy above 90% and has contrasted this with the lower estimated occupancy for HMI-115.[13]Absci. (no date). ABS-201™ for Androgenetic Alopecia. Absci. Available at: https://www.absci.com/abs-201-case-study/ (Accessed: September 2026) The founder’s concern is that partial blockade might leave substantial signaling intact.
“Even if you’re at 60, 70, even 80% receptor occupancy, you could still have full activity of the actual pathway until you block it substantially.”
Whether this degree of signaling reserve operates in human AGA-affected follicles, and whether 90% is the relevant threshold, remains to be established.
The general pharmacology is plausible. Drug binding and biological effect do not always move in a simple, one-to-one fashion. Some biological systems have what pharmacologists call receptor reserve or signaling reserve, meaning that activating a fraction of the available receptors can still generate a substantial downstream response because cellular signaling pathways amplify the original signal.[14]Berg, K.A., Clarke, W.P. (2018). Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. International Journal of Neuropsychopharmacology. 21(10). 962-977. Available at: … Continue reading In such a system, partially blocking a receptor may reduce signaling without being sufficient to produce a clinically visible effect.
Think of it like a faucet rather than a light switch. Turning the tap halfway off reduces water flow, but it may still leave enough water running to fill a container. If prolactin-receptor signaling in a miniaturizing follicle has a similar degree of biological reserve, a treatment may need to block a large number of receptors before downstream signals involved in follicle regression are meaningfully reduced.
However, the key uncertainty is the number itself. Public academic literature does not currently establish that human scalp follicles require 90% PRLR occupancy for hair regrowth, nor does it establish that 60-70% occupancy is inadequate. The proposed threshold appears to be a company-specific, model-informed development assumption rather than a clinically validated cutoff for AGA.
This also means the suggestion that earlier HMI-115 studies were “underdosed” should be treated with caution. It is one possible explanation for the modest, uncontrolled Phase 1b signal reported with HMI-115, but it is not a proven conclusion. Small sample size, absence of a placebo group, dose exposure, treatment duration, participant selection, hair-counting methodology, and intrinsic differences between antibodies could all contribute to the results.
For ABS-201, the most informative future analysis would connect four pieces of evidence:
If high and sustained PRLR blockade does matter, the next question is which biological process it might alter within the follicle. Absci’s leading explanation centers on follicular stem and progenitor cells.
Hair follicles contain epithelial stem-cell populations, including cells in the bulge region. During normal cycling, stem cells and their progeny participate in rebuilding the lower follicle and initiating a new anagen (growth) phase. In AGA, researchers have suggested that stem cells may be retained while their conversion into downstream progenitor populations becomes impaired. In other words, the follicle may retain some regenerative “hardware” but struggle to activate it effectively.
This concept has scientific support. Experimental studies have linked androgen signaling and altered Wnt/beta catenin signaling to impaired hair-follicle stem cell differentiation in AGA.[15]Kretzschmar, K., Cottle, D.L., Schweiger, P.J., Watt, F.M. (2015). The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. Journal of Investigative Dermatology. 135(11). … Continue reading
Absci’s proposed model is that PRLR blockade may help sustain anagen, reduce catagen-associated signaling, and restore a more growth-permissive environment for follicular stem and progenitor cells. In our interview, Absci presented preliminary experiments using cultured human scalp tissue. In samples from three men with AGA, the company compared untreated tissue with tissue exposed to prolactin, ABS-201, or both. It reported greater hair-shaft growth and more follicles remaining in the growth phase after exposure to ABS-201 over a three-day period. Added prolactin had the opposite effect, while the combined treatment appeared to counteract it.
Absci also described ex vivo findings involving K15-positive stem-cell markers, CD34-positive progenitor-cell markers, and collagen XVII. The company interprets these observations as suggesting that PRLR blockade could protect or improve the follicular stem cell environment. But marker changes over several days cannot establish that an injection restores that environment, reverses miniaturization, or produces durable regrowth in a patient.
We asked whether Absci had tested non-balding scalp tissue alongside the AGA-affected samples. Its founder confirmed that it had not.
Without that comparator, these experiments cannot tell us whether the response is distinctive to balding follicles.
Terms such as “stem-cell activation,” “follicle regeneration,” and “reversal of miniaturization” can sound more definitive than the current evidence warrants. Ex vivo human scalp experiments are useful because they use human tissue, but they do not replicate the full biology of chronic pattern hair loss in a living person. They cannot, on their own, establish that a treatment will produce durable cosmetic improvement in a large, diverse patient population.
The ongoing HEADLINE study, registered as NCT07317544, is a randomized, double-blind, placebo-controlled Phase 1/2a trial of ABS-201 in healthy adults with and without AGA. The study is designed to enroll up to 227 participants across single- and multiple-ascending-dose cohorts.[16]National Library of Medicine. (2026). Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia. National Library of Medicine. Available at: … Continue reading

Absci’s study design.[17]Absci. (no date). Absci’s HEADLINE Study Design. Absci. Available at: https://www.absci.com/abs-201-case-study/ (Accessed: September 2026)
The early single-ascending-dose portion tested intravenous doses of 150 mg, 450 mg, 900 mg, and 1,800 mg. In Absci’s June 2026 update, 32 healthy adults had been enrolled across four cohorts. The company reported no serious adverse events at the data cutoff. Treatment-related adverse events were described as mild, with headache the most commonly reported event overall.
These findings are preliminary and blinded, which means they cannot yet tell us whether ABS-201 is more effective than, or even meaningfully different from, placebo for hair regrowth.
The multiple-ascending dose component is evaluating subcutaneous doses of 300 mg, 600 mg, and 1,200 mg in participants with AGA. The trial includes the following objective endpoints:
These measures matter because hair count alone does not tell the complete cosmetic story. A person may grow more hair, but if that hair remains very thin or lightly pigmented, the visual benefit may be limited. Conversely, increases in shaft diameter and pigmentation can materially contribute to perceived density.
Absci plans to report an exploratory 13-week readout in December 2026. In our recent interview, its founder described this as a “directional” assessment rather than a definitive efficacy test. He said the company had not set a firm hair-count target for that readout, but hoped it would show a path toward an increase of more than 30 hairs/cm2 at 26 weeks. Participants will also be followed for a year after treatment to assess how any changes evolve over time.
The presence of placebo control, blinding, objective imaging, and multiple hair endpoints makes the HEADLINE trial substantially more informative than an uncontrolled before-and-after study. Still, early trials can be difficult to interpret, especially in the context of hair loss.
One issue is prior treatment washout. The trial excludes topical minoxidil use within 3 months of screening; oral minoxidil and other stimulators within 6 months; finasteride within 6 months; and dutasteride within 12 months.
These washout periods are not inherently inappropriate. They are common attempts to reduce confounding. But they leave interpretive questions. People who discontinue minoxidil may experience delayed shedding and subsequent changes in the hair cycle. People stopping anti-androgen therapy may also continue to change for months after discontinuation. If these dynamics are unevenly distributed between the treatment and placebo groups, particularly in a modestly sized trial, they can complicate hair-count results.
A second issue is the definition of hairs counted by imaging systems. In AGA trials, the threshold chosen to classify a hair as non-vellus or terminal can materially influence apparent efficacy. Readers should look not only for the headline change in hairs/cm2 but also for the pre-specified diameter threshold, baseline hair characteristics, changes in width, standardized photography methods, and placebo-adjusted results.
A third issue is the ascertainment of safety. PRLR is not a scalp-exclusive target, and systematic anti-PRLR therapy may affect tissues beyond the hair follicle. A credible program needs more than a low count of voluntarily reported adverse events. It should transparently describe how adverse events were elicited, categorized, adjudicated, and followed up, as well as how laboratory and hormonal parameters were monitored and how pregnancy-related risks were managed.
During our interview, we asked specifically how adverse events would be elicited and whether outcomes relevant to reproductive health would be actively assessed. The founder discussed the rigor of the clinical team and the blinded, placebo-controlled design, but did not provide details on adverse-event collection methods or a list of reproductive endpoints in his answer. That does not imply that the trial lacks appropriate monitoring, but it does mean that we should be on the lookout for them in the protocol and, when available, in the results.
We also asked how Absci intends to present its interim results, given how difficult hair-loss trial announcements can be to interpret when they emphasize selective subgroups or changes from baseline without a clear placebo comparison. The founder responded:
“I can promise you that we will have a non-controversial data cut. It’s going to be clear-cut data that will be easy to interpret.”
That is a useful commitment, but its value will depend on the actual release of interpretable treatment-versus-placebo results, endpoint definitions, sample sizes, missing-data information, and safety findings.
The best outcome for ABS-201 would not simply be “more hairs than baseline”. A convincing Phase 2 signal would include several converging features:
ABS-201 is one of the more scientifically interesting drugs in the current AGA pipeline because it targets a pathway outside the conventional DHT/minoxidil framework. Research in human hair follicles, mice, and primates supports the idea that PRLR signaling can influence hair cycling and regression.
But plausibility is not the same as proof. The early ABS-201 safety data are reassuring, in a limited sense, in that a small, blinded, single-dose study had not identified any serious safety signals as of the company’s June 2026 update. However, they do not yet demonstrate that the drug regrows hair.
Our interview made Absci’s hypothesis more specific: the company believes that sustained, high-level PRLR blockade could affect hair cycling and the follicular stem-cell environment in ways earlier anti-PRLR treatment may not have achieved. It also clarified what we still cannot know, from the absence of non-balding comparator tissue in the ex vivo experiments to the unvalidated human receptor-occupancy threshold. The placebo-controlled ABS-201 results will be far more informative than either a compelling mechanism or striking macaque photographs. Until then, ABS-201 remains a promising research question, not a proven hair-loss treatment.
References[+]
| ↑1, ↑6 | Jin, S-E., Kim, J., Sung, J-H. (2024). Recent approaches of antibody therapeutics in androgenetic alopecia. Frontiers in Pharmacology. 15(1434961). Available at: https://doi.org/10.3389/fphar.2024.1434961 |
|---|---|
| ↑2 | absci. (no date). Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR). Absci. Available at: https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial |
| ↑3, ↑4 | Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human Scalp Hair Follicles Are Both a Target and a Source of Prolactin, which Serves as an Autocrine and/or Paracrine Promoter of Apoptosis-Driven Hair Follicle Regression. The American Journal of Pathology. 168(3). 748-756. Available at: https://doi.org/10.2353/ajpath.2006.050468 |
| ↑5 | Grymowicz, M., Rudnicka, E., Podfigurna, A., Napierala, P., Smolarczyk, R., Smolarczyk, K., Meczekalski, B. (2020). Hormonal Effects on Hair Follicles. International Journal of Molecular Sciences. 21(15). 5342. Available at: https://doi.org/10.3390/ijms21155342 |
| ↑7 | Foitzik, K., Krause, K., Conrad, F., Nakamura, M., Funk, W., Paus, R. (2006). Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. American Journal of Pathology. 168(3). 748–756. Available at: https://doi.org/10.2353/ajpath.2006.050468 |
| ↑8 | Lutz, G. (2012). Hair loss and hyperprolactinemia in women. Dermato Endocrinology. 4(1). 65-71. Available at: https://doi.org/10.4161/derm.19472 |
| ↑9 | Langan, E.A., Ramot, Y., Hanning, A., et al. (2010). Thyrotropin-releasing hormone and oestrogen differentially regulate prolactin and prolactin receptor expression in female human skin and hair follicles in vitro. British Journal of Dermatology. 162(5), 1127–1131. Available at: https://doi.org/10.1111/j.1365-2133.2010.09676.x |
| ↑10 | Ekkehard, M., Joachim, S., Jorn, K., Christiane, O. (2017). Prolactin receptor antibody for male and female pattern hair loss. World Intellectual Property Organization. Available at: https://patentimages.storage.googleapis.com/56/cc/a3/7d3ac32f1537b2/WO2019011719A1.pdf (Accessed: 23 April 2023) |
| ↑11 | Hope Medicine. (2024). Positive Outcome from a Phase Ib Study in Australia Treating Patients with Androgenic Alopecia. Hope Medicine. Available at: https://www.hopemedinc.com/company-release-37 (Accessed: September 2026) |
| ↑12 | Absci. (2026). Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR). Absci. Available at: https://investors.absci.com/news-releases/news-release-details/absci-announces-positive-interim-phase-1-data-headlinetm-trial (Accessed: September 2026) |
| ↑13 | Absci. (no date). ABS-201™ for Androgenetic Alopecia. Absci. Available at: https://www.absci.com/abs-201-case-study/ (Accessed: September 2026) |
| ↑14 | Berg, K.A., Clarke, W.P. (2018). Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity. International Journal of Neuropsychopharmacology. 21(10). 962-977. Available at: https://doi.org/10.1093/ijnp/pyy071 |
| ↑15 | Kretzschmar, K., Cottle, D.L., Schweiger, P.J., Watt, F.M. (2015). The Androgen Receptor Antagonizes Wnt/β-Catenin Signaling in Epidermal Stem Cells. Journal of Investigative Dermatology. 135(11). 2753-2763. Available at: https://doi.org/10.1038/jid.2015.242 |
| ↑16 | National Library of Medicine. (2026). Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic Alopecia. National Library of Medicine. Available at: https://clinicaltrials.gov/study/NCT07317544 (Accessed: September 2026) |
| ↑17 | Absci. (no date). Absci’s HEADLINE Study Design. Absci. Available at: https://www.absci.com/abs-201-case-study/ (Accessed: September 2026) |
Finding the right hair loss treatment can feel overwhelming, and expert guidance is essential to identify the best formula for your needs. The PhD-led team at Perfect Hair Health leverages emerging research and close collaborations with top innovators to provide readers with the most accurate and actionable reviews of hair restoration offerings. Topical finasteride is one of the most sought-after treatments on the market, boasting clinical support, targeted results, and easy application.
This comprehensive guide to the top-rated topical finasteride products is based on extensive research, expert recommendations, and the latest consumer feedback. Whether you’re just beginning your hair health journey or searching for better hair loss solutions, this article provides valuable information on safe and effective treatment options. Our recent partnership with Ulo enhances this guide with privileged insights on clinical findings and state-of-the-art protocols.
Read on for specialized guidance, insightful reviews, and proven recommendations of topical finasteride preparations from today’s leading brands.
Compounded finasteride for DHT control targeted at the follicle. Get prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Here’s a side-by-side comparison of our top recommended topical finasteride treatments. Read on for more details on each of these excellent products.
| Product | Price | Finasteride % | Customization | Application |
| Ulo | $64+/month | 0.005% – 0.2% | High | Solution |
| Strut Health | $59 | 0.1-0.25% | Medium | Solution/Gel |
| Happy Head | $59-99/month | 0.3% | Medium | Liposomal Gel |
| Roman | $50/month | 0.3% | Low | Spray |
| Hims | $35+/month | 0.3% | Low | Spray |
First, we will briefly explore the science behind topical finasteride, including its mechanism of action in treating hair loss and the advantages of topical formulations.
Topical finasteride is a clinically proven treatment for androgenic alopecia (AGA), a type of hair loss that affects more than 50% of men by the age of 50.[1]Jang, W.S., Son, I.P., Yeo, I.K., Park, K.Y., Li, K., Kim, B.J., Seo, S.J., Kim, M.N., Hong, C.K. (2013). The Annual Changes of Clinical Manifestation of Androgenetic Alopecia Clinic in Korean Males … Continue reading AGA is caused by dihydrotestosterone (DHT), a testosterone-derived hormone that damages hair follicles, causing them to shrink and produce thinner hair. Finasteride reduces DHT levels by inhibiting the enzyme 5-alpha-reductase, protecting the hair follicles to stop hair loss and encourage new growth.[2]Duran, R, C-D., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez. (2024). The Biology and Genomics of … Continue reading
While orally administered finasteride has been in use since 1997, topical formulations are a relatively new development. When applied to the scalp, finasteride provides targeted treatment with a reduced risk of systemic side effects associated with oral preparations. Topical finasteride is shown to reduce DHT levels on the scalp for greater hair count and density with comparable effectiveness to oral finasteride.[3]Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018). A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in … Continue reading
Numerous studies confirm that topical finasteride slows and reverses hair loss by boosting hair thickness, density, and growth cycles. These results are enhanced when combined with other topical treatments like minoxidil. Due to minimal systemic absorption and attendant side effects, topical formulas are considered a safer choice for prolonged use. Overall, topical finasteride is prized among clinicians and patients as a safe, effective, and convenient solution to pattern hair loss.[4]Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018). A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in … Continue reading,[5]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading
Because topical finasteride is applied directly to the scalp, it offers localized therapy and avoids the side effects associated with oral finasteride’s systemic exposure. Here is a brief overview of this and other primary advantages of topical formulas:
In short, research data indicate that topical finasteride yields comparable results with a more favorable safety profile than oral finasteride, making it a better option for long-term treatment. Further benefits of topical formulations include greater dose precision, synergistic adjuvants like minoxidil, and a range of delivery methods to support compliance.[6]Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018). A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in … Continue reading,[7]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading
When selecting the best topical finasteride products, we adhered to the following evaluation criteria, which are thoroughly supported by clinical findings and customer feedback.[8]Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray … Continue reading,[9]Suchonwanit, P., Iamsumang, W., Leerunyakul, K. (2020). Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. Journal … Continue reading
We assessed scientific data, DHT decrease rates, and real-world testimonies of hair count increases. The top products deliver measurable results in 3-6 months with continuous improvements in hair density throughout the first year and beyond.
Because finasteride is a prescription-only treatment, we verified that providers adhere to all safety regulations, including proper prescribing and monitoring protocols. Leading suppliers also provide full ingredient transparency to help assess potential side effects.
Premium brands offer treatment customization options tailored to patients’ needs and preferences, maximizing outcomes beyond those achieved with traditional, standardized approaches. These include concentration adjustments, synergistic add-on ingredients such as minoxidil, and various delivery methods.
Successful treatment outcomes depend on long-term compliance and a positive user experience. Factors such as ease of application, clear instructions, manageable dose frequency, and responsive support help ensure uninterrupted treatment.
The best providers balance superior quality with transparent and affordable pricing models that cover doctor consultations, prescriptions, and follow-up care. These are especially important concerns in the telehealth landscape, where many subpar platforms employ opaque billing practices to stack on hidden fees and unexpected charges.
When choosing the product that best meets your hair loss treatment needs, consider the extent of your hair loss and treatment aims, such as basic upkeep or intensive restoration. Also account for your preferred delivery method (i.e., gel, solution, or spray), desired add-ons, medical support requirements, and budget.
With the above key factors in mind, let’s turn now to our top recommended options that each offer unique advantages sure to satisfy.

| Pros: | Cons: |
| ✓ Clinically-proven combination therapy | ✗ Prescription products are only available in the USA |
| ✓ True personalization with custom concentrations and medical consultations | |
| ✓ PhD-scientist formulated | |
| ✓ Ongoing medical monitoring and a user-friendly platform | |
| ✓ Quality-tested ingredients free of irritants |
Ulo’s combination formula of high-strength finasteride with prescription-grade minoxidil takes the top spot, reflecting the platform’s commitment to providing safe, scientifically proven hair loss treatments tailored to meet individual needs. Every Ulo product is developed by a team of PhD scientists who deliver innovative interventions in hair restoration.
Their advanced finasteride and minoxidil solution blocks DHT and stimulates new growth in a targeted dual treatment that is proven superior to monotherapies in clinical trials. Ulo’s finasteride formulas are uniquely customizable and available in different concentrations (0.005% for maintenance and 0.2% for stronger protocols), with a series of synergistic add-ons like caffeine to boost circulation, tretinoin for better absorption, and melatonin for antioxidant protection.
The deluxe treatment begins at $64 per month, which includes an onboarding medical consultation to assess each client’s needs, a physician-crafted treatment plan, and continued dermatologist oversight. All Ulo products are strictly sourced from pharmacies that adhere to safety and quality regulations. The clinic’s licensed dermatologists provide customized treatment regimens with free home prescription deliveries and ongoing support.
Bottom Line: Ulo’s individualized hybrid treatment is the ultimate in advanced hair restoration technology. With precise formulation and continuous medical supervision, this tailored solution delivers exceptional results for a low monthly subscription fee starting at $64. Ulo’s guiding dedication to safety and efficacy makes this full-service platform the best option for those who are serious about combating hair loss.

| Pros: | Cons: | |
| ✓ Custom-compounded topical finasteride formulas (with optional add-ons) | ✗ Not available internationally, and currently cannot ship to Arkansas | |
| ✓ Online consult and prescriptions from U.S. board-certified physicians | ✗ Auto-refills by default; some reviews report difficulty canceling and customer service gaps | |
| ✓ Multiple formulation options (gel or solution; adjustable finasteride strength) | ||
| ✓ Convenient telehealth model with free, discreet shipping in most U.S. states. |
Strut Health is a U.S.-based telehealth provider offering customized topical finasteride for AGA. After an online questionnaire and photo-based evaluation, a board-certified clinician designs a compounded formula that may contain finasteride alone or in combination with other actives like minoxidil, tretinoin, fluocinolone, or biotin. The company’s finasteride hair-loss formulas typically use 0.1-0.25% topical finasteride, with optional minoxidil concentrations up to 7.5% and tretinoin in a gel or solution base, giving flexibility to tailor potency and tolerability.
Our in-house lab testing showed that Strut Health’s finasteride product contained the correct concentrations of ingredients (finasteride, minoxidil, and tretinoin), indicating that they can be trusted to provide a quality product.
However, there are trade-offs. Strut does not accept insurance, and pricing for topical finasteride (often around the mid-range of the telehealth market) may add up for long-term use. The company currently ships to nearly all U.S. states but cannot ship to Arkansas, and there is no international service. Public reviews highlight convenience for many users but also recurring concerns about auto-refills and difficulty canceling, as well as frustration with customer support responsiveness and refund policies.
Bottom Line: Strut Health’s topical finasteride offers a flexible, telehealth-delivered alternative for patients who want DHT-targeted treatment without taking a daily pill, with customizable formulas that can include or exclude minoxidil and other actives. Its convenience, physician oversight, and compounding flexibility are strong advantages, but subscription-based pricing and mixed customer service reviews may give more budget-conscious patients pause.

| Pros: | Cons: |
| ✓ Medical oversight by board-certified dermatologists | ✗ Price rises from $59 to $99 after the first six months |
| ✓ Higher concentrations of 0.3% finasteride + 8% minoxidil | ✗ Higher concentrations may increase side effect risk |
| ✓ Made with a delayed-release liposomal base | ✗ Gel formula cannot be customized |
| ✓ User-friendly platform and follow-up care | ✗ May irritate sensitive skin |
| ✓ Affiliate programs available | ✗ Possible shipping and customer service concerns |
Our next selection is from Happy Head, known for unique formulations and dermatologist oversight. The Topical Super Solution features a more concentrated combination of 0.3% finasteride with 8% minoxidil for targeted hair restoration.
Available in a mess-free pump dispenser, this gel is made with the brand’s proprietary liposomal delivery base that boosts scalp penetration with timed medication release and once-daily application. This helps minimize bloodstream absorption, reducing potential side effects, and is a notable safety feature for higher finasteride doses. That said, some ingredients in the carrier base should not be used on sensitive skin. Other products from the brand are more customizable and can be adapted to sensitive skin.
The starting price of Happy Head’s treatment is competitive at $59 for a monthly subscription that covers dermatologist oversight and prescription deliveries. However, the price increases to $99 after the first six months. Some reviews cite a lack of transparency regarding potential side effects, as well as intermittent shipping delays and inconsistent customer service.
Bottom Line: Happy Head’s potent dual therapy is a useful option for patients with intermediate to severe hair loss and normal skin. The delayed-release gel base increases medication absorption for more targeted treatment while decreasing systemic side effects and requires application only once a day. Advantages include dermatologist support and attractive pricing, but patients should be aware of reviews citing shipping and customer service issues.

| Pros: | Cons: |
| ✓ Transparent and competitive price of $50 per month | ✗ Contains potential irritants not suitable for sensitive skin |
| ✓ High finasteride concentration (0.3%) for aggressive treatment | ✗ High fixed concentration with a greater risk of side effects |
| ✓ Includes minoxidil and tretinoin for synergistic effects | ✗ Limited customization options |
| ✓ Convenient once-daily application | ✗ Standard delivery system lacks advanced features |
| ✓ Established telehealth provider with medical supervision |
Roman offers a simple topical finasteride formula designed for convenient, once-daily use and focused intervention. The spray contains three active ingredients: high-dose 0.3% finasteride with 6% minoxidil and tretinoin to enhance absorption. This product delivers a potent dose of finasteride on par with premium rivals through a no-frills spray system.
While tretinoin may improve minoxidil absorption, Roman’s spray has some drawbacks for users with sensitive skin or systemic side effect concerns. The 0.3% finasteride concentration cannot be tailored to individual response, and the standard delivery system does not have delayed-release technology to offset the risk of systemic absorption as seen in Happy Head’s liposomal gel. Inactive ingredients like ethyl alcohol and propylene glycol are also known irritants.
Roman is an accessible option for many users. The transparent and fixed monthly fee of $50 covers doctor consultations, prescription deliveries, and unlimited follow-ups. However, users with sensitive skin or more complex treatment needs may find Roman’s standardized and less gentle formulation to be unsuitable for long-term compliance.
Bottom Line: Roman offers a potent and affordable dual finasteride therapy with telehealth support features. Although it is not customizable like leading alternatives, this spray is a convenient choice for individuals with moderate to severe hair loss who can tolerate high dosages and potential irritants.

| Pros: | Cons: |
| ✓ Lowest starting rate of $35+/month | ✗ Standardized approach that lacks customization |
| ✓ Well-known brand with recognized platform | ✗ Minimal ongoing medical support |
| ✓ Simple ordering process and rapid shipping | ✗ Contains irritants not suitable for sensitive skin and fixed high dose |
| ✓ No lengthy consultations required | ✗ Basic telehealth features without specialist care |
| ✓ High-dose dual treatment | ✗ Concerns about the price transparency of subscription tiers |
Hims is a well-known brand that offers topical finasteride through its streamlined telemedicine platform. Their fixed-dose spray of 0.3% finasteride and 6% minoxidil is a convenient and affordable option without the customization features of premium competitors, appealing to those who value simplicity over tailored care.
Like similar high-dose sprays, this standardized formula from Hims is not suitable for patients with sensitive skin, complex treatment needs, or those requiring a lower maintenance dose.
This provider’s appeal is its wide accessibility. With low prices starting at just $35 per month, quick doctor consultations, and shipping in all 50 states, Hims is a gateway brand for many new hair loss patients. However, this entry-level approach lacks the treatment personalization and close medical supervision of established specialty providers.
Bottom Line: Hims’ topical finasteride spray is an affordable and easily accessible option backed by a recognized brand name. Although Hims fails to offer the precision treatment and close medical oversight of premium alternatives, it is a mainstay for patients who prioritize low costs and convenience.
After a comprehensive evaluation, Ulo emerges as our top choice for topical finasteride in 2026. Their genuine customization, science-backed formulations, and ongoing dermatologist supervision set the gold standard for personalized hair restoration.
While competitors offer standardized protocols or unproven technologies, Ulo delivers verified results through precision medicine tailored to individual needs. For patients seeking the highest quality care, Ulo’s scientific rigor and safety-first approach make it the clear winner.
Realistic treatment expectations facilitate long-term compliance and successful outcomes. Medical research has established the following evidence-based benchmarks of expected improvements with topical finasteride use as prescribed to treat androgenetic alopecia.
Clinical Timeline for Topical Finasteride Results
| Timeframe | What to Expect | Clinical Evidence |
| 3 Months | Terminal hair count starts to improve; increases in total hair count may not yet be observable | [10]B. Piraccini et al. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European … Continue reading,[11]Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, … Continue reading |
| 6 Months | Noteworthy increases in hair counts (total and terminal); visible increase in vertex hair growth | [12]B. Piraccini et al. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European … Continue reading,[13]Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, … Continue reading,[14]A. Rossi et al. (2020). Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 … Continue reading |
| 12-18 Months | Maximum improvement is typically observed; continuous improvements in hair coverage and density | [15]A. Rossi et al. (2020). Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 … Continue reading |
In the first 6-8 weeks, some experience a temporary increase in shedding as finasteride prompts new growth cycles to start. This is expected and is an encouraging indication that the treatment is taking effect.
There are several different topical finasteride delivery formats that each offer unique advantages to suit individual needs and preferences, as follows:
The best formulation choice depends on hair and skin type, lifestyle, and personal preferences. Patients are encouraged to consult a doctor to determine the ideal format for their individual needs.
Topical finasteride is noted for its favorable safety profile, especially in contrast to oral formulations; however, understanding potential risks and proper monitoring practices is recommended.
Topical finasteride is an important development in hair loss therapeutics, providing comparable results with a superior safety profile to oral medications. In today’s market, Ulo’s individualized, clinically rigorous approach sets a benchmark for comprehensive care, outperforming competitors primarily focused on budget or convenience factors.
Successful treatment with topical finasteride requires patience and persistence. Advances in hair restoration technology suggest that tailored medicine, rather than standardized approaches, represents the future. Ready to begin your own journey toward hair restoration?
Visit Ulo today to see how customized topical finasteride can enhance your results.
Yes, topical finasteride is a prescription-only medication in the USA. This ensures proper diagnosis, medical supervision, dosage, and quality control. Reputable telehealth providers like Ulo make the prescription process quick and easy via video consultations with licensed doctors specialized in hair restoration therapies. These elite platforms also offer ongoing medical supervision to monitor side effects and adjust treatment for optimization.
Avoid online platforms that market finasteride products without a prescription or those that fail to perform a proper medical consultation before prescribing treatment. Reputable platforms employ board-certified doctors licensed to practice in your state of residence with credentials clearly displayed or offered upon request. Sourcing topical finasteride products from unauthorized vendors without a prescription risks hazardous side effects and ineffectiveness.
Yes, topical finasteride can be beneficially combined with treatments like minoxidil, a popular additive in many available products. These formulas often pair finasteride with additional synergistic ingredients such as antioxidants, vasodilators, antifungals, and absorption enhancers.
Topical finasteride can also be safely used in conjunction with most non-prescription hair products, hair transplants, and low-level laser treatments. However, it should not be combined with oral DHT blockers (i.e., oral finasteride or dutasteride) due to the risk of systemic side effects. Medical approval is necessary before starting new treatments.
Most patients report stabilization of hair loss after 3-4 months, with notable regrowth in 6-12 months. Shedding within the first 6-8 weeks of starting treatment is considered normal and indicative of the treatment’s efficacy. Because DHT suppression takes time to significantly impact hair growth cycles, consistency and patience are essential for optimal treatment outcomes.
Treatment outcomes can vary between individuals. Consult a doctor to discuss influencing factors and form realistic treatment expectations. This grounded approach facilitates better long-term adherence and more desirable results.
Although the FDA has not yet authorized topical finasteride to treat AGA in women, it is occasionally prescribed for off-label use in postmenopausal patients with female pattern hair loss (FPHL). Because topical finasteride risks fewer hormonal adverse effects than oral finasteride, it is considered a safer option in these cases.
However, women of reproductive age are often recommended to completely avoid finasteride due to the risk of severe birth defects from exposure while pregnant. Non-pregnant women who may plan for pregnancy in the future should abstain from finasteride use unless under strict medical supervision with suitable contraception established. Newer low-dose formulations designed for women show promise, although more study is needed to verify long-term viability.
Ultimately, women considering finasteride therapy should speak with an experienced clinician to go over their medical history, weigh the benefits and risks, and review alternative treatment options, such as FDA-approved topical minoxidil.
The average monthly cost of topical finasteride without insurance can vary from $35 to $90, depending on the source, formulation, and services rendered. Direct-pay telehealth providers tend to offer lower rates than conventional in-person dermatology clinics with combined pharmacy fees. Bespoke formulas with advanced excipients can command higher prices. Patients should account for continued costs to budget for long-term treatment, which is often required for beneficial outcomes.
If regular topical finasteride treatment is discontinued, hair loss is expected to return gradually within 2-3 months of cessation. Most patients report a rebound to their baseline hair loss level within 6-12 months. Because this regression is gradual, patients have some flexibility regarding therapy breaks or medication transitions if needed.
Compared to oral finasteride, topical formulations have few contraindications due to lower systemic absorption rates. For your safety, inform your prescribing doctor of all current medications, especially blood thinners and other hormonal drugs. While topical finasteride is often safely combined with common medications, there may be exclusions.
Topical finasteride should be kept at room temperature out of direct light, moisture, and heat. With proper storage, most products maintain stability for 12-24 months. While refrigeration isn’t required, it may boost shelf life in temperate climates. Be sure to check expiration dates and safely dispose of expired products.
Yes, prescribed topical finasteride may be stored in carry-on luggage during domestic travel. When traveling internationally, it is recommended to bring the original prescription and label. Be mindful of TSA restrictions on liquid volumes over 3.4 oz.
Topical finasteride is applied directly to a clean and dry scalp with the product applicator. While specific instructions vary with delivery method, in general, the hair should be parted to expose the scalp and allow targeted application to the desired areas. Patients should consult product instructions for precise indications and dosing protocols. Avoid wetting hair for several hours after application, and thoroughly wash hands after use.
References[+]
| ↑1 | Jang, W.S., Son, I.P., Yeo, I.K., Park, K.Y., Li, K., Kim, B.J., Seo, S.J., Kim, M.N., Hong, C.K. (2013). The Annual Changes of Clinical Manifestation of Androgenetic Alopecia Clinic in Korean Males and Females: A Outpatient-Based Study. Annals of Dermatology. 25(2). 181-188. Available at: https://doi.org/10.5021/ad.2013.25.2.181 |
|---|---|
| ↑2 | Duran, R, C-D., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez. (2024). The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia. International Journal of Molecular Sciences. 25(5). 2542. Available at: https://doi.org/10.3390/ijms25052542 |
| ↑3, ↑4, ↑6, ↑16 | Lee, S.W, Juhasz, M., Mobasher, P., Ekelem, C., Mesinkovska, N.A. (2018). A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women. Journal of Drugs in Dermatology. 17(4). 457-463. Available at: PMID: 29601622 |
| ↑5, ↑7, ↑17 | Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738 |
| ↑8 | Piraccini, B.M., Blume-Peytavi, U., Scarci, F., Jansat, J.M., Falques, M., Otero, R., Tamarit, M.L., Galvan, J., Tebbs, V., Massana, E. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 36(2). 286-294. Available at: https://doi.org/10.1111/jdv.17738 |
| ↑9, ↑18 | Suchonwanit, P., Iamsumang, W., Leerunyakul, K. (2020). Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. Journal of Dermatological Treatment, 33(2), 643–648. Available at: https://doi.org/10.1080/09546634.2020.1782324 |
| ↑10, ↑12 | B. Piraccini et al. (2021). Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology, 36: 286 – 294. https://doi.org/10.1111/jdv.17738 |
| ↑11, ↑13 | Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Chinese medical journal. Available at: https://doi.org/10.1097/CM9.0000000000003495 |
| ↑14, ↑15 | A. Rossi et al. (2020). Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients. Dermatology Practical & Conceptual, 10 (2020). https://doi.org/10.5826/dpc.1002a39 |
| ↑19 | Cheng Zhou et al. (2025). Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Chinese medical journal. Available at: https://doi.org/10.1097/CM9.0000000000003495 |
| ↑20 | Mysore, V. (2012). Finasteride and sexual side effects. Indian Dermatology Online Journal, 3(1), 62. https://doi.org/10.4103/2229-5178.93496. |
Millions worldwide experience hair loss, with androgenic alopecia (AGA) as the leading cause. Also known as male- or female-pattern hair loss, AGA becomes more prevalent with age. It affects a majority of men over the age of 50 and a substantial number of postmenopausal women. Hair thinning and balding due to AGA is not just a cosmetic concern but can significantly detract from self-esteem and overall quality of life.
Among popular hair restoration treatments, topical dutasteride is a breakthrough solution to the serious side effects and plateaued results many experience. This potent DHT blocker offers more targeted therapeutic benefits with minimal systemic exposure and reduced risk. However, not all topical dutasteride products meet quality standards, so specialized guidance is key to selecting the right formula.
The PhD-directed board of experts at Perfect Hair Health draws from the latest clinical data and verified customer feedback to deliver this comprehensive guide to the best topical dutasteride products available in 2026. Through our research collaboration with leading innovators in the field, including our partnership with Ulo, we provide unique insights into the most advanced hair restoration protocols.
Read on for our detailed analysis and evidence-based product recommendations.
Get maximum DHT control in a targeted topical solution. Customize your formula to you and get prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Here’s a brief comparison of our most highly recommended topical dutasteride products. Continue reading for in-depth reviews.
| Product | Price | Dutasteride % | Delivery Method | Key Feature |
| Ulo | $84+/month | 0.02%-0.2% | Solution | PhD-developed extensive customization |
| XYON Health | $129+/month | 2% | Gel | Patented controlled-release technology |
| Strut Health | $69/month | Up to 0.1% | Gel | Alcohol-free and customizable |
| Blends | ~$45/month (90-day supply) | 0.3% | Gel | Proprietary hydrating formula |
| Happy Head | $59-89+/month | Up to 0.3% | Solution | Potency and customization |
| Maximus | $54.99 | 0.1% | Gel | Customizability, including the addition of antihistamines |
| Miiskin | $30-59 + Rx cost | Variable, custom | Solution | No subscription required |
| Musely | $33/month | 0.3% | Solution | Lowest cost option |
To begin, we will briefly explore the scientific background of topical dutasteride, including how it works to treat AGA and the distinct benefits of topical preparations.
Topical dutasteride is valued as a breakthrough treatment for AGA due to its powerful and targeted effects on the molecular levels of hair loss. The root cause of AGA is the testosterone-derived hormone dihydrotestosterone (DHT), which adheres to hair follicles and leads to follicular degeneration and hair loss over time. Dutasteride is classified as a DHT blocker, reducing DHT levels on the scalp to combat hair loss.[1]R. Cuevas-Díaz Durán., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carrillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez, A. (2024) The Biology and … Continue reading,[2]Dhurat, R., Sharma, A., Rudnicka, L., Kroumpouzos, G., Kassir, M., Galadari, H., Wollina, U., Lotti, T., Golubović, M., Binic, I., Grabbe, S., & Goldust, M. (2020). 5‐Alpha reductase … Continue reading
Among DHT-blocking treatments, dutasteride is considered the most potent due to its dual enzyme activity. Testosterone is converted into DHT through two forms of 5α-reductase enzymes: Type I is located in the skin and sebaceous glands, and Type II is in the hair follicles. Finasteride inhibits only Type II for about 70% DHT reduction, while dutasteride inhibits both types to elicit greater DHT suppression (up to 93% in the skin and 99% in the follicles).[3]Arif, T., Dorjay, K., Adil, M., & Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update.. Current clinical pharmacology, 12 1, 31-35. Available at: … Continue reading
Dutasteride’s powerful DHT inhibition leads to greater therapeutic outcomes in hair restoration. Clinical findings indicate dutasteride’s superior effects on hair count and mass in comparison to finasteride in terms of both quantitative and temporal metrics. While finasteride’s benefits tend to plateau after about 12 months of treatment, dutasteride demonstrates continued improvements up to 12 months and beyond.[4]Harcha, W., Martínez, J., Tsai, T., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy … Continue reading
Studies show that topical dutasteride is a safer option than oral with comparable and often better treatment outcomes. When applied locally to the scalp, dutasteride delivers targeted treatment with limited systemic exposure and a reduced risk of serious side effects. If present, adverse reactions to topical dutasteride tend to be transient and mild, in contrast to oral dutasteride’s potential systemic side effects like sexual dysfunction and mood disorders.[5]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,[6]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading
This and other clinically proposed advantages of topical dutasteride are briefly summarized as follows:
Plus, patients have a choice of different delivery methods (e.g., sprays, gels, solutions), which can offer greater convenience and adherence.
Combined, these factors locate topical dutasteride as a more effective and flexible hair restoration intervention with a greater safety profile than its oral counterpart.[7]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,[8]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading,[9]Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal … Continue reading
To help navigate the topical dutasteride market, we developed these quality benchmarks grounded in clinical expertise, scientific evidence, and patient feedback.
Quality dutasteride products demonstrate notable DHT reduction and improved hair growth within 3-6 months, with these effects continuing over 12 months or longer. The products recommended in this article were assessed based on documented DHT reductions, verified patient feedback, and peer-reviewed studies.
Given the prescription status of topical dutasteride, we verified each telehealth provider’s legitimacy in terms of physician supervision, adherence to legal requirements, and adherence to sound safety protocols. These include proper diagnostic procedures before prescribing, as well as close follow-up care to monitor for side effects and adjust the treatment as needed for optimal outcomes. Trustworthy providers exclusively partner with licensed physicians specialized in hair restoration.
When it comes to quality assurance, suppliers must partner only with authorized domestic pharmacies to source their compounded medications. Complete ingredient transparency and labeling of allergens establishes acceptable safety profiles.
Varied patient needs call for customizable treatments that exceed standard one-size-fits-all protocols. Outstanding brands provide a personalized approach through extensive customization options, including variable concentrations, adjuvant blends (e.g., minoxidil), and various delivery formats (e.g., solutions and controlled-release gels). These tailored therapies are physician-crafted to safely elicit the best results.
Prolonged, uninterrupted treatment is necessary to achieve positive results, highlighting the importance of user comfort and satisfaction. Practical considerations, such as application convenience, precise instructions, manageable dose routines, and excellent customer support, all influence treatment adherence.
Because treatment sustainability also depends on affordability, we also examined billing models and price transparency. Premium suppliers have honest and reasonable pricing that covers primary treatment costs (prescriptions, consultations, deliveries, and monitoring), free of hidden fees that are common among telehealth providers.
Begin by assessing your hair loss level and treatment objectives, determining whether moderate maintenance or intensive regrowth protocols are needed. Further considerations include application method preferences (gels, solutions, sprays, etc.), helpful adjuvants, and skin sensitivities. Budgetary limitations and your required level of physician involvement also come into play.
With these factors in mind, let’s dive into the following product reviews that highlight distinct approaches.

| Pros: | Cons: |
| ✓ PhD-scientist developed with thorough customization | ✗ USA-only service for prescription treatments |
| ✓ Customizable concentrations with adjuvant ingredients | |
| ✓ Board-certified physician oversight, monitoring, and tailored treatment protocols | |
| ✓ Verified quality and safety | |
| ✓ Full price transparency and free shipping |
The top position goes to Ulo, a leader in clinical rigor and precision hair loss medicine. Known for their highly individualized treatments, cutting-edge protocols, and PhD oversight, Ulo’s offerings are among the most comprehensive and patient-centered available. Their dual topical dutasteride solution with minoxidil delivers potent DHT suppression and new growth stimulation, proven to be more effective than either therapy alone.
Ulo’s topical systems feature customization across the spectrum, from dutasteride concentration (0.02% for lighter therapy to 0.2% for more aggressive intervention) to adjuvants like absorption enhancers, antioxidants, and vasodilators. Premium services include licensed dermatologist consultations, tailored treatment plans, and continued medical oversight, with a starting monthly subscription price of $84 and no added fees.
All Ulo safety and medication sourcing practices adhere to the highest regulatory standards, including partnerships with certified domestic pharmacies and strict follow-up protocols. Full ingredient transparency and irritant-free formulations establish excellent safety profiles. Patients enjoy free prescription deliveries and responsive support through Ulo’s sleek telehealth platform.
Our Verdict: Ulo’s advanced dual formula harnesses the power of customized topical dutasteride to deliver the gold standard of hair loss therapy. With PhD-developed formulas, genuine customization, and complete medical oversight, this platform offers proven benefits through a transparent monthly subscription that starts at $84. Their dedication to upholding the highest standards of safe and effective care positions Ulo as the best choice for your hair restoration needs.

| Pros: | Cons: |
| ✓ Proprietary SiloxysSystem™ Gel for timed release | ✗ Premium pricing at $129/month |
| ✓ Highest concentration (2% dutasteride) for aggressive protocols | ✗ Limited customization options |
| ✓ Physician oversight | ✗ Not recommended for sensitive skin |
| ✓ Service area includes the US and Canada |
XYON stands out for its innovative, technology-driven approach, exemplified by its proprietary SiloxysSystem Gel delivery base, which contains delayed-release topical dutasteride at a high concentration of 2%. This controlled-release method allows for a higher dutasteride concentration and more targeted treatment, protecting against systemic exposure and potentially serious side effects.
While this treatment is a strong option for advanced hair loss cases due to its potency, XYON emphasizes its advanced and proven delivery method over treatment customization features. Monotherapy involves a fixed dose of 2% dutasteride, which may be too strong for some patients. Excipients include ingredients like silicone that are not recommended for sensitive skin.
XYON’s premium price point reflects not only its forward-looking strategy but also its high medical standards, as the platform offers qualified physician support throughout the process.
Our Verdict: XYON’s topical dutasteride formulation delivers maximum treatment with minimal systemic risk through its unique delayed-release carrier gel. It is recommended for advanced hair loss patients who can tolerate higher doses and potential irritants, particularly those who don’t mind paying a premium for its advanced technology development.

| Pros: | Cons: |
|---|---|
| ✓ Good value at $69/month with full customization | ✗ Lower maximum dutasteride concentration (0.1%) |
| ✓ Alcohol-free, preservative-free options available | ✗ Moderate doses may be insufficient for advanced hair loss cases |
| ✓ Extensive customization of adjuvant ingredients | ✗ Occasional gaps in customer service are cited |
| ✓ Licensed medical oversight with hair loss specialization | ✗ Service area excludes Arkansas |
Strut Health is a solid mid-tier option that balances accessible pricing with medically guided customization, emphasizing cost-effectiveness over potency. The preservative- and alcohol-free dutasteride gel contains a moderate 0.1% dutasteride, with tailored add-on options including minoxidil, biotin, and tretinoin at varying concentrations. Capped at such a middling dose, this gentle gel formula is best for mild to moderate hair loss patients with sensitive or dry skin.
Fluocinolone, a corticosteroid, is also available as an adjuvant. While leading providers like Ulo avoid such ingredients due to potential safety concerns, Strut provides appropriate safety disclaimers and maintains an overall emphasis on ingredient transparency, backed by medical oversight.
Strut’s subscription fee of $69 per month for topical dutasteride treatment is a competitive offering, covering consultations, follow-ups, and prescription shipping. Patients cite flexible cancellation policies and rapid home deliveries as notable benefits. We detected some mixed reviews regarding delayed customer service responses and logistical issues.
Our Verdict: Strut Health offers a compelling value proposition with its topical dutasteride gel, priced at only $69 per month, and features that rival those of more expensive providers. The gentle formula with a limited 0.1% dutasteride concentration suits patients with moderate treatment needs who are seeking a budget-friendly option with flexible add-ons and legitimate medical oversight.

| Pros: | Cons: |
| ✓ Doctor-founded with hair restoration specialization | ✗ 90-day supply requirement may not suit all patients |
| ✓ Competitive pricing at ~$45/month (90-day supply) | ✗ Fixed formula despite “personalized” marketing claims |
| ✓ Preservative-free, alcohol-free formula with 5 active ingredients | ✗ Includes latanoprost with limited long-term safety data for scalp use |
| ✓ 0.3% dutasteride and 7.5% minoxidil offer powerful DHT inhibition | ✗ Lacks true customization compared to leading competitors |
| ✓ Proprietary hydrating gel base with advanced formulation |
Blends is a physician-founded company with a heavy focus on cutting-edge manufacturing methods and sophisticated formulations. Their small but specialized catalog includes this topical dutasteride treatment made with a proprietary gel base for timed medication release and scalp hydration. Free of alcohol and preservatives, the concentrated 0.3% dutasteride and 7.5% minoxidil formula offers powerful therapeutic effects.
Although Blends asserts the “personalized” and “customized” nature of its products, its Growth Pro Topical gel is actually a comprehensive fixed formula with three adjuvant ingredients in addition to dutasteride and minoxidil: tretinoin, latanoprost, and ketoconazole. Competitively priced at about $45/month (sold in 90-day batches), this offering stands out for its full ingredient transparency and high concentrations suited to aggressive treatment protocols.
However, the use of latanoprost poses concerns due to the lack of long-term studies confirming its safety and efficacy as a topical hair loss treatment. Despite marketing claims of customized protocols, Blends does not allow formulation adjustments to this fixed gel product. Although the monthly cost is lower than that of most leading brands of comparable quality, the minimum purchase requirement of a 90-day supply (~$135) may not suit all patients.
Our Verdict: This physician-crafted gel formula from Blends is competitively priced, featuring high concentrations of synergistic ingredients for advanced hair loss treatment. Its positioning as a mid-level selection rather than a top choice is due to its false personalization claims and unproven add-on ingredient.

| Pros: | Cons: |
| ✓ Dermatologist oversight with ongoing support | ✗ Limited dutasteride concentration options |
| ✓ 0.3% dutasteride and 8% minoxidil formula with customizable add-ons, including ketoconazole | ✗ Pricing increases after the initial months and can reach ~$109 |
| ✓ Established brand with a 6-month money-back guarantee | ✗ Some formulations contain potential irritants |
| ✓ User-friendly platform and free consultation | ✗ Shipping and customer service inconsistencies |
Happy Head represents a dependable option for targeted hair restoration, recognized for its dermatologist-backed and customizable treatments. This hybrid dutasteride-minoxidil solution offers a strong dose of 0.3% dutasteride with up to 8% minoxidil for effective DHT reduction. Elective adjuvants include retinoic acid and hydrocortisone. Anti-dandruff agent ketoconazole can be added for an additional fee.
While some clinicians warn against the use of topical corticosteroids like hydrocortisone, Happy Head seems to follow established medical safety protocols with appropriate disclaimers. Inactive ingredients like alcohol and propylene glycol can irritate and should be approached with caution. Highly concentrated DHT blockers with harsh excipients require close medical oversight, and patients with sensitive skin may want to seek other options.
Although transparent about costs, Happy Head’s variable pricing can grow quickly with treatment duration and formulation. Their topical dutasteride solution starts at $59 per month and shifts to $89 after the first six months. The anti-dandruff adjuvant can be added for $20, bringing the total to $109 per month, which exceeds the cost of some comparable providers. Mixed patient reviews cite issues with deliveries and logistical support.
Our Verdict: This combination treatment from Happy Head is a solid choice for patients in need of more aggressive treatment and concentrated formulas. Continued dermatologist oversight, personalization options, and potent formulations can help patients whose results may have stalled on other treatments. However, highly active ingredients and variable pricing may deter those seeking gentler therapies and fixed costs.

| Pros: | Cons: |
| ✓ High level of personalization with physician-driven telehealth oversight | ✗ Limited long-term safety data for some ingredient combinations |
| ✓ Competitive monthly pricing | ✗ Availability restricted to the U.S. |
| ✓ Physician-guided treatment plans and ongoing clinical support | ✗ No subscription flexibility (all via 90-day supply) |
| ✓ Proprietary gel base designed for scalp absorption and minimal mess | |
| ✓ Evidence-informed protocols supported by board-certified physicians |
Maximus Tribe’s Max-Absorb Gel is a highly customizable, prescription-only hair loss solution leveraging physician-driven telehealth and evidence-based formulation. At $54.99 for a 90-day supply, it offers a lot of value for those looking for efficacy and clinical support. The core formulation includes dutasteride (0.1%) with optional minoxidil, tretinoin, and fexofenadine, delivered in a proprietary gel base that is designed to minimize mess and maximize scalp coverage.
Maximus prioritizes convenience and targeted care: onboarding and ongoing support are managed by board-certified doctors, and the medication is shipped directly to the patient for easy home application. While ingredient customization and clinical guidance are strengths, choices remain limited in comparison to other telehealth options (like Ulo).
Our Verdict: Maximus offers a well-priced topical dutasteride gel that balances multi-ingredient efficacy with convenient home use and physician oversight.

| Pros: | Cons: |
| ✓ Direct board-certified dermatologist consultations | ✗ Total cost varies with third-party pharmacy fees |
| ✓ Custom-compounded formulations with up to 3 active ingredients | ✗ Basic compounding without advanced delivery systems |
| ✓ No automatic subscriptions—pay per order | ✗ Less specialized in hair loss compared to dedicated platforms |
| ✓ Legitimate medical oversight with prescription flexibility | |
| ✓ Serves both the USA and Mexico |
Miiskin differs from the subscription-based providers on this list, as it facilitates direct medical consultations between patients and qualified dermatologists. The pay-as-you-go model allows legitimate medical access without subscription requirements. Miiskin charges $59 for initial consultations and $30 for returning visits. Medication fees vary and are charged separately at the pharmacy where the medication is filled.
While the dermatologist-direct platform increases access to qualified care and prescription hair loss treatments, its simple compounded formulas lack the customization and specialization of leading brands. Ingredient disclosure is limited beyond general mentions of three-active-ingredient formulations and the listing of a combination of dutasteride and minoxidil therapy.
The model does not permit total cost calculation until third-party pharmacy checkout, separate from Miiskin’s billing process, which only covers prescribing dermatologist consultation fees.
Our Verdict: Although Miiskin offers medical legitimacy, the dermatology consultation platform lacks the treatment specialization and transparency of top dutasteride therapy sources. It may be a valuable tool for patients with hair loss to connect with qualified providers and access basic compounded formulas.

| Pros: | Cons: |
| ✓ Lowest cost option at $33/month | ✗ Minimal medical oversight compared to competitors |
| ✓ 0.3% dutasteride concentration in a customizable formula | ✗ Limited customization options |
| ✓ Aesthetic medicine platform with dermatologist involvement | ✗ Medical rigor lacking |
| ✓ Multi-ingredient formulations | ✗ Less specialized hair loss expertise |
| ✗ Some ingredients are not recommended for sensitive skin |
Musely’s topical dutasteride solution occupies the final slot on our list as the lowest-priced option at just $33 per month (plus a one-time $20 consultation fee at onboarding). The lower price point reflects less extensive offerings that are well-suited for patients who prefer a more self-directed approach. This tailored prescription formulation combines up to 0.3% dutasteride and 8% minoxidil with optional add-ons of ketoconazole to fight dandruff and hydrocortisone to reduce inflammation.
It is less customizable than other options, characteristic of Musely’s simplified strategy. Excipients like propylene glycol and alcohol may deter ingredient-conscious consumers due to irritant potential. While such potent formulas and highly active ingredients offer more powerful treatment, they also carry a greater risk of adverse reactions and call for qualified medical supervision.
However, unlike premium providers, Musely is not known for close medical oversight. In fact, the aesthetic medicine platform has a markedly superficial onboarding and assessment process that falls short of the thorough medical evaluations offered by top providers. Although clinicians are involved in the platform, follow-up care and specialized hair restoration knowledge are lacking, according to customer reviews.
Our Verdict: Musely is included as a purely budget-friendly option for cost-conscious patients who understand the importance of self-monitoring and supplement with appropriate medical consultation.
According to our thorough analysis, Ulo is the best choice for topical dutasteride therapy in 2026. This platform stands out for its rigorous scientific foundation, highly tailored treatments, and commitment to close medical oversight, outperforming the fixed protocols and misleading marketing claims of its peers.
Rather than standardized approaches, Ulo’s PhD-designed therapies with built-in customization features meet the individual needs of each patient, representing the pinnacle of evidence-based precision care in the rapidly evolving field of hair restoration medicine.
Clinical findings support the following timeline of expected treatment outcomes in topical dutasteride therapy. Familiarity with these will ground your therapy in a realistic outlook, encouraging patience and prolonged adherence.[10]Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in … Continue reading,[11]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading,[12]Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal … Continue reading
Topical dutasteride is considered a safe hair loss intervention, particularly when weighed against oral formulas that can carry substantial risk due to systemic exposure. Nonetheless, informed risk assessment and familiarity with safety protocols are recommended before beginning any new treatment. Here is a brief overview of medical data on the safety and side effects of topical dutasteride.[13]Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: … Continue reading
Adverse patient reactions to topical dutasteride are rare and typically limited to mild, localized scalp irritation that resolves in 2-4 weeks, occurring in only about 5-10% of new users. Depending on individual sensitivities and irritating formulation additives like alcohol, scalp dryness, flaking, and contact dermatitis are possible, though the latter is less common. Mild systemic side effects are extremely rare, documented in under 2% of patients.
Also rare are severe allergic reactions and pronounced systemic side effects, which can include sexual dysfunction, mood disorders, and gynecomastia. These all warrant prompt medical intervention. Topical dutasteride is not recommended in patients with active scalp infections and hormonal disorders.
Topical dutasteride is strongly contraindicated in pregnant or nursing women and in those planning future pregnancies due to the risk of birth defects. Patients with known hypersensitivity to DHT blockers should also avoid use.
Safety and optimal treatment outcomes depend on regular medical follow-up evaluations, typically at three-month intervals in the first year. This enables early identification of problems and treatment response evaluation.
Cutting-edge topical dutasteride formulations bridge the gap between pharmacological precision and patient satisfaction in hair restoration therapy. Available products represent a spectrum of targeted, proven treatments that are considered safer and more customizable than previous-generation modalities.
Our thorough review of the evolving market identified clear leaders, with Ulo setting itself apart as an exemplary provider of topical dutasteride. Its scientifically optimized protocols are tailored to meet the individual needs of each patient, with qualified medical supervision to ensure a safe and transformative treatment experience.
As hair restoration technology advances, leading topical dutasteride formulations, such as Ulo’s, are at the forefront, empowering users with convenient and clinically proven solutions that not only enhance appearance but also improve quality of life.
Explore Ulo’s advanced topical dutasteride treatments today.
Do I need a prescription for topical dutasteride? Yes, topical dutasteride is a prescription-only treatment in the United States. This ensures proper candidate screening and legitimate medical supervision throughout treatment.
When can I expect results? Initial DHT suppression on the scalp occurs within the first few days, but visible changes in hair growth typically emerge within 3-4 months. Benefits generally reach their peak after 12-18 months of consistent application.
How do I apply topical dutasteride? Use the product applicator to deposit the treatment directly onto clean, dry scalp areas where you are experiencing hair loss. Allow it to absorb fully before using other hair products. Following application, avoid wetting the hair for several hours and wash your hands thoroughly.
Can I combine topical dutasteride with other treatments? Yes, the benefits of topical dutasteride can be enhanced through combination therapies, such as minoxidil. Consult your prescribing doctor to learn about safe and effective hybrid treatments.
What will happen if I stop treatment? When treatment is halted, scalp DHT levels gradually return to starting levels, which typically leads to resumed hair loss after several months.
How much does topical dutasteride cost? Pricing varies from about $30 to $135+ for a monthly supply, depending on concentration, formulation, brand, and telehealth services included. Leading brands provide comprehensive medical oversight and customization, offering transparent and flat-rate monthly subscription fees.
References[+]
| ↑1 | R. Cuevas-Díaz Durán., Martinez-Ledesma, E., Garcia-Garcia, M., Gauzin, D.B., Sarro-Ramirez, A., Gonzalez-Carrillo, C., Rodriguez-Sardin, D., Fuentes, A., Cardenas-Lopez, A. (2024) The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia. International Journal of Molecular Sciences, 25. Available at: https://doi.org/10.3390/ijms25052542. |
|---|---|
| ↑2 | Dhurat, R., Sharma, A., Rudnicka, L., Kroumpouzos, G., Kassir, M., Galadari, H., Wollina, U., Lotti, T., Golubović, M., Binic, I., Grabbe, S., & Goldust, M. (2020). 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatologic Therapy, 33. Available at: https://doi.org/10.1111/dth.13379. |
| ↑3 | Arif, T., Dorjay, K., Adil, M., & Sami, M. (2017). Dutasteride in Androgenetic Alopecia: An Update.. Current clinical pharmacology, 12 1, 31-35. Available at: https://doi.org/10.2174/1574884712666170310111125. |
| ↑4 | Harcha, W., Martínez, J., Tsai, T., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. Journal of the American Academy of Dermatology, 70 3, 489-498.e3. Available at: https://doi.org/10.1016/j.jaad.2013.10.049. |
| ↑5, ↑7, ↑10 | Obeid, M., Fattah, N., Elfangary, M., & Husseni, R. (2024). Comparison between Topical Minoxidil 5% Alone versus Combined with Dutasteride (Topical 0.02% through Microneedling or Oral 0.5 mg) in Treatment of Androgenetic Alopecia. QJM: An International Journal of Medicine. Available at: https://doi.org/10.1093/qjmed/hcae175.207. |
| ↑6, ↑8, ↑11, ↑13 | Ding, Y., Wang, C., Bi, L., Du, Y., Lu, C., Zhao, M., & Fan, W. (2024). Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology, 240, 833 – 843. Available at: https://doi.org/10.1159/000541395. |
| ↑9, ↑12 | Radhakrishnan, P., Mariyappan, G., Karthi, J., & Jaisumi, K. (2024). Formulating, Optimizing and Evaluation of Dutasteride Loaded Insitu-Emulgel for Androgenetic Alopecia. International Journal of Pharmaceutical Research and Applications. Available at: https://doi.org/10.35629/4494-0906631659. |
Dutasteride is used off-label for androgenetic alopecia due to its ability to lower dihydrotestosterone (DHT), a major hormonal driver of pattern hair loss. At 0.5 mg daily, it suppresses circulating DHT more than finasteride and shows significantly more hair regrowth across multiple clinical trials. So what happens when the dose is increased fivefold, to 2.5 mg?
In a 24-week study, the higher dose produced the greatest numerical increase in hair counts and the greatest investigator-assessed photographic improvement. It reduced scalp DHT by 150% more than that of 0.5 mg, even though it suppressed blood DHT levels about the same. But there are important limitations:
Several anecdotes from users of 2.5 mg dutasteride have also been published online. Before reviewing those cases, we’ll look at what the clinical evidence reveals about 2.5 mg dutasteride.
But first, a primer on oral dutasteride.
2.5 mg is the most powerful dose of dutasteride and lowers DHT by inhibiting both type 1 and 2 5a-reductase. Studies show it may lower scalp DHT by more than 0.5 mg dutasteride. Available through a licensed Ulo provider. Choose a multi-month plan and get free full-size gifts.
*Only available in the U.S. Online medical consultation required. Restrictions apply. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Dutasteride is an oral medication originally approved to treat benign prostatic hyperplasia (BPH). It inhibits the type I and type II forms of 5-alpha-reductase, the enzyme responsible for converting testosterone into DHT. As we’ve already established, DHT is a primary driver of hair loss.
Finasteride, the gold standard for AGA treatment, primarily inhibits type II. At 1 mg, it lowers DHT levels by about 70%. In contrast, dutasteride acts on both, and consequently can reduce circulating DHT by more than 90% at the standard 0.5 mg dose.
Comparatively, 0.5 mg dutasteride generally outperforms 1 mg finasteride for hair regrowth, likely due to greater DHT suppression. [1]Harcha et al. (2014). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2013.10.049
For hair loss, the relevant daily doses are:
Potential adverse effects include decreased libido, erectile or ejaculatory changes, and, less commonly, breast tenderness or enlargement. Dutasteride is not FDA-approved for hair loss in the United States currently, however, 0.5 mg and 2.5 mg dutasteride are frequently prescribed off-label by a physician.
Studies on 2.5 mg dutasteride are limited. However, one dose-ranging trial compared various doses of oral dutasteride, including 0.5 mg and 2.5 mg. It measured more than just hair counts: the researchers also assessed standardized photographs, investigator and patient ratings, and DHT concentrations in both blood and scalp tissue.
Olsen et al. randomized 416 men aged between 21 and 45 with male pattern hair loss to placebo or various treatment arms: finasteride 5 mg, or dutasteride 0.05, 0.1, 0.5, or 2.5 mg daily for 24 weeks. Hair counts were taken from the same area near the crown at repeated visits, using a small tattoo to ensure accurate tracking. The investigators also evaluated standardized photographs of the frontal scalp and vertex.[2]Olsen et al. (2006). Journal of the American Academy of Dermatology. 55(6):1014–1023. https://doi.org/10.1016/j.jaad.2006.05.007
At 24 weeks, the study reported the following changes in hair counts:

Fig 2. Hair counts increases with 0.05 mg dutasteride, 0.1 mg dutasteride, 0.5 mg dutasteride, 2.5 mg dutasteride, and 5 mg finasteride.
Dutasteride showed a dose-dependent increase in target area hair counts, with the largest gain in hair counts in the 2.5 mg group. The trial established that 2.5 mg outperformed dutasteride 0.5 mg for increasing hair density.
Not necessarily. In AGA, hair follicles can produce very fine, miniaturized hairs that contribute little to visible scalp coverage. When a study counts those hairs alongside thicker terminal hairs, the increase in its reported hair count may look more impressive than the cosmetic result. This is why the minimum hair shaft diameter used to define a countable, non-vellus hair is important when comparing trials.
This is where other measurements, like photographic assessments and patient satisfaction come into play. And in this case, the other measurements also corroborate the hair count findings: the 2.5 mg group also had the greatest investigator-rated improvement in standardized frontal and vertex photographs, with patient assessments following a broadly similar pattern. These findings make it less likely that the numerical hair count difference was driven by fine hairs that are largely cosmetically insignificant.
In the Olsen trial, 0.5 mg dutas rteedridueced serum DHT by approximately 92% compared with 2.5 mg dutasteride. Judging by blood levels alone, increasing from 0.5 mg to 2.5 mg appears to add very little suppression.
In the scalp itself, however, the reductions were 51% with dutasteride 0.5 mg and 79% with dutasteride 2.5 mg – a much larger reduction. Because reducing DHT locally in the scalp is arguably the most important factor in addressing DHT-driven follicle miniaturization, this may explain why 2.5 mg dutasteride produced a better result.
One important consideration when choosing oral dutasteride is its formulation. Unlike finasteride and minoxidil, dutasteride has extremely low water solubility, meaning that how the medication is formulated can significantly affect its absorption.
This is why the original FDA-approved dutasteride medication, Avodart, was developed as a soft gelatin capsule. Rather than containing dutasteride as a dry powder, each capsule contains the drug pre-dissolved in a mixture of lipids (oils), emulsified with mono- and diglycerides. This lipid-based formulation helps overcome dutasteride’s poor water solubility, allowing it to be absorbed through the gastrointestinal tract.
And the superiority of this formulation is backed up by research.
2.5 mg is the most powerful dose of dutasteride and lowers DHT by inhibiting both type 1 and 2 5a-reductase. Studies show it may lower scalp DHT by more than 0.5 mg dutasteride. Available through a licensed Ulo provider. Choose a multi-month plan and get free full-size gifts.
*Only available in the U.S. Online medical consultation required. Restrictions apply. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
There is clinical evidence that these formulation differences matter. In 2016, Fossler et al. compared GSK’s marketed 0.5 mg dutasteride softgel with experimental 0.5 mg tablets and hard gelatin capsules in a randomized crossover study. Compared with the softgel, total drug exposure was approximately 76% with the tablet and 73% with the hard capsule. Peak drug concentrations were also lower. Neither experimental formulation met the criteria for bioequivalence, and neither was advanced for further development.[3]Fossler, M., Zhu, J., Roehrborn, C., McAleese, P., Manyak, M. (2016). Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies. Clinical Drug Investigation. … Continue reading
Would lower absorption also mean less DHT suppression? The study measured dutasteride exposure, not DHT levels or hair regrowth, so it cannot establish that directly. However, the researchers noted that earlier dose-finding data suggested lower drug exposure would likely result in less effective serum DHT suppression.
Unfortunately, not all oral dutasteride products use this approach.
As dutasteride has become increasingly popular for hair loss, many compounding pharmacies have begun offering combination capsules containing dutasteride, minoxidil, and other ingredients. While these formulations offer the convenience of taking multiple medications in a single pill, some contain powdered dutasteride without an established solubilization system.
This begs the question: are patients actually absorbing the amount of dutasteride they have been prescribed?
While we don’t have direct data to answer that question, one of our own PerfectHairHealth members did test this hypothesis. To do so, this male member took 1.5 mg of powdered dutasteride supplied by a compounding pharmacy, tested his DHT, and, despite the relatively high dose, his serum DHT levels fell by only approximately 13% in 12 hours.
While this doesn’t prove the powdered dutasteride doesn’t work, it does add evidence to GSK’s findings that subpar formulations may lead to subpar efficacy.
Fortunately, there is a straightforward way to identify oral dutasteride products with established bioequivalence.
The FDA maintains a database called the Orange Book, which identifies approved medications and their therapeutic equivalence ratings. Products with an AB rating have satisfied the FDA’s requirements for bioequivalence to an appropriate reference product. For approved generic dutasteride, this means comparable absorption to the reference formulation at the same dose.
Ulo’s dutasteride softgels are a verified bioequivalent formulation.
This distinction is particularly important for patients considering 2.5 mg dutasteride daily. The hair regrowth reported in clinical trials depends on adequate drug exposure. A compounded capsule containing 2.5 mg of dutasteride powder cannot be assumed to provide the same exposure as an equivalent dose of a proven formulation.
For patients using oral dutasteride, particularly those switching from finasteride or increasing their dose, verifying the formulation with their pharmacist is an important part of evaluating their treatment.
Now that we’ve covered the clinical evidence, let’s look at eight anecdotal accounts from Reddit users who reported taking 2.5 mg dutasteride.

Source: u/[deleted] via r/HairlossProgressPics (October 2024). Original Reddit post

Source: u/[deleted] via r/tressless (December 2024). Original Reddit post

Source: u/Glum_Low via r/tressless (December 2025 and April 2026). Original Reddit post
This user switched from 1 mg finasteride to 2.5 mg dutasteride after years of continued hair loss on 5 mg oral minoxidil. He reported shedding stopped after the first month, with new growth at the crown and top of the scalp by month two and near-complete coverage in those areas by month six. He noted temporary sexual and urinary symptoms that resolved during treatment. Spontaneous resolution of side effects with DHT-reducing medication occurs often, with the original 2.5 mg dutasteride clinical trial demonstrating that the majority of sexual side effects resolved during treatment.

Source: u/ashenfallls via r/tressless (February 2026). Original Reddit post
This Redditor took 2.5 mg oral dutasteride alongside oral minoxidil, which he increased from 2.5 mg to 5 mg daily, for four months. He experienced heavy shedding in the first six weeks, then faster growth from around month two, and was satisfied with his progress by month four. He did not report libido or blood pressure-related side effects.

Source: u/LobsterIndependent29 via r/tressless (September 2026). Original Reddit post
This poster used 0.5 mg oral dutasteride for three and a half years before increasing to 2.5 mg under his dermatologist’s supervision, alongside 5 mg oral minoxidil. Over five years of treatment, he reported improved density and greater satisfaction with his hair, with no additional side effects after the dose increase.

Source: u/Eastern_Talk_6727 via r/tressless (September 2026). Original Reddit post
This user used 2.5 mg oral dutasteride, 5% topical minoxidil, and 2% topical RU58841 for about a year, adding 2.5 mg oral minoxidil shortly before posting. With several treatments in use at once, the results demonstrated in these photos can’t be attributed to 2.5 mg dutasteride alone.

Source: u/gandalfpr via r/tressless (January 2025). Original Reddit post
This Redditor used 0.5 mg dutasteride for most of a year before increasing to 2.5 mg for the final two months, alongside finasteride, topical and oral minoxidil, topical antiandrogens, and light therapy. The short time at the higher dose and the number of concurrent treatments limit what can be attributed to 2.5 mg dutasteride.
To optimize your response to 2.5 mg dutasteride, consistency is key. Consistent use of medications and patience are your friends during treatment, as cosmetically significant regrowth can sometimes take 6-12 months to manifest.
Secondly, combination treatments may prove to be more effective than standalone therapies. Dutasteride suppresses DHT and can be combined with other treatments, like those that address additional mechanisms beyond DHT. Minoxidil acts as a hair growth stimulant, while treatments such as ketoconazole may help address inflammatory scalp conditions when indicated. Some patients also consider microneedling or other adjuncts.
There is no well-established long-term regrowth timeline specific to 2.5 mg dutasteride. However, 2.5 mg dutasteride likely follows the same timeline as other DHT inhibitors. The stages below are therefore a broad guide, not a perfect prediction:
Like 0.5 mg dutasteride, there is a risk of side effects when taking 2.5 mg dutasteride.
Studies show that dutasteride at a 0.5 mg dose typically has a low rate of side effects, comparable to, if not lower than, finasteride. However, at a 5x dose, there may be a higher risk of side effects when using 2.5 mg
According to the Olsen trial, overall adverse events were similar between 0.5 mg and 2.5 g, except there was a higher rate of decreased libido with the 2.5 mg dose.
However, no patients discontinued treatment for that reason; four reported resolution while continuing dutasteride, and two more reported resolution after stopping. This suggests that some symptoms were temporary and likely mild, given no participants dropped out due to the side effects.
Prostate studies using higher doses of dutasteride, like 2.5 mg, in prostate studies have also failed to find any significantly increased risks.
However, every risk profile is individual. If your goal is to use a higher dose of dutasteride, start with 0.5 mg, assess your tolerance, and titrate upwards if necessary.
2.5 mg is the most powerful dose of dutasteride and lowers DHT by inhibiting both type 1 and 2 5a-reductase. Studies show it may lower scalp DHT by more than 0.5 mg dutasteride. Available through a licensed Ulo provider. Choose a multi-month plan and get free full-size gifts.
*Only available in the U.S. Online medical consultation required. Restrictions apply. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Dutasteride is an off-label treatment for androgenetic alopecia, with growing popularity. It’s most commonly used at the 0.5 mg dose. However, 2.5 mg has also been explored as an escalated dose, demonstrating better improvements to hair density, steeper reductions to scalp DHT, and better overall hair growth compared to 0.5 mg. While it does come with an increased risk of decreased libido, studies suggest these effects are mild and often resolve with treatment. Given its profile, it represents a suitable option for escalating a hair loss protocol that ideally already includes 0.5 mg dutasteride or another DHT-reducing medication prior to switching.
References[+]
| ↑1 | Harcha et al. (2014). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2013.10.049 |
|---|---|
| ↑2 | Olsen et al. (2006). Journal of the American Academy of Dermatology. 55(6):1014–1023. https://doi.org/10.1016/j.jaad.2006.05.007 |
| ↑3 | Fossler, M., Zhu, J., Roehrborn, C., McAleese, P., Manyak, M. (2016). Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies. Clinical Drug Investigation. 36(9). 763–767. Available at: https://doi.org/10.1007/s40261-016-0419-6 |
Female hair loss remains a widely misunderstood and often under-treated condition, affecting nearly one-third of all women at some point in their lives and up to two-thirds after menopause. Unlike male pattern hair loss, research and treatment options for women have historically lagged, resulting in limited specialized solutions and significant emotional distress for those afflicted.
Minoxidil stands as the only FDA-approved medication for female pattern hair loss. Its efficacy is supported by robust data, particularly at the 2 and 5% concentrations for women. In this guide, we will showcase the six best minoxidil products for women, including the best overall, best value, and top specialized choices.
| Product | Strength | Format | Customization | Price | Best |
| Ulo Women’s Rx Minoxidil | 7% | Solution | High | $41.65 | Overall Topical |
| Ulo Sublingual Minoxidil | 1.25 mg or 2.25 mg | Orange-flavored sublingual tablet | High | From $39 | Overall Oral |
| Musely | 8% | Solution | High | $99 | Strength |
| Rogaine Women’s Foam | 5% | Foam | None | $49.97 | Sensitivity |
| Hers | 2%-5% | Solution/Foam | None | $30 | Value |
| Happy Head (Women’s Formula) | 6% | Solution | High | $79 | Alternative |
| Winona | 7% | Solution | None | $150 | Woman-centered care |
Before we get into our list, let’s first take a look at what female pattern hair loss is and how minoxidil works for women.
Rx-strength topical minoxidil, formulated without propylene glycol. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Female pattern hair loss (FPHL) is a chronic, non-scarring alopecia where genetically susceptible follicles on the central scalp progressively minaturize, leading to reduced hair density over time. Clinically, women usually show diffuse thinning over the crown and midline part with relative preservation of the frontal hairline rather than “bald patches”.[1]Bhat, Y.J., Saqib, N-U., Latif, I., Hassan, I. (2020). Female Pattern Hair Loss – An Update. Indian Dermatology Online Journal. 11(4). 493-501. Available at: … Continue reading
The Ludwig scale grades this pattern from I-III: mild central thinning (I), moderate widening of the part and density loss (II), and advanced, see-through vertex thinning (III). Trichoscopy and histology show increased hair shaft diameter variability and replacement of terminal hairs by finer, vellus-like hairs.[2]Kothari, C.R., Shivakumar, P. (2024). Trichoscopic Features in Female Pattern Hair Loss: 1-Year Hospital-Based Cross-Sectional Study. Clinical Dermatology Review. 8(2). 95-101. Available at: … Continue reading
FPHL arises from a mix of genetics, hormones, low-grade inflammation, oxidative stress, and microvascular and aging-related changes around the follicle. Unlike classic male pattern hair loss, many women have normal serum androgens, suggesting that local androgen sensitivity and non-androgen mechanisms both contribute.[3]Ramos, P.M., Miot, H.A. (2015). Female Pattern Hair Loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia. 90(4). 529-543. Available at: … Continue reading
Minoxidil functions as a potassium channel opener that promotes vasodilation, increasing blood flow and improving microcirculation around hair follicles.[4]Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: … Continue reading
It is also a prodrug that must be converted by the sulfotransferase enzyme into its active form, minoxidil sulfate. This conversion helps extend the anagen (growth) phase while shortening the telogen (resting) phase, thereby shifting a greater number of follicles into active growth cycles.[5]Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a … Continue reading
Additional evidence indicates that minoxidil stimulates the expression of growth-promoting factors, such as vascular endothelial growth factor (VEGF), and activates the Wnt/β-catenin signaling pathway, both of which further support hair regrowth.[6]Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: … Continue reading
While minoxidil does not directly address dihydrotestosterone (DHT), it can enhance the effectiveness of other therapies by targeting different biological pathways involved in hair loss. When used alongside anti-DHT treatments such as finasteride, which reduces the underlying hormonal driver of androgenic alopecia, minoxidil offers a complementary, non-hormonal mechanism of action. Clinical research demonstrates that the combined use of topical finasteride and minoxidil produces greater improvements in hair density in men compared to minoxidil alone.[7]Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs … Continue reading
In women, pattern hair loss is generally less strictly DHT-driven than in men, so microcirculation, oxidative stress, and local inflammatory pathways play a proportionately greater role.[8]Fabbrocini, G., Cantelli, M., Masara, A., Annunziata, M.C., Marasca, C., Cacciapuoti, S. (2018). Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal … Continue reading This helps explain why a vasodilatory, pro-anagen agent like minoxidil is often effective even when anti-androgens alone are insufficient.
Hormonal transitions like perimenopause/menopause, thyroid dysfunction, and polycystic ovary syndrome (PCOS) commonly unmask or accelerate FPHL by altering estrogen-androgen balance and cycling dynamics.[9]Aksenenko, M., Palkina, N., Komina, A., Ruksha, T. (2019). MiR-92a-1-5p and miR-328-3p Are Up-Regulated in Skin of Female Pattern Hair Loss Patients. Annals of Dermatology. 31(2). 256-259. Available … Continue reading
Over-the-counter (OTC) minoxidil for women typically comes at 2-5% concentrations, while prescription or compounded products may use 5-8% or higher strengths in customized products.
2% minoxidil is the classic, label-approved strength for women, with clear evidence of a benefit versus placebo.[10]van Zuuren, E.J., Fedorowicz, Z., Schoones, J. (2016). Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews. 2016(5). CD007628. Available at: … Continue reading
Compounded “high-strength” minoxidil (5-8%+) is prescription only and relies in part on carrier agent formulation.[11]Sattur, S.S., Sattur, I.S. (2021). Pharmacological Management of Pattern Hair Loss. Indian Journal of Plastic Surgery. 54(4). 422-434. Available at: https://doi.org/10.1055/s-0041-1739254 Simply raising the percentage does not guarantee better results and may raise the risk of irritation, hypertrichosis, or systemic absorption of the drug.[12]Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic … Continue reading
So, with that in mind, let’s take a look at our top seven minoxidil brands of 2026.

| Pros: | Cons: |
| ✓ Prescription-only 7% minoxidil, higher than standard OTC strengths | ✗Prescription products are only available in the USA |
| ✓ Optional evidence-based add-ons | |
| ✓ Quality-tested ingredients free of irritants | |
| ✓ Includes medical consultation and ongoing monitoring |
Ulo Women’s Rx Minoxidil+ is our go-to product for topical minoxidil treatment. It is designed for those who want more than “pink-labeled” 2-5% solutions and are comfortable with a prescription approach guided by specialists. The 7% concentrated and layered actives (including cetirizine 1%, tretinoin 0.01%, melatonin 0.01%, and caffeine 0.2%) target multiple facets of hair loss with a level of customization that goes beyond typical off-the-shelf products.
Bottom Line: Ulo offers the most precise, clinically guided minoxidil-based treatment for women in 2026, combining higher-strength therapy with thoughtful formulation and ongoing medical oversight.
| Pros: | Cons: |
| ✓ Convenient, sublingual oral minoxidil | ✗ Premium pricing |
| ✓ Orange-flavored sublingual tablet | ✗ Only available in the USA |
| ✓ Available in 1.25 mg and 2.25 mg minoxidil strengths | |
| ✓ No scalp application or disruption to hair styling | |
| ✓ Online medical consultation and ongoing provider support |
Ulo’s Sublingual Minoxidil tablets offer a minoxidil alternative for women who are interested in oral minoxidil but prefer the sublingual delivery format. Researchers believe bypassing the liver’s first-pass metabolism through sublingual delivery may reduce the effect of minoxidil on the cardiovascular system. In one study, heart palpitations were reported in approximately 9% the conventional oral minoxidil group versus none of the sublingual oral minoxidil group.[13]Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C. and Müller Ramos, P. (2025), Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized … Continue reading
The orange-flavored sublingual tablets dissolve rapidly in the mouth, allowing users a convenient (and delicious) way to deliver minoxidil sublingually.
This may be particularly beneficial for women with longer hair, sensitive scalps, or styling routines that make topical minoxidil difficult to apply consistently. The two available minoxidil strengths, 1.25 mg and 2.25 mg, also provide ample flexibility when selecting an appropriate dose.
Bottom Line: Ulo Sublingual Minoxidil offers a convenient, pill-free way to take prescription oral minoxidil sublingually, particularly for women who find topical treatments difficult to incorporate into their daily hair care routine.
A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

| Pros: | Cons: |
| ✓ High-strength 8% prescription minoxidil. | ✗ Use of corticosteroids increases the risk of skin thinning. |
| ✓ Optional evidence-based add-ons like dutasteride and spironolactone for hormonal control. | ✗ Propylene glycol and ethyl alcohol base, which can sting or dry out sensitive scalps. |
| ✓ Additional scalp-supporting actives like tretinoin, ketoconazole, caffeine, and melatonin. | ✗ More expensive than simpler OTC or lower-strength prescription options. |
| ✓ Includes periodic medical follow-up. |
Musely’s 8% “Classic” Hair Topical is designed for women with advanced thinning or those who have plateaued on conventional strengths, combining high-dose minoxidil with potent anti-androgens and supportive ingredients in a single solution, including optional add-ons such as dutasteride 0.3%, spironolactone 0.075%, tretinoin 0.01%, ketoconazole 2%, hydrocortisone 1%, plus adjuncts like caffeine and melatonin.
It functions more as an intensive, prescription-only protocol than a starter product, and is best reserved for users willing to tolerate a stronger propylene glycol/ethyl alcohol vehicle, and possible skin thinning if using long-term due to the addition of corticosteroids.
Bottom line: For women with stubborn, progressive hair loss who have outgrown basic 5% formulas, Musely’s high-strength, multi-active topical offers one of the most powerful at-home options, provided they are comfortable with higher cost and higher irritation risk.

| Pros: | Cons: |
| ✓ Propylene-glycol-free foam vehicle, often better tolerated on sensitive or irritated scalps. | ✗No medical consultation or follow-up after buying |
| ✓ Widely available OTC | ✗ No customization. |
Rogaine Women’s Foam is a classic choice for those looking for a gentle-on-the-scalp option of minoxidil. The propylene-glycol-free foam base, robust clinical evidence, and once-daily 5% option make it a gentle yet effective starting point for treating female pattern thinning. It should be noted that if you wanted to try the lower dose option (2%), you need to buy the solution, which contains propylene glycol, and so may not be as beneficial for those with sensitive skin.
Bottom Line: Get the foam if you have a sensitive scalp or are a beginner, wanting a low-irritant minoxidil option.

| Pros: | Cons: |
| ✓ Budget-friendly option at around $30 for a 2-month supply. | ✗No advanced customization available. |
| ✓ Offers both 2% and 5% strengths at the same price. | |
| ✓ Available in solution and foam formats. |
Hers Minoxidil is designed for women who want a clinically supported minoxidil treatment without paying premium prices for branding or heavy telehealth layering. With standard 2 and 5% options in familiar vehicles, it delivers an approachable, budget-conscious package for those comfortable managing a simple daily routine themselves.
Bottom Line: For cost-conscious women who want an easy, no-frills entry into proven minoxidil therapy, Hers Minoxidil offers standard concentrations with good value.

| Pros: | Cons: |
| ✓ Prescription-strength 6% minoxidil, higher than standard OTC options but below ultra-high-dose protocols. | ✗ Uses a propylene glycol-containing vehicle, which can increase irritation, dryness, or stinging on sensitive scalps. |
| ✓ Customizable blends that include spironolactone, tretinoin, and hydrocortisone | ✗ Inclusion of topical corticosteroids carries a risk of skin thinning and barrier damage if used long-term. |
| ✓ Strong telehealth model with online prescribing and adjustments to treatments over time. | ✗ More expensive than generic 5% minoxidil and some standard telehealth offerings. |
| ✓ Good fit for women who need more than basic 2-5% formulas but do not want to jump straight to 8%+ multi-drug cocktails. |
Happy Head’s 6% formulas are aimed at women who want a personalized, prescription-only topical that goes beyond standard strengths while still staying below the most aggressive high-dose regimens. By combining minoxidil with spironolactone, retinoic acid, and short-term hydrocortisone in a single bottle, it offers a modular approach that can be tuned to individual tolerance and response rather than a one-size-fits-all solution. It should be noted that Happy Head uses corticosteroids in their topicals to offset the potential irritation from propylene glycol usage. However, this can cause skin thinning with long-term use.
Bottom line: For women who need a tailored, mid-high-strength minoxidil blend with added anti-androgens and supportive ingredients, but prefer not to escalate to ultra-high-dose, steroid-heavy cocktails, Happy Head provides a strong option.

| Pros: | Cons: |
| ✓ Women-focused clinic model that addresses broader menopausal health alongside hair loss. | ✗ Uses a propylene glycol-containing vehicle, which can increase irritation, dryness, or stinging on sensitive scalps. |
| ✓ Prescription-strength 7% minoxidil specifically targeted to menopausal and perimenopausal thinning. | ✗ No customization |
| ✓ Guided supportive care pathway, with structured programs, check-ins, and follow-up. | ✗ Premium pricing at around $150 for a 3-month supply. |
| ✓ Treatment plans that can integrate other menopause therapies where appropriate |
Winona’s 7% minoxidil is designed for women who want more than a stand-alone bottle and value a structured, woman-centered approach that fits into a broader menopause-care framework. The higher-strength prescription formula, combined with clear guidance, follow-up, and attention to hormonal context, makes it particularly suited to postmenopausal and perimenopausal hair loss rather than general early thinning. However, it should be noted that its carrier agent, propylene glycol, may be irritating for sensitive scalps.
Bottom line: For women seeking a guided, menopause-focused program built around prescription-strength minoxidil, Winona offers a structured, woman-centered care pathway, albeit at a higher price and with a more irritant-prone vehicle.
Setting realistic expectations is essential when beginning topical minoxidil for female pattern hair loss. Unlike quick cosmetic fixes, minoxidil works by gradually altering the hair growth cycle, and visible changes take time to develop.
| Timeframe | What to Expect | Clinical Evidence |
| Months 0-3 | An initial increase in shedding may occur as follicles shift out of the resting (telogen) phase and re-enter growth. This temporary “dread shed” phase typically improves within 4–8 weeks and is considered a normal response to treatment initiation. | [14]Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during … Continue reading |
| Months 3-6 | Early visible signs of improvement may appear, including reduced shedding and the emergence of fine, new hairs (vellus to terminal transformation), particularly along the part line and crown. | [15]Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal … Continue reading |
| Months 6-12 | More noticeable cosmetic improvements are typically seen, including increased overall density, thickening of existing strands, and improved scalp coverage in areas of diffuse thinning. For many women, this is the point at which changes become easily visible in the mirror and in photos. | [16]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading |
| Months 12+ | Hair density gains typically plateau. At this point, continued use is required to maintain results and prevent gradual regression back toward baseline. Stopping treatment may allow thinning to resume over time. | [17]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading |
Topical minoxidil works by extending the anagen (growth) phase of the hair cycle and shortening the telogen (resting) phase, thereby increasing the amount of time that follicles spend actively producing hair. Maintaining this effect requires regular, consistent application. When doses are frequently missed, follicles spend less cumulative time in a growth-biased state, which reduces the likelihood of noticeable improvement.[18]Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: … Continue reading
This principle is especially important in women, whose hair loss is often more diffuse and gradual, making subtle changes harder to notice in the early months. Because the human scalp hair cycle progresses slowly, with the anagen phase potentially lasting several years, many follicles need prolonged, uninterrupted exposure to minoxidil before visible gains in density and coverage can be achieved.[19]Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: … Continue reading
For this reason, most clinical guidance advises committing to at least six months of daily, consistent use before evaluating the effectiveness of treatment, with continued use required to sustain and build upon results.
You can find topical minoxidil in several different delivery vehicles, each with its own advantages in terms of scalp tolerability, ease of use, and fit for a woman’s lifestyle and hair type. In most cases, the “best” option is not defined by pure strength alone, but by how well the formula matches skin sensitivity, styling habits, and consistency of application.
Foam – Best for Sensitive Skin
Propylene glycol–free foam formulations were developed to reduce the risk of contact dermatitis, itching, and dryness that can occur with traditional liquid solutions. Clinical observations suggest that foam is generally better tolerated and faster-drying, making it a strong choice for women with sensitive scalps or those who wash and style their hair frequently.[20]Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714
Liquid – Best for Cost and Precision
Classic liquid solutions, usually formulated with alcohol and propylene glycol, remain widely available and affordable. While effective, they may cause itching, dryness, or flaking in some women. These solutions can work well for individuals without scalp sensitivity who prefer a more targeted, dropper-based application, especially along the part line.
Spray – Best for Quick, Even Coverage
Spray or mist-style applicators make it easier to cover larger areas of diffuse thinning, such as along the crown or upper scalp. However, they can be less precise, with some product landing on the hair shafts or surrounding skin rather than directly on the scalp.
Gel – Best for Targeted Areas
Gel or cream-gel formulations tend to stay in place, minimizing runoff and improving control. These are helpful for women treating specific areas of thinning, such as the temples, frontal hairline, or post-partum thinning zones.
Liposomal Delivery
Some prescription and premium products use liposomal or phospholipid-based carriers that are designed to improve follicular penetration while reducing irritation and systemic absorption. These advanced bases may be especially attractive for women who need stronger formulations but have experienced irritation with traditional vehicles.
Topical minoxidil is generally well tolerated by women, but like any active medication, it can produce local scalp irritation, a brief increase in shedding during the early treatment phase, and, in very rare cases, systemic side effects, particularly in individuals with underlying skin or cardiovascular conditions.
Common local reactions may include:
These symptoms are typically mild, tend to improve as the scalp adapts, and can often be reduced by switching to a foam-based formula, lowering concentration, or using a gentler vehicle.
Systemic and heart-related reactions are extremely uncommon with proper topical use. However, isolated case reports and safety data recommend seeking medical attention if symptoms such as chest tightness, heart palpitations, lightheadedness, dizziness, or unexplained swelling develop, as these could indicate increased systemic absorption or accidental ingestion. The risk of cardiovascular effects is significantly higher with oral minoxidil or improper dosing, where hypotension, tachycardia, and even heart failure have been reported.[21]Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: … Continue reading
To minimize the risk of side effects, many clinicians recommend starting with once-daily application, gradually increasing only if tolerated. Women with reactive skin often benefit from foam formulations, lower-alcohol bases, or liposomal delivery systems, which can reduce irritation and improve comfort during long-term use.
Individuals with active inflammatory scalp conditions, such as psoriasis, eczema, or severe seborrheic dermatitis, are generally advised to first address the underlying condition before beginning minoxidil therapy. Applying treatment to an inflamed or compromised skin barrier can increase irritation, worsen symptoms, and lead to unpredictable absorption patterns.[22]Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. … Continue reading
Although topical minoxidil has lower systemic absorption than oral formulations, it is generally not recommended during pregnancy or while breastfeeding unless specifically advised by a healthcare provider. Women who are pregnant, trying to conceive, or nursing should consult a qualified medical professional to fully review potential risks and alternative treatment options.
A range of minoxidil-based options is available to support different needs among women experiencing hair thinning, from strength-focused prescriptions to gentle, sensitivity-friendly alternatives and highly customized compounded formulas. While each product relies on the same core ingredient, differences in concentration, delivery vehicle, add-on actives, and level of medical support can significantly influence both tolerability and long-term adherence.
Whichever option you choose, consistent use of minoxidil remains one of the most evidence-backed ways to slow progression and improve hair density in women with pattern hair loss. With today’s expanded access to prescription platforms, foam-based formulations, and individualized treatment models, it is now easier than ever to find an approach that aligns with your scalp sensitivity, stage of hair loss, and lifestyle needs.
References[+]
| ↑1 | Bhat, Y.J., Saqib, N-U., Latif, I., Hassan, I. (2020). Female Pattern Hair Loss – An Update. Indian Dermatology Online Journal. 11(4). 493-501. Available at: https://doi.org/10.4103/idoj.IDOJ_334_19 |
|---|---|
| ↑2 | Kothari, C.R., Shivakumar, P. (2024). Trichoscopic Features in Female Pattern Hair Loss: 1-Year Hospital-Based Cross-Sectional Study. Clinical Dermatology Review. 8(2). 95-101. Available at: https://doi.org/10.4103/cdr.cdr_123_21 |
| ↑3 | Ramos, P.M., Miot, H.A. (2015). Female Pattern Hair Loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia. 90(4). 529-543. Available at: https://doi.org/10.1590/abd1806-4841.20153370 |
| ↑4 | Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: https://doi.org/10.1002/ski2.472 |
| ↑5 | Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947 |
| ↑6 | Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: https://doi.org/10.1159/0000531890 |
| ↑7 | Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs in Dermatology. 23(11). 1003-1008. Available at: https://doi.org/10.36849/JDD.7826 |
| ↑8 | Fabbrocini, G., Cantelli, M., Masara, A., Annunziata, M.C., Marasca, C., Cacciapuoti, S. (2018). Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal of Women’s Dermatology. 4(4). 203-211. Available at: https://doi.org/10.1016/j.ijwd.2018.05.001 |
| ↑9 | Aksenenko, M., Palkina, N., Komina, A., Ruksha, T. (2019). MiR-92a-1-5p and miR-328-3p Are Up-Regulated in Skin of Female Pattern Hair Loss Patients. Annals of Dermatology. 31(2). 256-259. Available at: https://doi.org/10.5021/ad.2019.31.2.256 |
| ↑10 | van Zuuren, E.J., Fedorowicz, Z., Schoones, J. (2016). Interventions for female pattern hair loss. Cochrane Database of Systematic Reviews. 2016(5). CD007628. Available at: https://doi.org/10.1002/14651858.CD007628.pub4 |
| ↑11 | Sattur, S.S., Sattur, I.S. (2021). Pharmacological Management of Pattern Hair Loss. Indian Journal of Plastic Surgery. 54(4). 422-434. Available at: https://doi.org/10.1055/s-0041-1739254 |
| ↑12 | Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment. 32(2). 236-241. Available at: https://doi.org/10.1080/09546634.2019.1654070 |
| ↑13 | Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C. and Müller Ramos, P. (2025), Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized clinical trial. J Eur Acad Dermatol Venereol, 39: e700-e702. https://doi.org/10.1111/jdv.20508 |
| ↑14 | Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation. JAAD International. 15. 220-224. Available at: https://doi.org/10.1016/j.jdin.2024.03.005 |
| ↑15 | Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus. 15(7). E41681. Available at: https://doi.org/10.7759/cureus.41681 |
| ↑16, ↑17 | Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available at: https://doi.org/10.1016/s0190-9622(87)70092-9 |
| ↑18 | Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: https://doi.org/https://doi.org/10.1111/j.1365-2133.2004.05785.x |
| ↑19 | Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499948/ (Accessed: November 2025) |
| ↑20 | Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714 |
| ↑21 | Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: https://doi.org/10.7759/cureus.66039 |
| ↑22 | Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. Acta Dermato-Venereologica. 105. 42401. Available at: https://doi.org/10.2340/actadv.v105.42401 |
Men’s hair loss is a booming multi-billion-dollar industry, yet the vast majority of over-the-counter products fall short when measured against rigorous clinical evidence. This landscape is cluttered with quick-fix promises, leaving consumers sifting through marketing claims with little scientific support. Among all topical hair regrowth options, minoxidil is one of the most extensively studied. It is also one of two FDA-approved treatments for male pattern hair loss (in its topical form).
In this comprehensive guide, we rank our top minoxidil picks of 2026 across Best Overall, Best Value, and other categories to help you navigate the crowded hair loss market with more clarity and confidence.
| Product | Strength | Format | Customization | Price | Best: |
| Ulo | 7% | Solution | High | $41.65 | Overall |
| Ulo | 1.25 mg / 2.25 mg | Sublingual Minoxidil | High | $39 | Convenience for Sublingual Delivery |
| Kirkland Minoxidil | 5% | Solution | None | $17.99 | Value |
| Rogaine | 5% | Solution/Foam | None | $49.97 | Sensitive Scalp |
| Keeps | 5% | Solution/Foam/Spray | Low | $16.67 | Subscription Convenience |
| Happy Head | 5-8% | Solution/Gel | High | $59 | Strength |
Minoxidil was originally developed to treat high blood pressure and is now widely used in both topical and oral forms as a first-line therapy for androgenic alopecia (AGA).
Minoxidil was first introduced in the 1970s as a powerful oral vasodilator for resistant hypertension. Clinicians soon noticed a frequent side effect, generalized increased hair growth (hypertrichosis).[1]Gupta, A.K., Talukder, M., Venkataraman, M., Bamimore, M.A. (2021). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: … Continue reading This led to the development of topical formulations specifically for AGA. Today, 2-5% topical minoxidil is FDA-approved for both male and female pattern hair loss and is used off-label for other alopecias.
Minoxidil is a potassium-channel opener that causes vasodilation and improves microcirculation around hair follicles.[2]Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: … Continue reading It also acts as a prodrug; sulfotransferase converts it to minoxidil sulfate, which prolongs the anagen (growth) phase and shortens the telogen (resting) phase, shifting more hair follicles into active growth.[3]Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a … Continue reading Additional data suggests that induction of key growth factors like vascular endothelial growth factor (VEGF) and activation of Wnt/ꞵ-catenin signaling further support hair regrowth.[4]Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: … Continue reading
Although minoxidil doesn’t target dihydrotestosterone, it can improve the effectiveness of other treatments by targeting multiple other targets. When combined with anti-DHT drugs like finasteride, which reduce the hormonal trigger of AGA, minoxidil provides a complementary, non-hormonal pathway. The two treatments have been shown to provide synergistic improvement in hair density in men.[5]Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs … Continue reading
Rx-strength topical minoxidil, formulated without propylene glycol. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Over-the-counter (OTC) minoxidil solutions (2% and 5%) can be effective for many men, but absorption and vehicle limits mean “stronger” drug percentages above 5% often add irritation rather than results unless the entire formulation is engineered and supervised medically.
Early minoxidil development work showed a clear dose-response between low strengths (1-2%) and mid-strength (5%) solutions, with 5% yielding larger gains in hair counts and shaft diameter in AGA.[6]Olsen, E.A., Dunlap, F.E., Funicella, T., Koperski, J.A., Swinehart, J.M., Tschen, E.H., Trancik, R.J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and … Continue reading
Other companies offer concentrations of 10% or over; however, recent head-to-head studies have shown that 5% topical minoxidil is moderately superior to the higher concentration.[7]Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic … Continue reading Additionally, the 10% minoxidil was associated with more marked irritation.
So, with that in mind, let’s take a look at some of our top minoxidil picks of 2026.

| Pros: | Cons: |
| ✓ Clinically-backed combinations | ✗Prescription products are only available in the USA |
| ✓ Ongoing medical monitoring and a user-friendly platform | |
| ✓ Quality-tested ingredients free of irritants |
Ulo’s Minoxidil Rx takes the top spot for men who want a data-driven, medically supervised approach rather than a one-size-fits-all bottle. Custom strengths and evidence-based optional add-ons allow precise targeting for hair regrowth.
Their high-strength concentration can be combined with tretinoin 0.01% to enhance absorption and efficacy, as well as cetirizine 1%, melatonin 0.01% for antioxidant protection, and caffeine 0.2% to boost circulation, which further improves the product’s effectiveness.
This treatment begins at $49 per month, increasing to $54 if you choose to have all of the add-ons.
Bottom Line: Ulo’s customizable, science-driven minoxidil prescription offers one of the most advanced, value-conscious options for men who are serious about long-term hair regrowth.
| Pros: | Cons: |
|---|---|
| ✓ Rapid-dissolve, orange-flavored chewable tablet | ✗ Premium pricing |
| ✓ No water required, just let it dissolve under the tongue | |
| ✓ Available with 1.25 mg or 2.25 mg oral minoxidil | |
| ✓ Option to combine minoxidil with 1 mg finasteride in one daily dose | |
| ✓ Prescription and ongoing support from licensed providers |
Ulo’s Dissolving Chews are designed for men who want the convenience of oral minoxidil but with the benefits of sublingual minoxidil. These orange-flavored tablets dissolve rapidly in the mouth and taste delicious.
Ulo is the only telehealth company currently offering a convenient sublingual tablet for dosing minoxidil. By administering minoxidil sublingually, it bypasses the sulfotransferase enzymes in the liver responsible for converting minoxidil into its active form. When activated in the liver, it transports active minoxidil throughout the body, supporting hair growth, but also impacting the cardiovascular system.
Sublingual minoxidil still produces active minoxidil in the hair follicles, however, it is theorized to reduce the delivery of active minoxidil to sensitive cardiovascular tissue. In one clinical trial, no palpitations were reported in the sublingual minoxidil group versus 9% of the conventional oral minoxidil group.[8]Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C. and Müller Ramos, P. (2025), Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized … Continue reading
The formula is available with 1.25 mg or 2.25 mg minoxidil, with the option to add 1 mg finasteride for men who want to address both hair growth and DHT-related miniaturization in a single daily treatment. This makes it particularly convenient for those already using both medications separately or who find topical applications difficult to maintain.
Bottom Line: For men who prefer oral minoxidil, Ulo’s Sublingual Minoxidil offer a convenient, delicious way to implement sublingual delivery, with the added option of combining minoxidil and finasteride in one daily dose.
A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.

| Pros: | Cons: |
| ✓ Lowest cost we could find for 6 months’ worth. | ✗Contains propylene glycol, which can cause irritation or dryness in some users. |
| ✓ Same core 5% minoxidil strength. | ✗ No customization possible for strength or add-on ingredients. |
| ✓ Widely available at multiple stores, including Amazon, Costco, etc. | ✗ No medical consultation or tailoring of treatment included. |
| ✓ Simple formula. |
Kirkland Signature Minoxidil 5% is the classic value choice for me who want an over-the-counter treatment without paying for branding or bundled medical services. You get a standard 5% solution similar in strength to more expensive competitors, making it ideal for cost-conscious users who are happy to follow a simple twice-daily routine and do not need personalized compounding.
Bottom line: If you want the most affordable entry point into 5% minoxidil, Kirkland’s no-frills formula is hard to beat for sheer value per effective dose.

| Pros: | Cons: |
| ✓ Clinically proven 5% minoxidil strength | ✗On the higher end in terms of price. |
| ✓ Foam vehicle is propylene glycol-free, so it is usually better tolerated on sensitive or irritated scalps. | ✗ Fixed strength for men with no customization or add-on actives. |
| ✓ Quick drying, less greasy texture | ✗ No medical consultation or tailoring of treatment included. |
| ✓ Widely available OTC |
Rogaine 5% is a strong pick for men who need minoxidil but find traditional liquid formulas too irritating or cosmetically heavy. The foam format avoids common irritants found in many solutions and tends to be more comfortable for daily use, which can improve adherence and long-term outcomes.
Bottom Line: For sensitive scalps that still need full-strength 5% minoxidil, Rogaine Foam provides a gentler, easy-to-use option that balances proven efficacy with better tolerability.

| Pros: | Cons: |
| ✓ Automatic subscription refills so you rarely run out or miss doses. | ✗More expensive than buying generic minoxidil in bulk. |
| ✓ Offers both 5% foam and 5% solution to suit different scalp and styling preferences. | ✗ Limited to preset strengths and formulas with no true custom compounding. |
| ✓ Option to bundle with finasteride and other treatments for a complete regimen. | |
| ✓ Online prescribing and follow-up. |
Keeps Minoxidil is designed for men who value a set-and-forget routine, trading a price increase ($16.67 for 3 months compared to Kirkland’s $17.99 for 6 months) for automatic deliveries and integrated telehealth support. The ability to pair minoxidil with finasteride and keep everything managed through a single platform could make adherence simpler for busy users.
Bottom Line: If you want 5% minoxidil with minimal hassle, Keeps’ subscription model is a strong fit for convenience-focused men who prefer not to manage refills and prescriptions on their own.

| Pros: | Cons: |
| ✓ Offers high-strength minoxidil concentrations beyond standard 5%. | ✗Higher strengths may carry a greater risk of irritation or systemic absorption. |
| ✓ Can be combined with topical finasteride and other actives in a single solution. | ✗ More expensive than generic 5% minoxidil and some standard telehealth offerings. |
| ✓ Telehealth model with online consultation and prescription management. | ✗Corticosteroids used to offset irritation from propylene glycol. |
| ✓ Multiple formula options aimed at men who have plateaued on basic OTC products. |
Happy Head is built for men who want to move past entry-level minoxidil and explore higher-strength, prescription-only blends under medical oversight. By pairing elevated minoxidil concentrations (8%) with agents like tretinoin and topical finasteride, Happy Head targets users seeking a more comprehensive protocol. With that said, some ingredients included, like the carrier agent propylene glycol, which is used in their base formula, can cause irritation. To offset this, Happy Head uses corticosteroids; however, this may cause skin thinning long-term.
You can read more about corticosteroid usage in hair loss treatments here.
Bottom Line: Happy Head delivers a good jump in strength for minoxidil users who need to increase efficacy.
It’s important that realistic expectations are set for regrowth when starting out on your minoxidil usage journey.
| Timeframe | What to Expect | Clinical Evidence |
| Months 0-3 | This is the initial shedding phase, which usually resolves in the first 4-8 weeks. | [9]Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during … Continue reading |
| Months 3-6 | Early visible improvements, like the appearance of new hairs, can be expected. | [10]Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal … Continue reading |
| Months 6-12 | Cosmetic changes peak, with stronger hair, increased density, and most coverage is seen. | [11]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading |
| Months 12+ | Further gains plateau, continued use needed to maintain improvements. | [12]Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available … Continue reading |
Minoxidil works by prolonging the anagen phase and shortening the telogen phase. Regular dosing maintains these effects at the follicle level; repeatedly missing applications reduces the cumulative time that hair follicles spend in a pro-growth, anagen-biased state.[13]Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: … Continue reading
Because human scalp follicles cycle slowly (anagen can last years), many follicles need months of uninterrupted exposure before visible density gains can be seen.[14]Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: … Continue reading This is why most guidance recommends at least 6 months of continuous use before judging the response.
Minoxidil is not disease-modifying for AGA, meaning that it does not correct androgen-driven miniaturization but counteracts it while present by improving hair cycle dynamics and follicle size. When treatment is stopped, these pharmacologic effects wane, and follicles gradually revert toward their genetically determined, androgen-sensitive pattern.
Clinical and patient information sources consistently note that any gain from minoxidil is maintained only while therapy continues. After discontinuation, increased shedding and loss of density over months are typical, ultimately leading to a reversal of gains to the original starting point.
You can buy minoxidil in several different vehicles that differ mainly in tolerability, practicality, and how well they fit a given scalp and routine. Choosing the “best” format is less about raw efficacy and more about matching the base to skin sensitivity and your preference of application.
Minoxidil is generally well tolerated, but like any active drug, it can cause local irritation, a transient shedding phase, and very rare systemic effects, especially in people with underlying skin or cardiovascular issues.
Common local side effects include:
Systemic and heart-related side effects are very rare with correctly used topical minoxidil, but case reports and product information advise seeking medical help if symptoms like chest pain, palpitations, dizziness, or unexplained swelling occur, as these could reflect systemic absorption or accidental ingestion. Risk is higher with oral minoxidil or overdose, where hypotension, tachycardia, and even heart failure have been documented.[16]Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: … Continue reading
To minimize problems, many clinicians suggest starting once daily and titrating up, choosing foam or gentler vehicles to reduce dermatitis, and using custom compounded formulas (for example, lower alcohol, lower strength, or liposomal bases) in those with sensitive or disease-prone scalps.
People with chronic inflammatory scalp conditions such as active psoriasis, eczema, or severe seborrheic dermatitis are typically advised to get the primary condition under control before adding topical minoxidil or other actives, as applying them to an inflamed barrier increases irritation, may worsen the disease, and can unpredictably alter absorption.[17]Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. … Continue reading
In 2026, several minoxidil-based options stand out for different priorities, from cost to customization. All of them rely on the same core ingredient, but vehicle, strength, and add-ons make a real-world difference in adherence and results.
Whichever route you choose, there is strong evidence that consistent minoxidil use can stabilize loss and improve density for many men, and modern platforms make it easier than ever to find a formulation that fits your scalp, schedule, and risk tolerance.
References[+]
| ↑1 | Gupta, A.K., Talukder, M., Venkataraman, M., Bamimore, M.A. (2021). Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 33(4). 1896-1906. Available at: https://doi.org/10.1080/09546634.2021.1945527 |
|---|---|
| ↑2 | Hussein, R.S., Dayel, S.B., Abahussein, O., El-Sherbiny, A.A. (2024). Applications and efficacy of minoxidil in dermatology. Skin Health and Disease. 4(6). E472. Available at: https://doi.org/10.1002/ski2.472 |
| ↑3 | Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947 |
| ↑4 | Gupta, A.K., Talukder, M., Shemer, A., Piraccini, B.M., Tosti, A. (2023). Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 9(6). 423-437. Available at: https://doi.org/10.1159/0000531890 |
| ↑5 | Asad, N., Naseer, M., Ghafoor, R. (2024). Efficacy of Topical Finasteride 0.25% with Minoxidil 5% versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of Drugs in Dermatology. 23(11). 1003-1008. Available at: https://doi.org/10.36849/JDD.7826 |
| ↑6 | Olsen, E.A., Dunlap, F.E., Funicella, T., Koperski, J.A., Swinehart, J.M., Tschen, E.H., Trancik, R.J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 47(3). 377-385. Available at: https://doi.org/10.1067/mjd.2002.124088 |
| ↑7 | Ghonemy, S., Alarawi, A., Bessar, H. (2021). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia: a trichoscopic evaluation. Journal of Dermatological Treatment. 32(2). 236-241. Available at: https://doi.org/10.1080/09546634.2019.1654070 |
| ↑8 | Sanabria, B., Miot, H.A., Sinclair, R., Chaves, C. and Müller Ramos, P. (2025), Sublingual Minoxidil 5 mg versus Oral Minoxidil 5 mg for male androgenetic alopecia: A double-blind randomized clinical trial. J Eur Acad Dermatol Venereol, 39: e700-e702. https://doi.org/10.1111/jdv.20508 |
| ↑9 | Nohria, A., Desai, D., Sikora, M., Mandal, S., Shapiro, J., Lo Sicco, K. (2024). Combating “dread shed”: The impact of overlapping topical and oral minoxidil on temporary hair shedding during oral minoxidil initiation. JAAD International. 15. 220-224. Available at: https://doi.org/10.1016/j.jdin.2024.03.005 |
| ↑10 | Amit, K., Mansukh, G., Satyaprakash, M., Dhiraj, D., Hanmant, B. (2023). Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus. 15(7). E41681. Available at: https://doi.org/10.7759/cureus.41681 |
| ↑11, ↑12 | Katz, H.I., Hien, N.T., Prawer, S.E., Goldman, S.J. (1987). Long-term efficacy of topical minoxidil in male pattern baldness. Journal of the American Academy of Dermatology. 16(3). 711-718. Available at: https://doi.org/10.1016/s0190-9622(87)70092-9 |
| ↑13 | Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 2(1). 186-194. Available at: https://doi.org/https://doi.org/10.1111/j.1365-2133.2004.05785.x |
| ↑14 | Hoover E, Alhajj M, Flores JL. Physiology, Hair. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499948/ (Accessed: November 2025) |
| ↑15 | Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714 |
| ↑16 | Tripathee, S., Benyovszky, A., Devbhandari, R., Quiza, K., Boris, J. (2024). A Very Bad Hair Day: Minoxidil Ingestion Causing Shock and Heart Failure. Cureus. 16(8). E66039. Available at: https://doi.org/10.7759/cureus.66039 |
| ↑17 | Junge, A., Jic-Hoesli, S.R., Bossart, S., Simon, D., de Viragh, P., Hunger, R.E., Heidemeye, K., Seyed Jafari, S.M. (2025). Contact Dermatitis Caused by Topical Minoxidil: Allergy or Just Irritation. Acta Dermato-Venereologica. 105. 42401. Available at: https://doi.org/10.2340/actadv.v105.42401 |
Oral minoxidil has become a widely used off-label option for androgenic alopecia (AGA) in men and women, despite initially being approved only as an antihypertensive medication decades ago.
Oral minoxidil is increasingly offered to address specific unmet needs in AGA treatment:
Regrowth with oral minoxidil can be variable, however. This variability mainly stems from biological differences between patients. Because minoxidil is a prodrug that requires conversion by the enzyme sulfotransferase (SULT1A1) into its active form, individual variation in enzyme activity strongly influences response.[1]Ramos, P.M., Goren, A., Sinclair, R., Miot, H.A. (2020). Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern … Continue reading
Get growing with a once-daily pill for growth support with no application, drying time, or residue. Prescribed 100% online. Choose a multi-month plan and get up to 25% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Unfortunately, what most people see online are extremely successful oral minoxidil before and after photos (which you’ll see below), which can lead people to believe that they will experience more regrowth than they actually might.

Source: u/pomidorich via r/FemaleHairLoss.
In this article, we will explore what the likely (not just possible) results are and what the clinical trials show.
But first, let’s have a quick refresher on what oral minoxidil is.
Oral minoxidil is a tablet medication originally developed as a vasodilator for severe hypertension, but now increasingly used off-label at low doses to treat AGA and other hair loss conditions. It enhances scalp flow and prolongs the growth phase (anagen) of hair follicles, primarily by increasing prostaglandin E2 and vascular endothelial growth factor (VEGF).
Oral minoxidil acts by opening ATP-sensitive potassium channels in vascular smooth muscle, which increases perifollicular blood flow. It also prolongs the anagen phase of the hair cycle. Unlike topical minoxidil, which requires local sulfotransferase enzyme activity in the scalp for conversion to its active form, oral minoxidil is metabolized systemically via hepatic sulfotransferase, potentially bypassing poor scalp enzyme activity in some individuals.[2]Kaiser, M., Abdin, R., Gaumond, S.I., Issa, N.T., Jiminez, J.J. (2023). Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology. 16. … Continue reading
For hair loss, oral minoxidil is prescribed at significantly reduced dosages compared to antihypertensive therapy – typically:
While oral minoxidil is not FDA-approved for hair loss, a number of studies show its efficacy.
A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
You can see a complete table of oral minoxidil studies here, but we have picked a few to show.
Vahabi-Amlashi et al (2021) conducted a triple-blind, randomized clinical trial in 72 women with female pattern hair loss, comparing oral minoxidil 0.25 mg daily to 2% topical minoxidil twice daily over 36 weeks.[4]Vahabi-Amlashi, S., Layegh, P., Kiafar, B., Hoseininezhad, M., Abbaspour, M., Khaniki, S.H., Forouzanfar, M., Sabeti, V. (2021). A randomized clinical trial on the therapeutic effects of 0.25 mg oral … Continue reading
Panchaprateep and Lueangarun (2020) conducted an open-label, prospective single-arm study in 30 men with AGA, treated with 5 mg oral minoxidil once daily for 24 weeks.[5]Panchaprateep, R., Lueangarun, S. (2020). Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic … Continue reading
Feaster et al. (2023) performed a multicenter retrospective study in 210 patients (50 men, 160 women) with AGA and/or telogen effluvium (TE), comparing low-dose oral minoxidil (0.625 – 2.5 mg daily) to a control (no minoxidil or other non-minoxidil treatments) over 52 weeks.[6]Feaster, B., Onamusi, T., Cooley, J.E., McMichael, A.J. (2023). Oral minoxidil use in androgenetic alopecia and telogen effluvium. Archives of Dermatological Research. 315(2). 201-205. Available at: … Continue reading
Overall, these studies demonstrate that oral minoxidil is an effective and generally well-tolerated treatment option for both AGA and TE in men and women. Across the studies, clinical improvements were observed, with similar efficacy to topical minoxidil.
However, the results that people show online are usually more dramatic than what is seen in clinical studies.
When reviewing outcomes, such as oral minoxidil before and after photos, it’s essential to distinguish what can happen from what is likely to happen. Take a look at the example we have created below. The scattered data points represent the full spectrum of possible individual results, while the central trendline shows the average, reflecting the most common or expected response.

Figure 1: A graph we created showing possible and probable results. The arrows point to possible results, and the trendline shows probable results.
These anecdotes (arrows on the graphs) often highlight “hyper-responders”. These are individuals who experience notably dramatic hair regrowth. They may have higher SULT1A1 activity, leading to higher levels of minoxidil activation.

Figure 2: Anecdotal results often look significantly more dramatic than clinical results.
These accounts, although genuine, illustrate results that surpass what most people can achieve. Problems can then arise when people fixate on these exceptional outcomes and assume that their experience will be similar. If their own hair growth is slower or less impressive, they might discontinue treatment early, or wrongly conclude that it isn’t working.

Figure 3: This leads to high expectations when the reality is that results will often be a lot less dramatic.
Impressive results are more frequently shared than modest improvements as a result of survivorship bias. This bias happens when only the most impressive successes receive attention, while the many cases with typical or less remarkable outcomes are overlooked or not reported.
Survivorship bias can distort our understanding of how hair loss treatments perform. Online narratives often draw attention to the most extreme cases, either astonishing successes or clear failures, while the more typical moderate outcomes that most people experience are rarely seen or discussed.
Now that we have covered the clinical evidence, strategies, and reasonable expectations for oral minoxidil, let’s now look into 10 firsthand accounts of oral minoxidil before and after photos shared by real users on Reddit.
Keep in mind that the experiences below are purely anecdotal in nature and are not subject to any independent verification. They strictly reflect the individual journeys of each poster and should not be construed as reliable clinical evidence or medical advice.

Source: u/jeffersonsteelflex94 via r/tressless.
This Redditor began oral minoxidil monotherapy at a dose of 2.5 mg before increasing to 5 mg once nightly. He had switched from topical minoxidil after a year of subpar results. He experienced shedding in the early months of therapy, with visible regrowth by month 3, and a major improvement in hair density by 11 months. Overall, the patient was satisfied with thicker scalp coverage, a fuller beard and brows, and did not report any significant side effects.

Source: u/GriffsChoice via r/tressless.
This 26-year-old used a combination of 1 mg finasteride and 2.5 mg oral minoxidil once daily, having switched from topical to oral minoxidil one year into treatment. He reported notable improvement one year into therapy, with visible regrowth by the 4-month mark. He did not report any shedding or other side effects after switching from topical to oral formulations. After two years of treatment, the patient reported marked hair thickening and cosmetic improvement.

Source: u/[deleted] via r/FemaleHairLoss.

Source: u/pomidorich via r/FemaleHairLoss.
This 24-year-old began minoxidil monotherapy with 5% foam nightly, before adding oral minoxidil 0.625 mg three months later, and titrating to 1.25 mg nightly the following month. She continued both nightly for six months. She did not note any noticeable shedding on the foam, nor after incorporating 0.625 mg orally. She reported steady baby hairs and a reduction in hair loss at ~6-9 months alongside thickening compared to the baseline, and mentioned that her hair felt and looked much closer to its pre-loss condition overall. She also reported faster growth of facial/body hair (hypertrichosis), water retention, and bloating after salt meals, and occasional stronger heartbeat at night, after incorporating oral minoxidil, though this last symptom did resolve.

Source: u/No_Pop2289 via r/tressless.
This male Redditor used oral minoxidil 5 mg once daily in addition to microneedling once weekly with a pen device. The poster also noted no side effects from finasteride, implying that they might have used it alongside the other treatments. He reported an initial shedding phase at around week 3 and rapid visible coverage by week 6 into treatment. In commenting on the progress to date, he noted fuller coverage compared to baseline and said his beard was slightly thicker without any apparent increase in body hair. He did not report any side effects.

Source: u/monicatheshark5 via r/FemaleHairLoss.
The poster took oral minoxidil 1.25 mg once daily, in addition to spironolactone 50 mg once daily (started at 100 mg but reduced the dose due to drowsiness). She noted visible improvement after about 5 months of consistent use, with shedding slowing markedly around weeks 7-8. At the one-year mark, she reported noticeably fuller hair at the part and temples, with ongoing gradual thickening, and “good hair days”. She reported increased body and facial hair from oral minoxidil, which she managed by waxing, and did not report any noticeable weight gain or low-blood-pressure symptoms.

Source: u/Aggressive_Space_121 via r/FemaleHairLoss.
This female Redditor took oral minoxidil 1.25 mg once daily for six months, having started from the initial dose of 0.625 mg. She supplemented with vitamin B12 injections every two weeks for pernicious anemia, daily shampooing, higher protein intake, and therapy/stress management. She reported steady improvement in hair through month 6, despite a brief “dread shed” in the initial month. Unfortunately, the images don’t show the same hair pulled back, so we can’t see exactly how much improvement was gained. She did report increased facial hair, which she has been managing by shaving/dermaplaning.

Source: u/neptunesummer via r/FemaleHairLoss.
This user took oral minoxidil 1.25 mg once daily for one year. She also used Nizoral shampoo on the same timeline. Her hair loss was first diagnosed as telogen effluvium that did not resolve, and she now suspects AGA. She reported modest shedding in the first 2 months, then gradual thickening over the year. The photos showed some improvement, but the patient stated that she is not fully back to baseline. Regarding side effects, she noted increased body hair growth and mild dizziness in the first month that resolved.

Source: u/Frosty_Wedding8706 via r/tressless.
This male Redditor switched from applying topical minoxidil to drinking a diluted solution mixed with water. He reported taking “a few drops” per dose, having discontinued application of the topical preparation to the scalp. At the three-month mark, the Redditor reported clearly greater overall density and said results were still improving. He did not report any side effects, except for some extra body hair.
We should mention that we do not recommend ingesting topical minoxidil – if oral therapy is pursued, it is advised to use a prescribed oral dose under medical supervision to control dosing and avoid health risks.

Source: u/blahblahyayah via r/FemaleHairLoss.
This user reported taking oral minoxidil at an unspecified dose for about one year. The photos show modest improvements around the parting. The poster did not report any side effects. Notwithstanding the sparse information provided by this Redditor, multiple commenters observed hair thickening and density gains in the before-and-after photos.
To maximize the benefits of oral minoxidil, consistent use and patience are essential as optimal regrowth often takes 6-8 months to fully manifest. Combining oral minoxidil with other treatments like finasteride or dutasteride, platelet-rich plasma (PRP), or low-level laser therapy (LLLT) can improve results for those who do not respond sufficiently to minoxidil alone. Recent studies support the efficacy of combination regimens, particularly oral minoxidil plus finasteride, with one retrospective study finding significant and clinically meaningful improvements.[7]Johnson, H., Huang, D., Clift, A.K., Bersch-Ferreira, A., Guimaraes, G.A. (2025). Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service … Continue reading

Figure 4: Percentage of patients who are stable or improved, or improved only, across increasing Norwood severities after combination finasteride and oral minoxidil treatment.[8]Johnson, H., Huang, D., Clift, A.K., Bersch-Ferreira, A., Guimaraes, G.A. (2025). Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service … Continue reading Image used in accordance with the PMC Copyright notice.
People using oral minoxidil, especially at 2.5 mg or more and in combination with other treatments, should keep an eye on potential side effects. This can help catch rare but potentially serious side effects like edema or changes in blood pressure. Regular follow-ups can ensure that any adverse effects are detected early and that the regimen can be safely adjusted to maintain a balance between safety and efficacy. This patient-tailored management increases the likelihood of achieving the best possible outcomes while minimizing health risks.
Based on the available evidence, the expected regrowth timeline for oral minoxidil is around 8 months.
Months 0-3: Possible increased shedding; no visible gains
Months 3-6: First positive density changes for many
Months 6-8: Maximal visible benefits
Months 8-12+
While oral minoxidil can avoid local irritation occurring with the topical formulation, some safety concerns do remain.
Oral minoxidil use does carry a risk of cardiovascular issues like pericardial effusion, especially at the high doses used for blood pressure control. At hair loss doses (0.25 – 5 mg), such events are rare and tend to be individual rather than predictable.
The majority of side effects, such as excess body hair, mild ankle swelling, lightheadedness, or palpitations, are mild and usually resolve with dose adjustments or stopping the medication.
Large safety studies have shown that serious side effects are exceedingly rare in otherwise healthy individuals taking low-dose oral minoxidil, with only a small percentage discontinuing treatment due to adverse effects.
A gradual dose escalation is recommended to minimize side effects with oral minoxidil. Recent studies have shown that a 2.5 mg daily dose is as effective as 5 mg for treating male pattern hair loss, but with a better safety profile, and this supports 2.5 mg as a preferred starting dose for men.[9]Fonseca, L.P.C., Miot, H.A., Chaves, C.R.P., Ramos, P.M. (2025). Oral Minoxidil 2.5 mg vs 5 mg for Male Androgenetic Alopecia: A Double-Blind Randomized Clinical Trial. Journal of the American … Continue reading
If you want to use a higher dose, sublingual minoxidil may be beneficial for reducing the risk of cardiovascular side effects.[10]Gupta, A.K., Bamimore, M.A., Williams, G., Talukder, M. (2025). Comparative Efficacy of Minoxidil and 5-Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta-Analysis Study … Continue reading
Oral minoxidil use is growing, but should be recognized as an off-label option (albeit backed by a solid body of emerging evidence.. Most users can expect stabilization or noticeable yet modest regrowth rather than dramatic transformation. The best outcomes come with realistic expectations, consistent use over several months, and regular medical supervision to ensure safety. By focusing on average, evidence-based results rather than rare hyper-responder anecdotes, patients can make balanced decisions and maintain long-term adherence to their treatment plan.
References[+]
| ↑1 | Ramos, P.M., Goren, A., Sinclair, R., Miot, H.A. (2020). Oral minoxidil bio-activation by hair follicle outer root sheath cell sulfotransferase enzymes predicts clinical efficacy in female pattern hair loss. Journal of the European Academy of Dermatology and Venereology. 34(1). E40-e41. Available at: https://doi.org/10.1111/jdv.15891 |
|---|---|
| ↑2 | Kaiser, M., Abdin, R., Gaumond, S.I., Issa, N.T., Jiminez, J.J. (2023). Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology. 16. 1387-1406. Available at: https://doi.org/10.2147/CCID.S385861 |
| ↑3 | Bloch, L.D., Carlos, R.M.D. (2024). Side Effects’ Frequency Assessment of Low Dose Oral Minoxidil in Male Androgenetic Alopecia Patients. Skin Appendage Disorders. 11(1). 14-18. Available at: https://doi.org/10.1159/00539969 |
| ↑4 | Vahabi-Amlashi, S., Layegh, P., Kiafar, B., Hoseininezhad, M., Abbaspour, M., Khaniki, S.H., Forouzanfar, M., Sabeti, V. (2021). A randomized clinical trial on the therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss. Dermatological Therapy. 34(6). E15131. Available at: https://doi.org/10.1111/dth.15131 |
| ↑5 | Panchaprateep, R., Lueangarun, S. (2020). Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatology and Therapy. 10. 1345-1357. Available at: https://doi.org/10.1007/s13555-020-00448-x |
| ↑6 | Feaster, B., Onamusi, T., Cooley, J.E., McMichael, A.J. (2023). Oral minoxidil use in androgenetic alopecia and telogen effluvium. Archives of Dermatological Research. 315(2). 201-205. Available at: https://doi.org/10.1007/s00403-022-02331-5 |
| ↑7 | Johnson, H., Huang, D., Clift, A.K., Bersch-Ferreira, A., Guimaraes, G.A. (2025). Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation. Cureus. 17(1). E77549. Available at: https://doi.org/10.7759/cureus.77549 |
| ↑8 | Johnson, H., Huang, D., Clift, A.K., Bersch-Ferreira, A., Guimaraes, G.A. (2025). Effectiveness of Combined Oral Minoxidil and Finasteride in Male Androgenetic Alopecia: A Retrospective Service Evaluation. Cureus. 17(1). E77549. Available at: https://doi.org/10.7759/cureus.77549 |
| ↑9 | Fonseca, L.P.C., Miot, H.A., Chaves, C.R.P., Ramos, P.M. (2025). Oral Minoxidil 2.5 mg vs 5 mg for Male Androgenetic Alopecia: A Double-Blind Randomized Clinical Trial. Journal of the American Academy Dermatology. 15. Available at: https://doi.org/10.1016/j.jaad.2025.09.031 |
| ↑10 | Gupta, A.K., Bamimore, M.A., Williams, G., Talukder, M. (2025). Comparative Efficacy of Minoxidil and 5-Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta-Analysis Study of Current Empirical Evidence. Journal of Cosmetic Dermatology. 62(2). 257-259. Available at: https://doi.org/10.1111/ijd.163737 |
Topical minoxidil has been a cornerstone of androgenic alopecia (AGA) treatment since its FDA approval in the 1980s. With millions of users worldwide, it stands as one of the most widely adopted therapies for hair loss, supported by decades of clinical evidence, and an enormous body of real-world anecdotes, reviews, and before-and-after photos.
However, results with minoxidil can be highly variable, and this variability can be traced in part to biological differences, particularly in the activity of the sulfotransferase enzyme (SULT1A1), which is responsible for converting minoxidil into its active form. Not everyone sulfates minoxidil effectively, meaning that while some achieve meaningful regrowth, others see little to no improvement.
Rx-strength topical minoxidil, formulated without propylene glycol. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Adding to this challenge is the influence of online topical minoxidil before and after photos (like you can see below), which can create inflated expectations compared to the more modest, probable outcomes seen in practice.

Source: u/United_Speaker3381 via r/tressless.
This article will break through that noise to answer a critical question: when it comes to minoxidil, what is actually the most probable result, not just possible?
First, let’s take a look at what topical minoxidil is.
Topical minoxidil was the first therapy ever approved by the FDA for the treatment of AGA, making it a landmark in the medical management of pattern hair loss.[1]Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786 Introduced in the 1980s, it has since become one of the most widely available and researched treatments across the globe. Its primary action is as a potassium channel opener, which helps to stimulate blood flow, prolong the hair’s growth phase (anagen), and increase follicle size, mechanisms that together can support thicker, denser hair regrowth over time.[2]Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 150(2). 186-194. Available at: https://doi.org/10.1111/j.1365-2133.2004.05785.x
Minoxidil is known as a “pro-drug”, meaning that it needs to be activated within the body to exert its effect. The enzyme responsible for this is called sulfotransferase or, more specifically, SULT1A1. The level of sulfotransferase activity differs depending on the individual, which means that the effectiveness of treatment also differs depending on who you are.[3]Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a … Continue reading
Formulations typically come in 2% and 5% strengths. The 2% solution was originally FDA-approved for women, while the 5% concentration was approved for men; however, both are now commonly used off-label across genders. Beyond these standard strengths, compounding pharmacies have made higher concentrations available for patients seeking more individualized treatment approaches, with some online telehealth providers (such as Ulo) offering customized formulations. Standard dose topical minoxidil is available over-the-counter in most countries, ensuring accessibility without the need for a prescription.
A rapidly-dissolving sublingual tablet with minoxidil. Available in 1.25 mg and 2.5 mg doses. Prescribed 100% online. Choose a multi-month plan and get up to 30% plus a free gift bundle.
*Only available in the U.S. Prescription requires an online medical consultation at no extra cost. Off-label products are not endorsed by the FDA. Free gifts included with select multi-month plans while supplies last. Ulo is a partner of Perfect Hair Health; we may earn a commission on purchases.
Topical minoxidil’s robust efficacy for hair regrowth is supported by dozens of high-quality randomized controlled trials (RCTs) and meta-analyses across men and women, consistently demonstrating average increases in hair count of around 10-20% over 6-12 months.
We have collated many of these studies into a table, which you can look at here. However, we have summarised some of the most recent topical minoxidil studies.
Overall, when you look across all of the data, consistent benefits are seen with topical minoxidil usage. However, these results are variable. The key reason for this is differences in sulfotransferase activity. As we mentioned before, minoxidil is a pro-drug, and it needs to be enzymatically activated to exert its effect. We will go into more detail about this below.
When evaluating treatment outcomes, especially online minoxidil before and after photos, it’s important to separate possibility from probability. The scattered data points below show the full range of what might occur for individuals, while the central trendline reflects the average outcome (i.e., what typically happens).

Figure 1: A graph showing possible and probable results. The data points show possible results, and the trendline shows probable results.[8]Badenhorst CE, Dawson B, Goodman C, Sim M, Cox GR, Gore CJ, Tjalsma H, Swinkels DW, Peeling P. Influence of post-exercise hypoxic exposure on hepcidin response in athletes. Eur J Appl Physiol. 2014 … Continue reading
Online anecdotes often showcase what we would call “hyper-responders” – people who experience dramatic results. These people may also have higher levels of sulfotransferase activity.

Figure 2: Anecdotal results are often way more dramatic than the typical.
These stories, while real, represent outcomes that are well above average. The issue arises when patients focus only on these peak results and expect the same for themselves. If their own progress seems slower or less dramatic, they may stop prematurely or mistakenly believe the treatment is ineffective.

Figure 3: Expected results are often far more dramatic than probable results.
Dramatic results are often showcased more than modest outcomes because of survivorship bias. This bias occurs when only the most striking successes are noticed or shared, while the many average or less impressive results go unreported.

Figure 4: Survivorship bias skews perception of hair loss treatments. Online accounts often highlight extreme outcomes, either exceptional success or very poor results, while the typical, average outcomes experienced by most remain underrepresented.
Minoxidil must be converted into minoxidil sulfate by the sulfotransferase enzyme SULT1A1, which is present in the outer root sheath of hair follicles, to become pharmacologically active and stimulate hair growth.
Several peer-reviewed studies confirm that the level of SULT1A1 activity in scalp follicles is a key determinant of how well a patient responds to minoxidil therapy.[9]Goren, A., Castano, J.A., McCoy, J., Bermudez, F., Lotti, T. (2014). Novem enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy. 27(3). 171-173. … Continue reading Enhancing SULT1A1 activity, such as by using enzyme-boosting adjuvants, has been shown in recent trials to convert a majority of prior non-responders into responders, further confirming the mechanistic role of this enzyme.[10]Chandrashekar, B.S., Chandu, M., Shenoy, C., Chander, A., Roopa, M.S. (2024). SULT1A1 enzyme booster to amplify topical minoxidil response in androgenic alopecia: a single-center prospective study. … Continue reading
This enzyme-based variability explains why two people can apply minoxidil in the same way but see very different outcomes, and why more than half of users may see only limited or no benefit despite consistent application.
A number of evidence-based strategies exist to improve minoxidil response. These include microneeding, retinoic acid co-application, formulation changes, consistency, and combination therapy.
Multiple systematic reviews and clinical trials confirm microneedling significantly improves minoxidil efficacy. A 2023 meta-analysis showed that combining the two led to a significantly greater increase in hair count compared to minoxidil alone, regardless of needle depth or device used. Hair count improvements are notable after 12 to 24 weeks of combined treatment.[11]Ahmed, K.M.A., Kozaa, Y.A., Abuawwad, M.T., Al-Najdawi, A.I., Mahmoud, Y.W., Ahmed, A.M., Taha, M.J.J., Fadhli, T., Giannopoulou, A. (2025). Evaluating the efficacy and safety of combined … Continue reading
You can read more about how microneedling improves minoxidil efficacy here.
Topical tretinoin has been shown in peer-reviewed studies to upregulate follicular SULT1A1, thereby enhancing the conversion of minoxidil to its active form. In a 2019 study, tretinoin not only improved clinical response in difficult cases but also increased scalp SULT1A1 activity, supporting its role as a mechanistic booster.[12]Sharma, A., Goren, A., Dhurat, R., Agrawal, S., Sinclair, R., Trueb, R.M., Vano-Galvan, S., Chen, G., Tan, Y., Kovacevic, M. (2019). Tretinoin enhances minoxidil response in androgenetic alopecia … Continue reading
You can see the benefits of adding retinoic acid in our Compare Treatments graph below.

Figure 5: Combining topical minoxidil with retinoic acid significantly boosts regrowth potential.
Learn more about retinoic acid and its effects on sulfotransferase here.
Clinical research shows that 5% minoxidil is more effective than 2% for both men and women. Foam is as effective as a solution but better tolerated, with reduced risk of contact dermatitis due to the absence of propylene glycol. Some evidence suggests liquid formulations might yield slightly higher absorption, but both forms are clinically comparable.[13]Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714
Missed doses can reduce topical minoxidil efficacy. Some clinical guidance suggests that missing minoxidil applications even once per week can diminish results, and consistent, daily use is necessary to achieve and maintain hair regrowth.[14]Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatology and Therapy. 13(5). 1157-1169. Available at: … Continue reading
Combining minoxidil with finasteride/dutasteride, PRP, low-level laser therapy (LLLT), or, in resistant cases, oral minoxidil, provides superior results versus monotherapy. Meta-analyses and randomized trials consistently find greater improvement in hair density, count, and patient satisfaction when using combination regimens.[15]Xia, Y., Chen, H., Chen, Y., Chen, Z. (2025). Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis based on randomized controlled … Continue reading
So, what do online topical minoxidil before and after photos look like?
Now that we have discussed how topical minoxidil works, potential regimens, and likely timelines, here are 10 reports published by Reddit users with before and after photos.
Disclaimer: The stories below are unverified anecdotes. Consequently, they illustrate individual outcomes and should not be construed as clinical proof or medical advice.

Source: u/Dual270x via r/tressless.
This individual applied 5% topical minoxidil once daily for six months. They chose topical minoxidil out of a general preference for avoiding oral medications. From the before-and-after photos, diffuse thinning can be observed from the center of the crown, and the protocol yielded a noticeable increase in crown density by month six. No side effects or early shedding have been reported.

Source: u/maddogyr via r/FemaleHairLoss.
This user applied 5% topical minoxidil once nightly for about 5 months, using a liquid solution that she purchased over the counter after a telemedicine consult. She stated that she had AGA and did not note any other treatment. Based on both her comments and photos, she experienced marked improvement in hair density and coverage, stating that minoxidil “saved her hair” and that she wishes she had started earlier. She did not describe any notable early shedding, but noted dry scalp and some dandruff as potential side effects.

Source: u/[deleted] via r/tressless.

Source: u/Hyper-Fang via r/FemaleHairLoss.
This user had AGA with prior telogen effluvium, reporting diffuse thinning along the part and temples and a reportedly high daily shedding. She began therapy with Rogaine Men’s Foam 5% once nightly, supported by Ketoconazole 2% shampoo once weekly. At 2 months of treatment, “peach fuzz”/baby hairs were visible at the hairline and temples. At 6 months, there was a noticeable density across the top with new hairs evident but still short. After 1 year and 5 months of therapy, she notes ongoing thickening and widespread new hair growth. She also reported that her shower shed decreased from ~70 hairs to ~10-15, with visual density improving at the part and temples. She reported a mild scalp itch at the start and subtle peach-fuzz on the upper lip and chin as side effects.

Source: u/pcybits via r/tressless.
This male user, likely with AGA, reported recession at the hairline and thinning at the crown after 2.5 months of using a Rogaine-style 5% liquid at 2 mL/day, without any concurrent DHT blocker. He experienced an early shedding phase ~1 month into treatment, which stabilized with continued use. He exhibited visible thickening at the hairline and crown by 2.5 months of therapy. He did not report any systemic or local side effects and plans to continue minoxidil while considering adding weekly microneedling and/or topical finasteride if progression resumes.
Other Redditors have used combination treatments to further improve their hair regrowth. As you can see below, some of the results look dramatic.

Source: u/United_Speaker3381 via r/tressless.
This user had thinning at the hairline and vertex areas of the scalp and began treatment to improve hair density and maintenance. He applied a single compounded solution (Novegrow) containing minoxidil 5% and finasteride 0.1%, once nightly, for three months before reporting on progress. Additionally, he dermarolled his scalp with a 0.5 mm needle twice weekly and supplemented with daily biotin and a multivitamin. He reported mild shedding in the first two weeks of therapy, and by month 3, he noted visible thickening and improved coverage. He did not report any side effects and added that the once-daily schedule was practical and helped with adherence.

Source: u/Jordan_cadagan via r/tressless.
This Redditor exhibited typical AGA with frontal recession and diffuse vertex thinning. His core regimen is oral finasteride 1 mg daily and minoxidil 5% foam (Kirkland) once daily. He noted he took regular ice/cold baths, ensured an increased water intake, engaged in exercise, avoided junk food, and did not smoke. He saw noticeable thickening from around 6 months after several shedding cycles. By month 11, he experienced substantial cosmetic improvement, with some commenters even comparing the results to transplant-level density. He did not report any adverse effects from finasteride or minoxidil, and subjectively felt less “brain fog” after starting finasteride.

Source: u/Far-Instance268 via r/tressless.
This male had crown-predominant thinning with a stable hairline at baseline. His core regimen is a single combined solution containing minoxidil 5% and finasteride 0.1%, applied to the crown only. He did not report any microneedling or supplementation. He reported that shedding began around week 3 and was “heavy” for approximately 4 weeks. The shedding tapered and largely stopped at the 2.5-month mark. By month 4, he achieved visible crown regrowth and thickening compared to the baseline, despite the application being limited to the crown. He perceived an increase in overall density and did not report any side effects.

Source: u/iTsundere via r/tressless.
This male reported on his progress after using a combination of topical finasteride 0.3% and minoxidil 6% treatment twice daily for nearly one year. He first experienced hair thinning and hairline recession beginning in his late 20s. Alongside the topical treatments, he also applied a dermastamp at approximately 1.5 mm every 10 days. He reported significant shedding during the first two months of treatment along with mild chest tenderness in the first month, which resolved after temporarily halving the topical dose. He reported month-on-month thickening, with clear improvement by months 7-8 and robust density by the one-year mark.

Source: u/M3ga_Shniz via r/tressless.
This user with early temple recession began a combination therapy of finasteride 1 mg oral daily, minoxidil 5% foam twice daily, and dermaoll 1.5 mm weekly. He experienced noticeable shedding at weeks 3-6 of therapy, and at the 90-day progress mark, he reported visible filling in of the temple and general thickening of the hair. He did not report any side effects and noted that pushing through the initial shedding phase was crucial to his progress thus far.
Based on the available evidence, we have mapped out a likely regrowth timeline (although some may experience results faster or later).
Months 0-3: Initial shedding
Months 3-6: Early cosmetic improvements
Months 6-12: Peak cosmetic changes
Months 12+: Plateau, maintenance, & slight regression
Local side effects are relatively common with topical minoxidil, especially with the liquid formulations. The principal culprits are propylene glycol and ethanol, which frequently cause redness, itching, dryness, and a dandruff-like scaling of the scalp.[16]Makhlouf, A., Elnawawy, T. (2023). Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser … Continue reading Patients with sensitive skin are particularly prone to these adverse reactions and may experience contact dermatitis, which can make long-term use uncomfortable.
The foam formulation is generally better tolerated because it lacks propylene glycol. Most clinical trials and user surveys report fewer cases of scalp irritation, itching, or flaking with foam compared to the liquid version.[17]Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714
While systemic absorption of topical minoxidil is rare, some users may experience unwanted side effects such as dizziness and the growth of facial or body hair away from the application site. These effects are more likely if the medication is used excessively or applied to broken or abraded skin, which can increase absorption. We do not recommend using topical products if you have an inflammatory scalp condition – deal with that problem first, and then take a look at topical hair regrowth products.
Overall, when used as directed, topical minoxidil has a strong safety profile, with most side effects limited to mild local irritation.
When evaluating minoxidil, it is important to recognize it as the most widely accessible and evidence-backed treatment for androgenetic alopecia. While outcomes can vary, most users see stabilization and modest regrowth rather than dramatic reversal. Success depends on realistic expectations, consistent use, and optimized regimens that may include adjunctive therapies. Applying a framework that emphasizes the likely trendline over anecdotal extremes can help you stay committed, avoid discouragement, and make informed decisions grounded in evidence and personal treatment goals.
References[+]
| ↑1 | Suchonwanit, P., Thammarucha, S., Leerunyakul, K. (2019). Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 13. 2777-2786 |
|---|---|
| ↑2 | Messenger, A.G., Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology. 150(2). 186-194. Available at: https://doi.org/10.1111/j.1365-2133.2004.05785.x |
| ↑3 | Pietrauszka, K., Bergler-Czop, B. (2020). Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Advances in Dermatology and Allergology. 39(3). 472-478. Available at: https://doi.org/10.5114/ada.2020.99947 |
| ↑4 | Liang, X., Chang, Y., Wu, H., Liu, Y., Zhao, J., Wang, L., Zhuo, F. (2022). Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Frontiers in Medicine. 11(9). 905140. Available at: https://doi.org/10.3389/fmed.2022.905140 |
| ↑5 | Hassan, G.F.R., Sadoma, M.E.T., Elbatsh, M.M., Ibrahim, Z.A. (2022). Treatment with oral vitamin D alone, topical minoxidil, or combination of both in patients with female pattern hair loss: A comparative clinical and dermoscopic study. Journal of Cosmetic Dermatology. 21(9). 3917-3924. Available at: https://doi.org/10.1111/jocd.14743 |
| ↑6 | Bao, L., Zong, H., Fang, S., Zheng, L., Li, Y. (2019). Randomized trial of electrodynamic microneedling combined with 5% minoxidil topical solution for treating androgenetic alopecia in Chinese males and molecular mechanistic study of the involvement of the Wnt/ꞵ-catening signaling pathway. Journal of Dermatological Treatment. 33(1). 483-493. Available at: https://doi.org/10.1080/09546634.2020.1770162 |
| ↑7 | Singh, S.K., Kumar, V., Rai, T. (2020). Comparison of efficacy of platelet-rich plasma therapy with or without topical 5% minoxidil in male-type baldness: A randomized, double-blind placebo control trial. Indian Journal of Dermatology, Venereology, and Leprology. 86(2). 150-157. Available at: https://doi.org/10.4103/ijdvl.IJDVL_589_18 |
| ↑8 | Badenhorst CE, Dawson B, Goodman C, Sim M, Cox GR, Gore CJ, Tjalsma H, Swinkels DW, Peeling P. Influence of post-exercise hypoxic exposure on hepcidin response in athletes. Eur J Appl Physiol. 2014 May;114(5):951-9. doi: 10.1007/s00421-014-2829-6. Epub 2014 Feb 1. PMID: 24487960. |
| ↑9 | Goren, A., Castano, J.A., McCoy, J., Bermudez, F., Lotti, T. (2014). Novem enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy. 27(3). 171-173. Available at: https://doi.org/10.1111/dth.12111 |
| ↑10 | Chandrashekar, B.S., Chandu, M., Shenoy, C., Chander, A., Roopa, M.S. (2024). SULT1A1 enzyme booster to amplify topical minoxidil response in androgenic alopecia: a single-center prospective study. International Journal of Research in Medical Sciences. 12(11). Available at: https://doi.org/10.18203/2320-6012.ijrms20243362 |
| ↑11 | Ahmed, K.M.A., Kozaa, Y.A., Abuawwad, M.T., Al-Najdawi, A.I., Mahmoud, Y.W., Ahmed, A.M., Taha, M.J.J., Fadhli, T., Giannopoulou, A. (2025). Evaluating the efficacy and safety of combined microneedling therapy versus topical Minoxidil in androgenetic alopecia: a systematic review and meta-analysis. Archives of Dermatological Research. 317(1). 528. Available at: https://doi.org/10.1007/s00403-025-04032-1 |
| ↑12 | Sharma, A., Goren, A., Dhurat, R., Agrawal, S., Sinclair, R., Trueb, R.M., Vano-Galvan, S., Chen, G., Tan, Y., Kovacevic, M. (2019). Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatologic Therapy. 32(3). E12915. Available at: https://doi.org/10.1111/dth.12915 |
| ↑13, ↑17 | Purnak, T., Senel, E., Sahin, C. (2011). Liquid formulation of minoxidil versus its foam formulation. Indian Journal of Dermatology. 56(4). 462. Available at: https://doi.org/10.4103/0019-5154.84714 |
| ↑14 | Shadi, Z. (2023). Compliance to Topical Minoxidil and Reasons for Discontinuation among Patients with Androgenetic Alopecia. Dermatology and Therapy. 13(5). 1157-1169. Available at: https://doi.org/10.1007/s13555-023-00919-x |
| ↑15 | Xia, Y., Chen, H., Chen, Y., Chen, Z. (2025). Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis based on randomized controlled trials. Frontiers in Medicine. 12. Available at: https://doi.org/10.3389/fmed.2025.1638496 |
| ↑16 | Makhlouf, A., Elnawawy, T. (2023). Hair regrowth boosting via minoxidil cubosomes: Formulation development, in vivo hair regrowth evaluation, histopathological examination and confocal laser microscopy imaging. International Journal of Pharmacology. 634. 122665. Available at: https://doi.org/10.1016/j.ijpharm.2023.122665 |
Ketoconazole shampoo has long been used for dandruff and seborrheic dermatitis, two common scalp conditions associated with flaking, itching, redness, and changes in the scalp microbiome. More recently, ketoconazole has gained attention among people with androgenetic alopecia (AGA). Human studies have reported reductions in shedding and improvements in hair-shaft diameter and anagen hair percentage, although the evidence for hair growth is still far smaller than that for established treatments like minoxidil and finasteride.[1]Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther. 2020;33(1):e13202. https://doi.org/10.1111/dth.13202
Ketoconazole shampoos typically come in 1% and 2% concentrations, with 2% only available as a prescription. Shampoo formulations can also vary significantly in surfactant content, fragrance, and overall tolerability. For people with thinning, dry, chemically treated, or easily damaged hair, those differences are as important as strength. In this guide, we compare the 10 best ketoconazole shampoos of 2026 across OTC, prescription, telehealth, and online pharmacy options to help you choose formulas that balance efficacy, tolerability, and convenience.
The top natural ingredients for hair growth. Take the next step in your hair growth journey with a world-class ketoconazole shampoo. Ingredients, doses, & concentrations built by science.Ketoconazole Shampoo
| Ulo Thickening+ Ketoconazole Shampoo | 0.9% | Online / Provider-guided | Overall |
| Nizoral 2-in-1 Shampoo + Conditioner | 1% | OTC | Conditioning |
| Nizoral Anti-Dandruff Shampoo | 1% | OTC | OTC |
| Keeps Ketoconazole Shampoo | 2% | Prescription / Telehealth | Men’s hair loss telehealth |
| Generic Ketoconazole Shampoo | 2% | Prescription / Pharmacy | Value prescription |
| Strut Health Ketoconazole Shampoo | 2% | Prescription / Telehealth | Men’s & women’s hair loss telehealth |
| EasyDerm Ketoconazole Shampoo | 2% | Prescription / Teledermatology | Budget option |
| TelyRx Ketoconazole Shampoo | 2% | Prescription / Telehealth | Fast online access |
| AlgoRx Ketoconazole Shampoo | 2% | Prescription / Telehealth | Alternative telehealth |
| RedBox Rx Ketoconazole Shampoo | 2% | Prescription / Telehealth | Low-cost telehealth |
Before we get into our list, let’s take a look at what ketoconazole is, how it works, and why it has become increasingly popular among people with hair loss.
Ketoconazole is an antifungal medication used to treat fungal and yeast-associated skin conditions. On the scalp, it’s used primarily for dandruff and seborrheic dermatitis, both of which are strongly associated with Malassezia yeasts. Malassezia normally lives on the scalp, but changes in yeast populations, sebum composition, barrier function, and inflammatory signaling can contribute to symptoms. Ketoconazole works by interfering with ergosterol synthesis, an important component of fungal cell membranes, which helps reduce Malassezia populations.
The anti-dandruff effects of ketoconazole are well established. In one multicenter study of patients with seborrheic dermatitis or moderate to severe dandruff, 2% ketoconazole shampoo used twice weekly for two to four weeks produced an excellent response in a large majority of participants. [2]Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, … Continue reading Another randomized study compared 2% ketoconazole with 1% zinc pyrithione in 331 people with severe dandruff or seborrheic dermatitis. Both worked, although ketoconazole produced a greater reduction in total dandruff severity after four weeks.[3]Piérard-Franchimont C, Goffin V, Decroix J, Piérard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin … Continue reading Thus, for dandruff and seborrheic dermatitis, ketoconazole has a strong body of evidence to support its use.
There is less evidence for ketoconazole as a hair-loss treatment than for its efficacy in dandruff treatment. Nevertheless, a few human studies have reported improvements in hair shedding, hair-shaft diameter, and the proportion of hairs in anagen, particularly in men with androgenetic alopecia and dandruff.
One of the longest studies followed 39 men with AGA for 21 months. Twenty-seven used 2% ketoconazole shampoo two to four times weekly, while 12 used an unmedicated shampoo. Researchers also followed 22 age-matched men without AGA, split between ketoconazole and unmedicated shampoo, to see whether any change was specific to people with pattern hair loss.
Based on the study, the researchers created an AGA pilary index, which combined the number of hairs in anagen with average hair-shaft diameter. Because both measures tend to deteriorate as AGA progresses, a rising index would suggest an improvement in the overall condition.
Among men without AGA, shampoo choice made little difference to the pilary index. Among men with AGA, however, the treatment appeared to have a beneficial effect. The unmedicated-shampoo group showed a gradual decline, while the ketoconazole group began to improve after roughly six months, plateauing around month 15.[4]Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477. … Continue reading
A second study looked at 150 men with telogen effluvium related to AGA and associated dandruff. Participants were randomized to use one of three anti-dandruff shampoos — 1% ketoconazole, 1% piroctone olamine, or 1% zinc pyrithione — two to three times weekly for six months.
Researchers tracked hair shedding, hair density, anagen percentage, hair-shaft diameter, and sebum output as their parameters for treatment efficacy (or lack thereof).
All three shampoos rapidly improved itching and dandruff, but none produced a meaningful change in hair density. The more notable changes were in shedding, anagen percentage, and hair-shaft diameter.
Hair shedding fell by 17.3% with ketoconazole, 16.5% with piroctone olamine, and 10.1% with zinc pyrithione. Anagen percentage increased by 4.9%, 7.9%, and 6.8%, respectively. Mean hair-shaft diameter increased by 5.4% with ketoconazole and 7.7% with piroctone olamine, while it decreased by 2.2% with zinc pyrithione. Sebum output fell by 4.8% with ketoconazole and 2.9% with piroctone olamine, but increased by 5.5% with zinc pyrithione.
In this study, 1% ketoconazole had no measurable effect on total hair density, but it did reduce shedding, increase the proportion of hairs in anagen, and increase average shaft diameter. For someone with dandruff plus shedding, those are potentially useful effects even without a significant increase in hair count.[5]Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE. Nudging hair shedding by antidandruff shampoos: a comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione … Continue reading
Ketoconazole has also been tested as a component of combination regimens. In one open randomized study of 100 men with AGA, the best results were seen with finasteride plus minoxidil, followed by finasteride plus ketoconazole, finasteride alone, and minoxidil alone. [6]Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489-498. https://doi.org/10.1111/j.1346-8138.2002.tb00314.x
A separate 15-man pilot study used a much more aggressive multidrug regimen that could include ketoconazole shampoo alongside finasteride, dutasteride, and minoxidil. All participants showed hair growth, but because several treatments were used at the same time, it is impossible to determine how much ketoconazole contributed individually.[7]Rafi AW, Katz RM. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatology. 2011:241953. https://doi.org/10.5402/2011/241953
Altogether, the evidence from human studies suggests that ketoconazole may improve certain hair-loss-related outcomes, particularly shedding, anagen percentage, and hair-shaft diameter. The evidence is still much weaker than for minoxidil, finasteride, or dutasteride, making it a reasonable adjunct but not a standalone therapy.
In the United States, ketoconazole shampoos are available over the counter but are limited to 1% or less ketoconazole. Shampoos containing 2% ketoconazole are available by prescription. Based on the available evidence, both 1% and 2% help to control dandruff, seborrheic dermatitis, and other inflammatory scalp conditions. The Rx-strength 2%, however, outperforms the 1% concentration for supporting scalp health and may also have an advantage for hair density.
The overall formulation of the shampoo also matters. Ketoconazole must be tolerable enough for consistent use, particularly for people already using topical hair-loss treatments that can cause dryness or irritation. While 1% ketoconazole formulations generally have more ingredient flexibility due to their over-the-counter status, prescription formulas generally contain the same generic ingredients across the board.
With that in mind, let’s take a look at our top 10 ketoconazole shampoos of 2026.
| ✓ Contains 0.9% ketoconazole | ✗ Lower ketoconazole concentration than prescription 2% shampoos |
| ✓ Sulfate-free | ✗ Less widely available than traditional OTC shampoos |
| ✓ Formulated to be non-drying | |
| ✓ Designed specifically for thinning hair | |
| ✓ The only ketoconazole shampoo with caffeine | |
| ✓ Integrated with a hair loss treatment platform |
Ulo’s Thickening+ Ketoconazole Shampoo is our go-to option for people who want to add ketoconazole to a broader hair-loss routine. It contains 0.9% ketoconazole in a sulfate-free base designed to be non-drying, which sets it apart from many traditional medicated shampoos that can leave the hair feeling dry, brittle, or difficult to manage.
Dryness itself does not accelerate androgenetic alopecia, but brittle or coarse hair can increase breakage that may affect the appearance of hair. For someone using ketoconazole several times per week, cosmetic tolerability is an important factor in treatment adherence.
Ulo also formulates the shampoo specifically for thinning hair, including additional supportive ingredients like caffeine, saw palmetto, and rosemary. The addition of these beneficial ingredients make it the most robust formulation on the list. At 0.9%, the ketoconazole concentration is slightly below the conventional 1% concentration, but it likely approximates the effect of 1% ketoconazole.
Ulo’s broad hair-loss telemedicine platform also provides additional treatments for hair loss, making it easy to access ketoconazole and other medications in one place.
Bottom Line: Ulo is our top overall option for people using ketoconazole as part of a longer-term hair-loss routine. Its gentle, sulfate-free formula approximates the 1% concentration seen in clinical studies for a shampoo that maximizes tolerability for long-term adherence. Ulo’s broader telemedicine platform makes it simple to access hair-loss medications alongside ketoconazole shampoo.
| ✓ Contains 1% ketoconazole | ✗ May still be drying compared with a dedicated conditioner |
| ✓ Available without a prescription | ✗ Contains sulfates |
| ✓ More conditioning than standard Nizoral | |
| ✓ Designed to leave hair softer and more manageable |
Nizoral 2-in-1 combines 1% ketoconazole with a more conditioning shampoo base, making it our preferred OTC option for people who like ketoconazole but dislike the way traditional medicated shampoos leave their hair feeling. It is intended for twice-weekly use and is marketed for color-treated, chemically processed, and gray hair.
However, the formula still contains sulfates and may still be relatively drying. Online reviews are mixed when it comes to post-wash dryness.[8]Walmart customer reviews. https://www.walmart.com/reviews/product/5761431665
Importantly, a 2-in-1 formula will not replace a dedicated conditioner for everyone, particularly if the mid-lengths and ends are already very dry or damaged.
Bottom Line: If standard ketoconazole works for your scalp but leaves your hair feeling too dry, Nizoral 2-in-1 offers the same 1% ketoconazole concentration in a more conditioning format. However, the formula does contain sulfates, and overall customer experiences with post-shower hair feel are mixed.
| ✓ 1% ketoconazole available without a prescription | ✗ May be drying for some hair types |
| ✓ Strong clinical evidence for dandruff | ✗ Contains drying sulfates |
| ✓ Widely available in the U.S. |
Nizoral Anti-Dandruff Shampoo is one of the most established ketoconazole shampoos available in the United States. It contains 1% ketoconazole and can be purchased without a prescription, making it a straightforward option for people who want to treat dandruff without going through a provider.
The main drawback of Nizoral is tolerability. Nizoral contains sulfates as its main surfactants, which can be drying to the hair and scalp. This may be an obstacle to long-term use.
Bottom Line: Nizoral Anti-Dandruff Shampoo remains one of the easiest ways to try clinically established 1% ketoconazole without a prescription, although dry or easily damaged hair may do better with a more conditioning formula.
| ✓ Prescription-strength 2% ketoconazole | ✗ Requires a prescription |
| ✓ Integrated telehealth platform | ✗ Only available for men |
| ✓ Accessible pricing | |
| ✓ Delivered directly to the patient |
Keeps offers prescription 2% ketoconazole shampoo through its telehealth hair-loss platform. It is intended for people who want a higher-strength option, particularly when over-the-counter treatment has not been sufficient or a protocol targeted toward hair density is desired. At $11 per month, it’s one of the more accessibly priced ketoconazole shampoos.
Keeps also makes sense for people who already use the platform for another hair-loss treatment. The convenience is the main selling point: Eligible users can complete the medical consultation online and have the prescription handled through the same platform.
However, Keeps does not provide its telehealth services to women. Women looking to use Rx-strength ketoconazole shampoo will need to look elsewhere.
Bottom Line: Keeps is a strong option for people who want 2% ketoconazole inside an existing telehealth hair-loss regimen, especially when OTC treatment has not been enough or a higher concentration is preferred for individual goals. However, Keeps is only available for men.
| ✓ Prescription-strength 2% ketoconazole | ✗ Requires a prescription in the U.S. |
| ✓ Insurance may cover treatment and pharmacies may offer specific discount pricing | ✗ Traditional formulations may be drying |
| ✓ Easy to access for those already seeing a physician | ✗ Less convenient if you don’t have access to a physician |
Generic 2% ketoconazole is the simplest prescription option for people who already have access to a healthcare provider or health insurance. Pharmacies may have specific discount pricing or insurance may cover the cost of treatment, making it one of the most accessible options for specific individuals.
Like others, the generic shampoo formulations likely contain sulfates that could be drying with consistent use. Appointment wait times and physician access may also be an impediment to medication access, compared to telehealth, which typically rolls prescription and pharmacy fulfillment into one convenient service.
Bottom Line: If you already have prescription access and simply want 2% ketoconazole without added treatment features, generic ketoconazole is the best option on this list.
| ✓ Prescription-strength 2% ketoconazole | ✗ Requires online medical review |
| ✓ Available for both men and women | ✗ No major formulation advantage over standard 2% ketoconazole shampoo |
| ✓ Starts at $25 for 120 mL | |
| ✓ Can be paired with other hair loss treatments through their telehealth platform |
Strut offers 2% ketoconazole through its telehealth platform for both men and women, which makes it one of the more flexible telehealth options on this list. A 120 mL bottle currently starts at $25, and the online process includes physician review, direct shipping, and access to other prescription hair-loss treatments through the same platform. Like other shampoos in the list, it likely contains sulfates that may contribute to hair dryness.
Bottom Line: Strut is a strong 2% option for men and women who want prescription ketoconazole integrated into a broader telehealth hair-loss routine.
| ✓ Prescription-strength 2% ketoconazole | ✗ Narrower hair-loss treatment platform |
| ✓ $15/month listed price | ✗ Generic formula may be drying |
| ✓ Dermatologist-reviewed treatment | |
| ✓ 120 mL listed as a three-month supply |
EasyDerm is one of the most accessible ketoconazole shampoos. Its 2% ketoconazole shampoo is currently listed at $15 per month, and is available for both men and women. Treatment is reviewed by a licensed dermatologist and shipped directly to the patient.
For someone whose main goal is getting prescription-strength ketoconazole at a low advertised monthly price, EasyDerm has a clear advantage. However, compared to other telehealth platforms, the breadth of its hair-loss treatments is narrower and there is no formulation advantage over other shampoos.
Bottom Line: EasyDerm is our best budget teledermatology option for 2% ketoconazole, particularly for people who want a dermatologist review without paying the higher monthly cost of some hair-loss platforms.
| ✓ 2% ketoconazole | ✗ $22 provider review fee for new prescriptions |
| ✓ No prior prescription needed to start | ✗ Standard generic formulation rather than a hair-focused shampoo |
| ✓ Licensed-provider review available online | |
| ✓ HSA/FSA eligible |
TelyRx is built around fast prescription access rather than a hair-loss program. It currently offers generic 2% ketoconazole shampoo at $38.99 for a 120 mL bottle. Patients who do not already have a prescription can complete an online health assessment and pay a one-time $22 provider review fee, while patients with an existing prescription can transfer it directly. But, unlike other telehealth platforms, a broad range of treatment options for hair loss is not available.
Bottom Line: TelyRx is a convenient option for fast online access to generic 2% ketoconazole, especially for people who want to avoid scheduling a traditional office visit.
| ✓ Prescription-strength 2% ketoconazole | ✗ Higher total cost once review and shipping are included |
| ✓ Fully online clinical review | ✗ Generic formula likely contains sulfates |
| ✓ Integrated with a broader hair-loss and general-health telemedicine platform | |
| ✓ HSA/FSA eligible |
AlgoRx offers 2% ketoconazole through a fully online prescription process and positions the shampoo within its broader telehealth platform. The product is available as a 120 mL bottle, with a one-time purchase currently listed at $45 and subscription medication pricing listed at $39.60 before provider review ($15) and shipping charges ($15), making it one of the more expensive options on this list. The main benefit is convenience for people who already use AlgoRx or want ketoconazole alongside other hair-loss treatments or treatments for other aspects of health.
Bottom Line: AlgoRx is a reasonable 2% telehealth option for people who value an integrated hair-loss and general-health telemedicine platform, but the shampoo itself remains a generic formulation with no distinct advantages over other options.
| ✓ Prescription-strength 2% ketoconazole | ✗ $25 consultation fee |
| ✓ $20/month medication-equivalent pricing | ✗ Focused on dandruff rather than broader hair-loss treatment |
| ✓ Online doctor consultation | |
| ✓ Free shipping and HSA/FSA eligibility |
RedBox Rx offers 2% ketoconazole through an online consultation, with transparent pricing and direct-to-home delivery. Its price at the time of writing is $60 for two 120 mL bottles. However, there is also a one-time $25 fee for an online doctor consultation, bringing the total to $85. Compared to other options, it’s a higher-cost option with no distinct formulation differentiation. Moreover, the breadth of hair-loss treatments offered on the telehealth platform is more limited than other telehealth platforms.
Bottom Line: RedBox Rx is a pricier route to prescription 2% ketoconazole with online medical review, and it offers fewer hair-loss-specific features than the platforms ranked above it, with minimal differentiation for formulation.
Ketoconazole shampoos do not need to be used every day. In fact, with sulfate-containing formulations, daily use could cause excessive dryness of the hair or scalp. Most clinical studies have employed frequencies of two to three times per week. In the 176-person study of 1% ketoconazole, participants applied the shampoo twice weekly for four weeks.[9]Go IH, Wientjens DP, Koster M. A double-blind trial of 1% ketoconazole shampoo versus placebo in the treatment of dandruff. Mycoses. 1992;35(3-4):103-105. … Continue reading The larger 2% study involving 575 participants also used ketoconazole twice weekly for two to four weeks. Responders could then move to less-frequent maintenance, with once-weekly treatment reducing relapse compared with placebo.[10]Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, … Continue reading
Directions also vary by product and company. TelyRx advises users to leave its ketoconazole shampoo on for about five minutes before rinsing, and Keeps similarly recommends approximately five minutes of contact time.[11]TelyRx. Ketoconazole Shampoo, 2%. https://telyrx.com/ketoconazole-shampoo. Accessed September 2026.)[12]Keeps. Ketoconazole Shampoo 2%. https://www.keeps.com. Accessed September 2026.)
Many shampoo formulations preclude more consistent use due to the drying effects of sulfates. However, gentler formulas like Ulo’s Thickening+ Ketoconazole Shampoo can be used as often as daily without the drying effects of sulfates. That said, whether daily use provides a significant advantage over two to three times weekly has yet to be proven.
Ketoconazole concentration is one important factor in treatment, but overall formulation also plays a role. Surfactant content (and the type of surfactants used) determines how aggressively a shampoo removes oil and debris, conditioning agents affect how the hair feels afterward, and fragrances, preservatives, and other ingredients can all influence tolerability.
This is relevant because dryness is one of the most common complaints with traditional medicated shampoos. A 2026 randomized comparison of selenium disulfide with 2% ketoconazole specifically noted that anti-dandruff shampoos can leave hair dry and difficult to manage, which may affect adherence.[13]Farris PK, Barbosa V, Houshmand EB, Kovylkina N. Beyond efficacy: 0.6% selenium disulfide shampoo matches 2% ketoconazole for seborrheic dermatitis with superior cosmesis. J Drugs Dermatol. … Continue reading
For people with androgenetic alopecia, this is more than a minor cosmetic detail. Dry, brittle, or frizzy hair can make existing thinning look worse even when existing density has not changed. Brittle hair can also contribute to breakage from styling, which may affect hair appearance and fullness, especially in individuals with longer hair.
Topical ketoconazole is generally well tolerated. A systematic review of 40 studies involving 4,566 participants found topical ketoconazole to be clinically effective for Malassezia-associated skin conditions and generally safe, although allergic contact dermatitis can occur.[14]Choi FD, Juhasz MLW, Atanaskova Mesinkovska N. Topical ketoconazole: a systematic review of current dermatological applications and future developments. J Dermatol Treat. 2019;30(8):760-771. … Continue reading
Potential local side effects include the following:
Prescription ketoconazole labeling also lists dry skin, skin irritation, and changes in hair texture among possible adverse effects.[15]Keeps. Ketoconazole Shampoo 2%. https://www.keeps.com. Accessed September 2026. It should be noted that irritation is not necessarily caused by ketoconazole itself. Surfactants, fragrance, preservatives, and other ingredients can independently contribute to dryness or irritation. If ketoconazole shampoos cause irritation, it may be worth shopping around to find a formula that works for your hair before giving up on ketoconazole altogether.
Ketoconazole is one of the better-supported medicated shampoo ingredients for dandruff, seborrheic dermatitis, and scalp inflammation. There is also some evidence suggesting that it may support hair growth in people with androgenetic alopecia, including reductions in shedding and improvements in hair-shaft diameter and percentage of anagen hairs. However, the evidence is still much smaller than what exists for more established treatments like minoxidil, finasteride, and dutasteride.
The best ketoconazole shampoo therefore depends on your goals and preferences. For more severe dandruff or seborrheic dermatitis, a 2% prescription formula may make the most sense. For milder dandruff, or for someone using ketoconazole alongside a long-term hair-loss routine, formulation and tolerability are of more importance, particularly if dryness makes consistent use difficult.
Ulo Thickening+ Ketoconazole Shampoo is our top pick because it combines 0.9% ketoconazole with a sulfate-free formula designed specifically for thinning hair. The sulfate-free formulation seeks to maximize tolerability and minimize obstacles to treatment adherence. Nizoral 2-in-1 and Nizoral Anti-Dandruff Shampoo are also notable OTC options, while Keeps, generic ketoconazole, Strut, EasyDerm, TelyRx, AlgoRx, and RedBox Rx all provide different routes to prescription-strength 2% ketoconazole.
Ultimately, ketoconazole is best utilized as a complementary treatment rather than a standalone solution for androgenetic alopecia. The evidence for its use is strongest for dandruff and seborrheic dermatitis, with the 2% concentration demonstrating a positive effect on hair density. However, its benefits, like all approaches to addressing hair loss, are dependent on consistency. A ketoconazole shampoo should therefore be selected based on your needs and preferences, including factors like tolerability or severity of existing scalp conditions. The good news is that there are now enough over-the-counter, prescription, and telehealth options that you should be able to find a solution that fits your scalp, hair type, treatment goals, and tolerance for long-term use.
References[+]
| ↑1 | Fields JR, Vonu PM, Monir RL, Schoch JJ. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review. Dermatol Ther. 2020;33(1):e13202. https://doi.org/10.1111/dth.13202 |
|---|---|
| ↑2, ↑10 | Peter RU, Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo: results of a multicentre, double-blind, placebo-controlled trial. Br J Dermatol. 1995;132(3):441-445. https://doi.org/10.1111/j.1365-2133.1995.tb08680.x |
| ↑3 | Piérard-Franchimont C, Goffin V, Decroix J, Piérard GE. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Physiol. 2002;15(6):434-441. https://doi.org/10.1159/000066452 |
| ↑4 | Piérard-Franchimont C, De Doncker P, Cauwenbergh G, Piérard GE. Ketoconazole shampoo: effect of long-term use in androgenic alopecia. Dermatology. 1998;196(4):474-477. https://doi.org/10.1159/000017954 |
| ↑5 | Piérard-Franchimont C, Goffin V, Henry F, Uhoda I, Braham C, Piérard GE. Nudging hair shedding by antidandruff shampoos: a comparison of 1% ketoconazole, 1% piroctone olamine and 1% zinc pyrithione formulations. Int J Cosmet Sci. 2002;24(5):249-256. https://doi.org/10.1046/j.1467-2494.2002.00145.x |
| ↑6 | Khandpur S, Suman M, Reddy BS. Comparative efficacy of various treatment regimens for androgenetic alopecia in men. J Dermatol. 2002;29(8):489-498. https://doi.org/10.1111/j.1346-8138.2002.tb00314.x |
| ↑7 | Rafi AW, Katz RM. Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia: the effects of atopy on AGA. ISRN Dermatology. 2011:241953. https://doi.org/10.5402/2011/241953 |
| ↑8 | Walmart customer reviews. https://www.walmart.com/reviews/product/5761431665 |
| ↑9 | Go IH, Wientjens DP, Koster M. A double-blind trial of 1% ketoconazole shampoo versus placebo in the treatment of dandruff. Mycoses. 1992;35(3-4):103-105. https://doi.org/10.1111/j.1439-0507.1992.tb00828.x |
| ↑11 | TelyRx. Ketoconazole Shampoo, 2%. https://telyrx.com/ketoconazole-shampoo. Accessed September 2026.) |
| ↑12 | Keeps. Ketoconazole Shampoo 2%. https://www.keeps.com. Accessed September 2026.) |
| ↑13 | Farris PK, Barbosa V, Houshmand EB, Kovylkina N. Beyond efficacy: 0.6% selenium disulfide shampoo matches 2% ketoconazole for seborrheic dermatitis with superior cosmesis. J Drugs Dermatol. 2026;25(4):338. https://jddonline.com/articles/beyond-efficacy-06-selenium-disulfide-shampoo-matches-2-ketoconazole-seborrheic-dermatitis-with-superior-cosmesis-S1545961626P9746X/ |
| ↑14 | Choi FD, Juhasz MLW, Atanaskova Mesinkovska N. Topical ketoconazole: a systematic review of current dermatological applications and future developments. J Dermatol Treat. 2019;30(8):760-771. https://doi.org/10.1080/09546634.2019.1573309 |
| ↑15 | Keeps. Ketoconazole Shampoo 2%. https://www.keeps.com. Accessed September 2026. |